Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.1.1.34 - hydroxymethylglutaryl-CoA reductase (NADPH)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acidosis
Maleate nephrotoxicity: mechanisms of injury and correlates with ischemic/hypoxic tubular cell death.
Acquired Immunodeficiency Syndrome
Endogenous sodium potassium ATPase inhibition related biochemical cascade and the acquired immunodeficiency syndrome--neural regulation of viral replication and immune response to the virus.
Hypothalamic digoxin, hemispheric dominance and the acquired immunodeficiency syndrome.
Acute Coronary Syndrome
Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
Defining the role of high-dose statins in PCI.
Early statin initiation and outcomes in patients with acute coronary syndromes.
Early statin therapy within 48 hours decreased one-year major adverse cardiac events in patients with acute myocardial infarction.
Early use of statins in acute coronary syndromes.
Effect on Short- and Long-Term Major Adverse Cardiac Events of Statin Treatment in Patients With Acute Myocardial Infarction and Renal Dysfunction.
HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats.
How aggressive should lipid lowering be among patients with acute coronary syndromes?
Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design.
Lipid-lowering efficacy and safety of varying doses of Simvastatin in patients with early stage acute coronary syndromes: one-year follow-up study.
Lipids and stroke: the opportunity of lipid-lowering treatment.
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
Statin withdrawal: clinical implications and molecular mechanisms.
T helper 1/T helper 2 balance and HMG-CoA reductase inhibitors in acute coronary syndrome: statins as immunomodulatory agents?
Update on acute coronary syndromes and ST-elevation myocardial infarction.
Utility of early high dose statins in acute coronary syndrome.
[Oxidized low-density lipoprotein enhances the expressions of SREBP-2 and HMGCR mRNA in macrophages derived from the monocytes of patients with acute coronary syndrome]
[Statins in the management of acute coronary syndrome]
Acute Kidney Injury
HMG CoA reductase inhibitors (statins) for preventing acute kidney injury after surgical procedures requiring cardiac bypass.
HMG-CoA Reductase Activation and Urinary Pellet Cholesterol Elevations in Acute Kidney Injury.
HMG-CoA reductase inhibitors (statins) and acute kidney injury: A secondary analysis of renal study outcomes.
Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine.
Renal ischemia-induced cholesterol loading: transcription factor recruitment and chromatin remodeling along the HMG CoA reductase gene.
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor.
[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors]
Acute Lung Injury
Long-term Simvastatin Administration Attenuates Lung Injury and Oxidative Stress in Murine Acute Lung Injury Models Induced by Oleic Acid and Endotoxin.
Protective effects of pravastatin in murine lipopolysaccharide-induced acute lung injury.
Adenocarcinoma
3-hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors.
?-ionone induces cell cycle arrest and apoptosis in human prostate tumor cells.
Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.
Reversion of transformed phenotype of human adenocarcinoma A549 cells by expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase complementary DNA.
Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.
Adenocarcinoma of Lung
Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non-Small Cell Lung Carcinogenesis.
Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549.
Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo.
[A 81-year old man of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy associated with lung adenocarcinoma cancer].
Adenocarcinoma, Bronchiolo-Alveolar
Inhibition of beta-oxidative respiration is a therapeutic window associated with the cancer chemo-preventive activity of PPARgamma agonists.
Adenoma
Reported use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors was not associated with reduced recurrence of colorectal adenomas.
Role of the Mevalonate Pathway in Adrenocortical Tumorigenesis.
Adrenoleukodystrophy
X-linked adrenoleukodystrophy mice demonstrate abnormalities in cholesterol metabolism.
Albuminuria
Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment.
Effects of the combination of an angiotensin II antagonist with an HMG-CoA reductase inhibitor in experimental diabetes.
Insulin Resistance, Oxidative Stress, and Podocyte Injury: Role of Rosuvastatin Modulation of Filtration Barrier Injury.
aldehyde dehydrogenase (nad+) deficiency
Acetaldehyde Dehydrogenase 2 regulates HMG-CoA reductase stability and cholesterol synthesis in the liver.
Alveolitis, Extrinsic Allergic
Polymyalgia, hypersensitivity pneumonitis and other reactions in patients receiving HMG-CoA reductase inhibitors: a report of ten cases.
Alzheimer Disease
A functional polymorphism in the HMGCR promoter affects transcriptional activity but not the risk for Alzheimer disease in Swedish populations.
Association between statin use and Alzheimer's disease.
Association of HMGCR polymorphism with late-onset Alzheimer's disease in Han Chinese.
Atorvastatin ameliorates cognitive impairment, A?1-42 production and Tau hyperphosphorylation in APP/PS1 transgenic mice.
Atorvastatin stimulates neuroblastoma cells to induce neurite outgrowth by increasing cellular prion protein expression.
Blockade of HMG-CoA reductase activity causes changes in microtubule-stabilizing protein tau via suppression of geranylgeranylpyrophosphate formation: implications for Alzheimer's disease.
Can statins put the brakes on Alzheimer's disease?
Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease.
Effect of HMGCR genetic variation on neuroimaging biomarkers in healthy, mild cognitive impairment and Alzheimer's disease cohorts.
Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid.
Effects of rs3846662 Variants on HMGCR mRNA and Protein Levels and on Markers of Alzheimer's Disease Pathology.
Effects of statins on cognitive function in patients with Alzheimer's disease in galantamine clinical trials.
Evaluation of the global association between cholesterol-associated polymorphisms and Alzheimer's disease suggests a role for rs3846662 and HMGCR splicing in disease risk.
High doses of simvastatin, pravastatin, and cholesterol reduce brain cholesterol synthesis in guinea pigs.
HMG-CoA reductase inhibitor simvastatin inhibits cell cycle progression at the G1/S checkpoint in immortalized lymphocytes from Alzheimer's disease patients independently of cholesterol-lowering effects.
HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advise to use one that crosses the blood-brain barrier.
HMGCR is a genetic modifier for risk, age of onset and MCI conversion to Alzheimer's disease in a three cohorts study.
Interaction between HMGCR and ABCA1 cholesterol-related genes modulates Alzheimer's disease risk.
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Mechanisms of statin-mediated inhibition of small G-protein function.
Patients with Alzheimer's disease may be particularly susceptible to adverse effects of statins.
Processing of amyloid precursor protein as a biochemical link between atherosclerosis and Alzheimer's disease.
Risk of Late-Onset Alzheimer's Disease by Plasma Cholesterol: Rational In Silico Drug Investigation of Pyrrole-Based HMG-CoA Reductase Inhibitors.
Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimer's Disease.
Simvastatin inhibits protein isoprenylation in the brain.
Statins and neuroprotection: a prescription to move the field forward.
Statins cause intracellular accumulation of amyloid precursor protein, beta-secretase-cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism.
Therapeutic approaches to the treatment of Alzheimer's disease.
[Direct neuronal effects of statins]
Amebiasis
Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and application of statins as a novel effective therapeutic approach against Acanthamoeba infections.
Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis-like conditions in possible association with cholesterol-lowering drugs: an analysis of patient reports to the University of California, San Diego (UCSD) Statin Effects Study.
Statins accelerate disease progression and shorten survival in SOD1(G93A) mice.
Anaphylaxis
Exercise-Induced Anaphylaxis in an Air Force Aviator Taking a HMG-CoA Reductase Inhibitor: A Case Report and Review of the Presentation, Diagnoses, and Treatment.
Anemia, Hypochromic
Overexpression of farnesyl diphosphate synthase in Arabidopsis mitochondria triggers light-dependent lesion formation and alters cytokinin homeostasis.
Aneurysm
A combination of PPAR-gamma agonists and HMG CoA reductase inhibitors (statins) as a new therapy for the conservative treatment of AAS (aortic aneurysm syndromes).
Medical management of small abdominal aortic aneurysms.
Angina Pectoris
Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography.
Angina, Stable
Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation.
Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization.
Angina, Unstable
Expression of HMG-CoA reductase in human coronary atherosclerotic plaques and relationship to plaque destabilisation.
Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?
Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering.
[Statins decreases expression of five inflammation-associated microRNAs in the plasma of patients with unstable angina].
Aortic Aneurysm, Abdominal
A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall.
A Randomised Placebo-controlled Double-blind Trial to Evaluate Lipid-lowering Pharmacotherapy on Proteolysis and Inflammation in Abdominal Aortic Aneurysms.
HMG-CoA reductase inhibitors (statins) decrease MMP-3 and MMP-9 concentrations in abdominal aortic aneurysms.
Aortic Valve Stenosis
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg).
Arterial Occlusive Diseases
Peripheral arterial disease: a review of disease awareness and management.
Arteriosclerosis
Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease.
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
HMG-CoA reductase inhibition improves anti-aging klotho protein expression and arteriosclerosis in rats with chronic inhibition of nitric oxide synthesis.
HMG-CoA reductase inhibitors in organ transplantation.
Protective effect of atorvastatin meditated by HMGCR gene on diabetic rats with atherosclerosis: An in vivo and in vitro study.
Arteritis
Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women.
Arthritis
Betulinic acid and fluvastatin exhibits synergistic effect on toll-like receptor-4 mediated anti-atherogenic mechanism in type II collagen induced arthritis.
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Arthritis, Experimental
Effects of pravastatin in murine collagen-induced arthritis.
Arthritis, Rheumatoid
Bone protective effect of simvastatin in experimental arthritis.
Effect of 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor on disease activity in patients with rheumatoid arthritis: a meta-analysis.
HMG-CoA reductase inhibitor simvastatin suppresses Toll-like receptor 2 ligand-induced activation of nuclear factor kappa B by preventing RhoA activation in monocytes from rheumatoid arthritis patients.
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.
Aspergillosis, Allergic Bronchopulmonary
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Asthma
Allergic asthma aggravated atherosclerosis increases cholesterol biosynthesis and foam cell formation in apolipoprotein E-deficient mice.
Effect of the anti-IL-17 antibody on allergic inflammation in an obesity-related asthma model.
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Increased patient co-payments and changes in PBS-subsidised prescription medicines dispensed in Western Australia.
Innovations in asthma therapy: is there a role for inhaled statins?
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Statin Exposure is Associated with Decreased Asthma-Related Emergency Department Visits and Oral Corticosteroid Use.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
[Simvastatin induces eosinophil apoptosis in vitro]
Atherosclerosis
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
A Comprehensive Review of Oxidative Stress as the Underlying Mechanism in Atherosclerosis and the Inefficiency of Antioxidants to Revert this Process.
A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA.
A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects--the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action.
A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits.
A systematic comparison of clinically viable nanomedicines targeting HMG-CoA reductase in inflammatory atherosclerosis.
Additive inhibitory effect of hydrocortisone and cyclosporine on low-density lipoprotein receptor activity in cultured HepG2 cells.
Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
Allergic asthma aggravated atherosclerosis increases cholesterol biosynthesis and foam cell formation in apolipoprotein E-deficient mice.
An in vitro method using vascular smooth muscle cells to study the effect of compounds on cell proliferation and intracellular lipid accumulation.
Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits.
Antihypercholesterolemic and antiatherosclerotic potencies of Pandanus tectorius fruits via increasing scavenger receptor-B1 genes expression and inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity.
Antioxidant effects of simvastatin in primary and secondary prevention of coronary heart disease.
Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins.
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Atherosclerosis: a redox-sensitive lipid imbalance suppressible by cyclopentenone prostaglandins.
Betulinic acid and fluvastatin exhibits synergistic effect on toll-like receptor-4 mediated anti-atherogenic mechanism in type II collagen induced arthritis.
Biological knowledge-driven analysis of epistasis in human GWAS with application to lipid traits.
CE: Triglycerides: Do They Matter?
Clinical evidence for Japanese population based on prospective studies-Linking clinical trials and clinical practice.
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Comparative tolerability of the HMG-CoA reductase inhibitors.
Contribution of Accelerated Degradation to Feedback Regulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Cholesterol Metabolism in the Liver.
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Coronary Plaque Burden at Coronary CT Angiography in Asymptomatic Men and Women.
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians.
Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada.
Development and progression of atherosclerosis in aorta from heterozygous and homozygous WHHL rabbits. Effects of simvastatin treatment.
Diabetes mellitus-associated atherosclerosis : mechanisms involved and potential for pharmacological invention.
Differential regulation of HMG-CoA reductase and Insig-1 by enzymes of the ubiquitin-proteasome system.
Drug Insight: using statins to treat neuroinflammatory disease.
Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis.
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition on serum matrix metalloproteinase-13 and tissue inhibitor matrix metalloproteinase-1 levels as a sign of plaque stabilization.
Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits.
Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits.
Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients.
Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells.
Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene.
Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery.
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Effects of HMG-CoA reductase inhibition on PDGF- and angiotensin II- mediated signal transduction: suppression of c-Jun and c-Fos in human smooth muscle cells in vitro.
Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease.
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Effects of pravastatin on the in vitro phagocytic function and hydrogen peroxide production by monocytes of healthy individuals.
Effects of statins on adhesion molecule expression in endothelial cells.
Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia.
Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
Genomic analysis of circulating cells: a window into atherosclerosis.
HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit.
HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis.
HMG-CoA reductase inhibitors (statins), inflammation, and endothelial progenitor cells-New mechanistic insights of atherosclerosis.
HMG-CoA reductase inhibitors suppress macrophage growth induced by oxidized low density lipoprotein.
HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis.
HMG-CoA reductase inhibitors: a look back and a look ahead.
HMG-CoA Reductase Inhibitors: Effects on Chronic Subacute Inflammation and Onset of Atherosclerosis Induced by Dietary Cholesterol.
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.
Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice.
Hyperlipidaemia in paediatric patients: the role of lipid-lowering therapy in clinical practice.
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
Identification of DKK-1 as a novel mediator of statin effects in human endothelial cells.
In vitro screening for ?-hydroxy-?-methylglutaryl-CoA reductase inhibitory and antioxidant activity of sequentially extracted fractions of Ficus palmata Forsk.
Influence of statins on MHC class I expression.
Inhibition of cultured vascular smooth muscle cell migration by simvastatin (MK-733).
Interaction of statins with phospholipid bilayers studied by solid-state NMR spectroscopy.
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Inverse Regulation of Confluence-Dependent ADAMTS13 and von Willebrand Factor Expression in Human Endothelial Cells.
Is Interleukin-38 a key player cytokine in atherosclerosis immune gene therapy?
Knowledge-driven analysis identifies a gene-gene interaction affecting high-density lipoprotein cholesterol levels in multi-ethnic populations.
L-arginine supplementation in hypercholesterolemic rabbits normalizes leukocyte adhesion to non-endothelial matrix.
Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease.
Low-dose cerivastatin inhibits spontaneous atherogenesis in heterozygous watanabe hyper lipidemic rabbits.
Lycopene regulation of cholesterol synthesis and efflux in human macrophages.
Macrophage 3-hydroxy-3-methylglutaryl coenzyme a reductase activity in sitosterolemia: effects of increased cellular cholesterol and sitosterol concentrations.
Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin.
Molecular mechanisms underlying the onset of degenerative aortic valve disease.
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Myeloid HMG-CoA (3-Hydroxy-3-Methylglutaryl-Coenzyme A) Reductase Determines Atherosclerosis by Modulating Migration of Macrophages.
Myeloid HMG-CoA Reductase Determines Adipose Tissue Inflammation, Insulin Resistance, and Hepatic Steatosis in Diet-Induced Obese Mice.
Optimizing cardiovascular outcomes in diabetes mellitus.
Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans.
Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo.
Pleiotropic effects of HMG-CoA reductase inhibitors.
Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase.
Pre-germinated brown rice extract ameliorates high-fat diet-induced metabolic syndrome.
Preservation of endogenous antioxidant activity and inhibition of lipid peroxidation as common mechanisms of antiatherosclerotic effects of vitamin E, lovastatin and amlodipine.
Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.
Protective effect of atorvastatin meditated by HMGCR gene on diabetic rats with atherosclerosis: An in vivo and in vitro study.
Proteomic analysis of endothelial cell secretome: a means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors.
Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects).
Regulation of HMGCoA Reductase Activity by Policosanol and Octacosadienol, a New Synthetic Analogue of Octacosanol.
Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors.
Rosuvastatin Improves Endothelial Function of db/db Mice: Role of Angiotensin II Type 1 Receptors and Oxidative Stress.
Rosuvastatin: a review of its effect on atherosclerosis.
Salsalate reduces atherosclerosis through AMPK?1 in mice.
Short-term effect of low-dose atorvastatin on haemorrheological parameters, platelet aggregation and endothelial function in patients with cerebrovascular disease and hyperlipidaemia.
Simvastatin Increases ADAMTS13 Expression in Podocytes.
Simvastatin inhibited oxLDL-induced proatherogenic effects through calpain-1-PPAR?-CD36 pathway.
Simvastatin potentiates tumor necrosis factor alpha-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA.
Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model.
Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.
Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders.
Statin treatment and progression of atherosclerotic plaque burden.
Statin-stimulated nitric oxide release from endothelium.
Statins and demyelination.
Statins in the treatment of central nervous system autoimmune disease.
Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages.
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, are able to reduce superoxide anion production by NADPH oxidase in THP-1-derived monocytes.
Studies of cholesterol and bile acid metabolism, and early atherogenesis in hamsters fed GT16-239, a novel bile acid sequestrant (BAS).
The effect of statins on postprandial lipemia.
The effects of HMG-CoA reductase inhibitor on vascular progenitor cells.
The effects of lipid-lowering therapy on paraoxonase activities and their relationships with the oxidant-antioxidant system in patients with dyslipidemia.
The HMG-CoA reductase gene and lipid and lipoprotein levels: the multi-ethnic study of atherosclerosis.
The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation.
The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease.
The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
The pathology of atherosclerosis: plaque development and plaque responses to medical treatment.
The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.
The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Torcetrapib + atorvastatin (Pfizer).
Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.
Use of Statins for Secondary Prevention.
Vasodilatory capacity of forearm resistance vessels is augmented in hypercholesterolemic patients after treatment with fluvastatin.
Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy.
[Anti-atherosclerotic actions of HMG-CoA reductase inhibitors]
[Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk]
[Fluvastatin in the treatment of hyperlipoproteinemia, initial experience]
[Pleiotropic effects of statins]
[Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis]
Atrial Fibrillation
Does statin therapy decrease the risk for bleeding in patients who are receiving warfarin?
Fluvastatin Reduces Pulmonary Vein Spontaneous Activity Through Nitric Oxide Pathway.
Improved survival associated with prophylactic implantable defibrillators in elderly patients with prior myocardial infarction and depressed ventricular function: a MADIT-II substudy.
Pharmacogenetics of Warfarin in a Diverse Patient Population.
Post-cardiothoracic surgery atrial fibrillation: a review of preventive strategies.
Potential use of statins to prevent atrial fibrillation after coronary artery bypass surgery.
Prevention of atrial fibrillation with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Simvastatin attenuates sympathetic hyperinnervation to prevent atrial fibrillation during post-myocardial infarction remodeling process.
Statin therapy for the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials.
Targeting inflammation and oxidative stress in atrial fibrillation: Role of HMG-CoA reductase inhibition with statins.
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.
The role of statins in cancer therapy.
Autoimmune Diseases
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Do the pleiotropic effects of statins in the vasculature predict a role in inflammatory diseases?
Effects of atorvastatin on the Th1/Th2 polarization of ongoing experimental autoimmune myocarditis in Lewis rats.
Immune-mediated necrotizing myopathy associated with statins: history and recent developments.
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Bacteremia
The role of statin therapy in sepsis.
Bacterial Infections
Simvastatin increases the in vivo activity of the first-line tuberculosis regimen.
Specific inhibitions of annonaceous acetogenins on class II 3-hydroxy-3-methylglutaryl coenzyme A reductase from Streptococcus pneumoniae.
Blepharitis
HMG-CoA reductase expression in human eyelid tissue and in a human meibomian gland epithelial cell line.
Blindness
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Blister
3-hydroxy-3-methyl glutaryl coenzyme A reductase: an essential actor in the biosynthesis of cantharidin in the blister beetle Epicauta chinensis Laporte.
Bone Resorption
Atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, reduces bone resorption in the elderly.
Bone protective effect of simvastatin in experimental arthritis.
The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity.
Brain Injuries
HMG CoA reductase inhibitors reduce ischemic brain injury of Wistar rats through decreasing oxidative stress on neurons.
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Statins improve outcome in murine models of intracranial hemorrhage and traumatic brain injury: A translational approach.
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
Brain Injuries, Traumatic
Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact.
Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury.
Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury.
Simvastatin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy.
Statins and neuroprotection: a prescription to move the field forward.
Brain Ischemia
Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors.
Aggravation of focal cerebral ischemia by tissue plasminogen activator is reversed by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor but does not depend on endothelial NO synthase.
Alterations of interneurons of the gerbil hippocampus after transient cerebral ischemia: effect of pitavastatin.
Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice.
HMG-CoA Reductase Inhibition Promotes Neurological Recovery, Peri-Lesional Tissue Remodeling, and Contralesional Pyramidal Tract Plasticity after Focal Cerebral Ischemia.
HMG-CoA Reductase Inhibitors Relieve Endoplasmic Reticulum Stress by Autophagy Inhibition in Rats With Permanent Brain Ischemia.
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
[Prevention of coronary heart disease--"evidence-based medicine" of antilipemic therapy]
Brain Neoplasms
3-hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors.
Breast Neoplasms
17 beta-Estradiol overcomes a G1 block induced by HMG-CoA reductase inhibitors and fosters cell cycle progression without inducing ERK-1 and -2 MAP kinases activation.
A Retrospective Hospital-Based Study of HMGCR Expression in HER2 IHC 2+ and 3+ Breast Cancer.
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.
Anti-Warburg effect by targeting HRD1-PFKP pathway may inhibit breast cancer progression.
Bergamot natural products eradicate cancer stem cells (CSCs) by targeting mevalonate, Rho-GDI-signalling and mitochondrial metabolism.
Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study.
Body mass index and the association between low-density lipoprotein cholesterol as predicted by HMGCR genetic variants and breast cancer risk.
Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.
Chromosome 13q12 encoded Rho GTPase activating protein suppresses growth of breast carcinoma cells, and yeast two-hybrid screen shows its interaction with several proteins.
CtBP promotes metastasis of breast cancer through repressing cholesterol and activating TGF-? signaling.
Dietary factors and the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase: implications for breast cancer and development.
Dysregulation of the mevalonate pathway promotes transformation.
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
Efficient Use of Exogenous Isoprenols for Protein Isoprenylation by MDA-MB-231 Cells Is Regulated Independently of the Mevalonate Pathway.
Factors released from human breast-cancer cells counteract the inhibitory effects of mevinolin on DNA-synthesis and morphology but not on hmg coa reductase-activity.
Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.
Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity.
HMG CoA reductase expression as a prognostic factor in Korean patients with breast cancer: A retrospective study.
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
Increased 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in a virilizing adrenal carcinoma.
Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell.
Interactions Between ABCB1 Genotype and Preoperative Statin Use Impact Clinical Outcomes Among Breast Cancer Patients.
Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7.
MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1.
Molecular and Biochemical Analysis of the Estrogenic and Proliferative Properties of Vitamin E Compounds.
Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells.
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Regulation of HMG-CoA reductase in MCF-7 cells by genistein, EPA, and DHA, alone and in combination with mevastatin.
Regulatory role of mevalonate in the growth of normal and neoplastic human mammary epithelial cells.
Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.
Statin use, HMGCR expression, and breast cancer survival - The Malmö Diet and Cancer Study.
Statins and cancer development.
Stimulation of human breast cancer MCF-7 cells with estrogen prevents cell cycle arrest by HMG-CoA reductase inhibitors.
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region.
Transcriptome-based identification of lovastatin as a breast cancer stem cell-targeting drug.
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.
Breast Neoplasms, Male
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.
Bronchitis, Chronic
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Carcinogenesis
A lipophilic statin, pitavastatin, suppresses inflammation-associated mouse colon carcinogenesis.
Atorvastatin inhibits pancreatic carcinogenesis and increases survival in LSL-Kras(G12D) -LSL-Trp53(R172H) -Pdx1-Cre mice.
Chemoprevention by pravastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, of N-methyl-N-nitrosourea-induced colon carcinogenesis in F344 rats.
Chemopreventive efficacy of low dose of pravastatin, an HMG-CoA reductase inhibitor, on 1,2-dimethylhydrazine-induced colon carcinogenesis in ICR mice.
Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models.
Fluvastatin Inhibits HMG-CoA Reductase and Prevents Non-Small Cell Lung Carcinogenesis.
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells.
Hypolipidemic effect of ginger in 1,2-dimethyl hydrazine-induced experimental colon carcinogenesis.
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Prevention of 1,2-dimethylhydrazine-induced colon tumorigenesis by HMG-CoA reductase inhibitors, pravastatin and simvastatin, in ICR mice.
Regulation of mevalonate synthesis in low density lipoprotein receptor knockout mice fed n-3 or n-6 polyunsaturated fatty acids.
Role of the Mevalonate Pathway in Adrenocortical Tumorigenesis.
Studies with the azoxymethane-rat preclinical model for assessing colon tumor development and chemoprevention.
Taxifolin binds with LXR (? & ?) to attenuate DMBA-induced mammary carcinogenesis through mTOR/Maf-1/PTEN pathway.
Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases.
Carcinoma
3-Hydroxy-3-methylglutaryl coenzyme a reductase activity in liver of athymic mice with or without an implanted human carcinoma.
?-ionone induces cell cycle arrest and apoptosis in human prostate tumor cells.
A New Survival Model Based on Cholesterol Biosynthesis-Related Genes for Prognostic Prediction in Clear Cell Renal Cell Carcinoma.
Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes mellitus.
Characterization of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human adrenal cortex.
Chemical Pathology of Homocysteine VIII. Effects of Tocotrienol, Geranylgeraniol, and Squalene on Thioretinaco Ozonide, Mitochondrial Permeability, and Oxidative Phosphorylation in Arteriosclerosis, Cancer, Neurodegeneration and Aging.
Diosgenin, a naturally occurring furostanol saponin suppresses 3-hydroxy-3-methylglutaryl CoA reductase expression and induces apoptosis in HCT-116 human colon carcinoma cells.
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
Fluvastatin is effective against thymic carcinoma.
Geranylgeraniol suppresses the viability of human DU145 prostate carcinoma cells and the level of HMG CoA reductase.
HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma.
HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma.
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
Human chorionic gonadotropin (hCG) interacts with lovastatin and ionizing radiation to modulate prostate cancer cell viability in vivo.
Increased 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in a virilizing adrenal carcinoma.
Inhibition of HMG-CoA reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cell.
Inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase pathway induces p53-independent transcriptional regulation of p21(WAF1/CIP1) in human prostate carcinoma cells.
Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas.
Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma.
Role of the Mevalonate Pathway in Adrenocortical Tumorigenesis.
SREBP2 is upregulated in esophageal squamous cell carcinoma and co?operates with c?Myc to regulate HMGCR expression.
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.
Synergistic Impact of d-?-Tocotrienol and Geranylgeraniol on the Growth and HMG CoA Reductase of Human DU145 Prostate Carcinoma Cells.
Carcinoma, Acinar Cell
Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas.
Carcinoma, Hepatocellular
A sensitive RNase protection assay for the quantitation of the mRNAs for the LDL receptor and HMG-CoA reductase in human total RNA. Effects of treatments on cells in culture designed to up- and down-regulate expression of the LDL receptor.
Activation of AMP-kinase by Policosanol Requires Peroxisomal Metabolism.
Altered activation state of hydroxymethylglutaryl-coenzyme A reductase in liver tumors.
An improved assay of 3-hydroxy-3-methylglutaryl-CoA reductase activity in Reuber H35 hepatoma cells without microsomes isolation.
Apoptosis induced by clofibrate in Yoshida AH-130 hepatoma cells: role of HMG-CoA reductase.
Cell cycle arrest and apoptosis induction in hepatocellular carcinoma cells by HMG-CoA reductase inhibitors. Synergistic antiproliferative action with ligands of the peripheral benzodiazepine receptor.
Chemoembolization Combined with Pravastatin Improves Survival in Patients with Hepatocellular Carcinoma.
Chlamydia trachomatis growth inhibition and restoration of LDL-receptor level in HepG2 cells treated with mevastatin.
Cholesterol-lowering effect of Aralia elata (Miq.) Seem via the activation of SREBP-2 and the LDL receptor.
Combined inhibitory effects of celecoxib and fluvastatin on the growth of human hepatocellular carcinoma xenografts in nude mice.
Comparison of regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in hepatoma cells grown in vivo and in vitro.
Differences between the regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor in human hepatoma cells and fibroblasts reside primarily at the translational and post-translational levels.
Differential regulation of hepatic triglyceride lipase and 3-hydroxy-3-methylglutaryl-CoA reductase gene expression in a human hepatoma cell line, HepG2.
Differential translational effects of myristic acid and eicosapentaenoic acid on 3-hydroxy-3-methylglutaryl-CoA reductase from Reuber H35 hepatoma cells.
Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Effect of ketoconazole on cholesterol synthesis and on HMG-CoA reductase and LDL-receptor activities in Hep G2 cells.
Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway.
Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density-lipoprotein-receptor activity in the human hepatoma cell line Hep G2.
Green and black tea extracts inhibit HMG-CoA reductase and activate AMP kinase to decrease cholesterol synthesis in hepatoma cells.
Growth-rate-related and hydroxysterol-induced changes in membrane fluidity of cultured hepatoma cells: correlation with 3-hydroxy-3-methyl glutaryl CoA reductase activity.
Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids.
HSP90 interacts with HMGCR and promotes the progression of hepatocellular carcinoma.
Human MicroRNA-548p Decreases Hepatic Apolipoprotein B Secretion and Lipid Synthesis.
Identification of insulin-responsive regions in the HMG-CoA reductase promoter.
Increase in the active form of 3-hydroxy-3-methylglutaryl coenzyme A reductase in human hepatocellular carcinoma: possible mechanism for alteration of cholesterol biosynthesis.
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in hepatoma tissue culture cells by pure cholesterol and several cholesterol derivatives. Evidence supporting two distinct mechanisms.20l.
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Morris hepatoma 7800 after intravenous injection of mevalonic acid.
Inhibition of adrenal cortical steroid formation by procaine is mediated by reduction of the cAMP-induced 3-hydroxy-3-methylglutaryl-coenzyme A reductase messenger ribonucleic acid levels.
Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation.
Lipoprotein-X fails to inhibit hydroxymethylglutaryl coenzyme A reductase in HepG2 cells.
MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1.
Modification of phospholipids fatty acid composition in reuber H35 hepatoma cells: effect on HMG-CoA reductase activity.
MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase.
NK-104, a potent 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, decreases apolipoprotein B-100 secretion from Hep G2 cells.
Partial "feedback control" of beta-hydroxy-beta-methylglutaryl coenzyme A reductase activity in primary hepatocellular carcinomas.
Phosphorylation of hepatic AMP-activated protein kinase and liver kinase B1 is increased after a single oral dose of green tea extract to mice.
Plasma membrane sphingomyelin and the regulation of HMG-CoA reductase activity and cholesterol biosynthesis in cell cultures.
Policosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinase.
Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Properties of 3-hydroxy-3-methylglutaryl coenzyme A reductase solubilized from rat liver and hepatoma.
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in hepatoma tissue culture cells by serum lipoproteins.
Regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase in minimal deviation hepatoma 7288C. Immunological measurements in hepatoma tissue culture cells.
Regulation of 3-hydroxy-3-methylglutaryl-CoA reductase mRNA contents in human hepatoma cell line Hep G2 by distinct classes of mevalonate-derived metabolites.
Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in human hepatoma cell line Hep G2. Effects of inhibitors of cholesterol synthesis on enzyme activity.
Regulation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in rat liver and Morris hepatomas 5123C, 9618A and 5123t.c.
Regulation of HMG-CoA reductase, apoprotein-B and LDL receptor gene expression by the hypocholesterolemic drugs simvastatin and ciprofibrate in Hep G2, human and rat hepatocytes.
Regulation of HMGCoA Reductase Activity by Policosanol and Octacosadienol, a New Synthetic Analogue of Octacosanol.
Regulation of the Lactobacillus Strains on HMGCoA Reductase Gene Transcription in Human HepG2 Cells via Nuclear Factor-?B.
Regulation of the rate of sterol synthesis and the level of beta-hydroxy-beta-methylglutaryl coenzyme A reductase activity in mouse liver and hepatomas.
Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
Reversible phosphorylation of 3-hydroxy-3-methylglutaryl CoA reductase in Morris hepatomas.
RHOA is a modulator of the cholesterol-lowering effects of statin.
Robinetinidol-flavone attenuates cholesterol synthesis in hepatoma cells via inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Role of mevalonate in regulation of cholesterol synthesis and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cultured cells and their cytoplasts.
Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.
Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.
Statins increase cytochrome P450 4F3-mediated eicosanoids production in human liver cells: A PXR dependent mechanism.
Studies on the biosynthesis of polyisoprenols, cholesterol and ubiquinone in highly differentiated human hepatomas.
SUGP1 is a novel regulator of cholesterol metabolism.
Supernatant protein factor requires phosphorylation and interaction with Golgi to stimulate cholesterol synthesis in hepatoma cells.
Suppression of rat liver tumorigenesis by 25-hydroxycholesterol and all-trans retinoic acid: differentiation therapy for hepatocellular carcinoma.
Synergistic effect of simvastatin plus NS398 on inhibition of proliferation and survival in hepatocellular carcinoma cell line.
Targeting the mevalonate pathway is a novel therapeutic approach to inhibit oncogenic FoxM1 transcription factor in human hepatocellular carcinoma.
The effect of (-)-hydroxycitrate on the activity of the low-density-lipoprotein receptor and 3-hydroxy-3-methylglutaryl-CoA reductase levels in the human hepatoma cell line Hep G2.
The effect of 25-hydroxycholesterol on the regulation of apolipoprotein E mRNA levels and secretion in the human hepatoma HepG2.
The regulation of beta-hydroxy-beta-methylglutaryl coenzyme A reductase in Morris hepatomas 5123C, 7800, and 9618A.
Upregulation of low density lipoprotein receptor by gemfibrozil, a hypolipidemic agent, in human hepatoma cells through stabilization of mRNA transcripts.
[Affinity of 3-beta-(2-hydroxyethoxy)-5-alpha-cholest-8(14)-ene-15-one to oxysterol binding protein and its metabolism in HepG2 hepatoma cells]
[Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellar carcinoma].
Carcinoma, Intraductal, Noninfiltrating
The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
Carcinoma, Mucoepidermoid
Simvastatin effects on a human lung carcinoma and cholesterol homeostasis of host and non-host mice.
Carcinoma, Ovarian Epithelial
Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Impact of statin therapy on survival in epithelial ovarian cancer.
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.
Carcinoma, Renal Cell
Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes mellitus.
HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma.
Insulin-induced gene 1 (INSIG1) inhibits HIV-1 production by degrading Gag via activity of the ubiquitin ligase TRC8.
Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma.
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Cardiomegaly
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.
HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.
Involvement of peptidyl-prolyl isomerase Pin1 in the inhibitory effect of fluvastatin on endothelin-1-induced cardiomyocyte hypertrophy.
Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Matrix Metalloproteinase-2 Mediates a Mechanism of Metabolic Cardioprotection Consisting of Negative Regulation of the Sterol Regulatory Element-Binding Protein-2/3-Hydroxy-3-Methylglutaryl-CoA Reductase Pathway in the Heart.
Regulation of phospholamban and sarcoplasmic reticulum Ca2+-ATPase by atorvastatin: implication for cardiac hypertrophy.
Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors.
Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis.
Simvastatin inhibits noradrenaline-induced hypertrophy of cultured neonatal rat cardiomyocytes.
Simvastatin prevents cardiac hypertrophy in vitro and in vivo via JAK/STAT pathway.
Statin therapy for cardiac hypertrophy and heart failure.
Statins and the myocardium.
Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy.
[Simvastatin attenuates cardiovascular effects and oxidative stress induced by angiotensin II]
Cardiomyopathies
Inflammation in chronic heart failure.
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Cardiomyopathy, Hypertrophic
HMG CoA reductase inhibition and left ventricular mass in hypertrophic cardiomyopathy: a randomized placebo-controlled pilot study.
Cardiotoxicity
Lovastatin-induced cardiac toxicity involves both oncotic and apoptotic cell death with the apoptotic component blunted by both caspase-2 and caspase-3 inhibitors.
Cardiovascular Diseases
3-Hydroxy-3-methylglutaryl-coenzyme A reductase modulator: toward age- and sex-personalized medicine.
?-Cell-Specific Deletion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) Reductase Causes Overt Diabetes due to Reduction of ?-Cell Mass and Impaired Insulin Secretion.
A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats.
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.
A review of high-dose statin therapy: targeting cholesterol and inflammation in atherosclerosis.
A Review on the use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis.
An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System.
An evolutionarily-conserved promoter allele governs HMG-CoA reductase expression in spontaneously hypertensive rat.
Anti-inflammatory effect of lovastatin is mediated via the modulation of NF-?B and inhibition of HDAC1 and the PI3K/Akt/mTOR pathway in RAW264.7 macrophages.
Anti-inflammatory effects of different drugs/agents with antioxidant property on endothelial expression of adhesion molecules.
Anti-Thrombotic Effects of Statins in Acute Coronary Syndromes: At the Intersection of Thrombosis, Inflammation, and Platelet-Leukocyte Interactions.
Are High-Risk Hypertensive Patients being Prescribed Concomitant Statin Therapy?: A Retrospective Cohort Study.
Association Between Statin Use and Prevalence of Exercise-Related Injuries: A Cross-Sectional Survey of Amateur Runners in the Netherlands.
Association of race with cumulative exposure to statins in dialysis.
Atorvastatin disrupts primary human brain microvascular endothelial cell functions via prenylation-dependent mitochondrial inhibition and oxidative stress.
Atorvastatin enhances endothelial adherens junctions through promoting VE-PTP gene transcription and reducing VE-cadherin-Y731 phosphorylation.
Atorvastatin inhibited TNF-? induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF-?B signaling.
Behavioral interactions of simvastatin and fluoxetine in tests of anxiety and depression.
Bone protective effect of simvastatin in experimental arthritis.
Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.
Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors.
CE: Triglycerides: Do They Matter?
Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.
Clinical implications of pharmacogenetic variation on the effects of statins.
Clinically relevant drug interactions between statins and antidepressants.
Combination Therapy of Amlodipine and Atorvastatin Has More Beneficial Vascular Effects Than Monotherapy in Salt-Sensitive Hypertension.
Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis.
Contribution of Accelerated Degradation to Feedback Regulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Cholesterol Metabolism in the Liver.
Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR).
Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Dendrimers, Carotenoids, and Monoclonal Antibodies.
Diabetogenic effect of pravastatin is associated with insulin resistance and myotoxicity in hypercholesterolemic mice.
Direct vascular effects of HMG-CoA reductase inhibitors.
Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol.
Dyslipidemia in older adults.
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Effect of atorvastatin on high-density lipoprotein apolipoprotein A-I production and clearance in the New Zealand white rabbit.
Effect of monthly atorvastatin treatment on hemostasis.
Effect of statins on breast cancer recurrence and mortality: a review.
Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes.
Effects of simvastatin on the pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, after oral and intravenous administration in rats: possible role of P-glycoprotein and CYP3A4 inhibition by simvastatin.
Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis.
Effects of statins on the secretion of human serum albumin in cultured HepG2 cells.
Essential role of TGF-beta/Smad pathway on statin dependent vascular smooth muscle cell regulation.
Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
Ezetimibe attenuates experimental diabetes and renal pathologies via targeting the advanced glycation, oxidative stress and AGE-RAGE signalling in rats.
Functional Implications of HMG-CoA Reductase Inhibition on Glucose Metabolism.
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.
HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein-1 expression in early lesions from hypercholesterolemic swine independently of their effect on plasma cholesterol levels.
Human skeletal muscle drug transporters determine local exposure and toxicity of statins.
Identification of novel inhibitors of dietary lipid absorption using zebrafish.
Implications of recent statin trials for primary care practice.
Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care.
Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
Inflammation in atherosclerosis and psoriasis: common pathogenic mechanisms and the potential for an integrated treatment approach.
Influence of simvastatin on the thromboxane and prostacyclin pathways, in vitro and in vivo.
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.
Lipid lowering drugs in atherosclerosis--the HMG-CoA reductase inhibitors.
Lipid lowering in liver and chronic kidney disease.
Lipid-lowering therapy for the primary prevention of cardiovascular disease in the elderly: opportunities and challenges.
Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal.
Management of the Metabolic Syndrome and the Obese Patient with Metabolic Disturbances: South Asian Perspective.
Modulation of heat shock proteins by statins.
Molecular mechanisms underlying the effects of statins in the central nervous system.
Multitasking of the 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor: beyond cardiovascular diseases.
Neuroprotective Effect of Simvastatin via Inducing the Autophagy on Spinal Cord Injury in the Rat Model.
On- and Off-Target Pharmacology of Torcetrapib: Current Understanding and Implications for the Structure Activity Relationships (SAR), Discovery and Development of Cholesteryl Ester-Transfer Protein (CETP) Inhibitors.
Optimal therapy of low levels of high density lipoprotein-cholesterol.
Optimizing cardiovascular outcomes in diabetes mellitus.
Patients with abdominal aortic aneurysm: are we missing the opportunity for cardiovascular risk reduction?
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.
Pitavastatin Exerts Potent Anti-Inflammatory and Immunomodulatory Effects via the Suppression of AP-1 Signal Transduction in Human T Cells.
Platelet deposition on eroded vessel walls at a stenotic shear rate is inhibited by lipid-lowering treatment with atorvastatin.
Pleiotropic effects of HMG-CoA reductase inhibitors.
Pleiotropic effects of statins in atherosclerotic disease: focus on the antioxidant activity of atorvastatin.
Pleiotropic effects of statins on the treatment of chronic periodontitis - a systematic review.
Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
Potent suppression of proliferation of a10 vascular smooth muscle cells by combined treatment with lovastatin and 3-allylfarnesol, an inhibitor of protein farnesyltransferase.
Potential role of statin therapy in heart failure, atrial fibrillation and aortic stenosis.
Potential therapeutic role of statins in neurological disorders.
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.
Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease.
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Regulation of lipid metabolism in chicken liver by dietary cereals.
Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.
Role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, angiotensin-converting enzyme inhibitors, cyclooxygenase-2 inhibitors, and aspirin in anti-inflammatory and immunomodulatory treatment of cardiovascular diseases.
Role of bile acid sequestrants in the treatment of type 2 diabetes.
Role of C-reactive protein in cardiovascular disease.
Role of HMG-CoA Reductase Inhibitors in Neurological Disorders : Progress to Date.
Selecting methods for the prediction of future events in cost-effectiveness models: a decision-framework and example from the cardiovascular field.
Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin.
Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery.
Simvastatin enhances hippocampal long-term potentiation in C57BL/6 mice.
Simvastatin inhibits catecholamine secretion and synthesis induced by acetylcholine via blocking Na+ and Ca2+ influx in bovine adrenal medullary cells.
Simvastatin modulates remodeling of Kv4.3 expression in rat hypertrophied cardiomyocytes.
Simvastatin Suppresses Human Breast Cancer Cell Invasion by Decreasing the Expression of Pituitary Tumor-Transforming Gene 1.
Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Small GTP-binding proteins and mitogen-activated protein kinases as promising therapeutic targets of vascular remodeling.
Squalene synthase inhibitors : clinical pharmacology and cholesterol-lowering potential.
Statin mediated protection of the ischemic myocardium.
Statin therapy and myocardial no-reflow.
Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?
Statin use and breast cancer: do we need more evidence and what should this be?
Statin Use in Prostate Cancer: An Update.
Statin-Associated Necrotizing Myopathy Leading to Acute Kidney Injury: A Case Report.
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
Statins and ALS: the possible role of impaired LXR signaling.
Statins and cardioprotection - More than just lipid lowering?
Statins and Higher Diabetes Mellitus Risk: Incidence, Proposed Mechanisms and Clinical Implications.
Statins and the liver.
Statins and the Liver.
Statins and venous thromboembolism: do they represent a viable therapeutic agent?
Statins decrease neuroinflammation and prevent cognitive impairment after cerebral malaria.
Statins for the primary prevention of cardiovascular events in older adults: a review of the evidence.
Statins impact primary embryonic mouse neural stem cell survival, cell death, and fate through distinct mechanisms.
Statins impair glucose uptake in tumor cells.
Statins in acute coronary syndrome: very early initiation and benefits.
Statins in chronic kidney disease and kidney transplantation.
Statins in COPD: A Systematic Review.
Statins in the 21st century: end of the simple story?
Statins in the spectrum of neurologic disease.
Statins potently reduce the cytokine-mediated IL-6 release in SMC / MNC cocultures.
Statins' effect on plasma levels of Coenzyme Q10 and improvement in myopathy with supplementation.
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90? in human colorectal cancer.
Statins, cardiovascular disease, and drug safety.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
The beneficial effects of statins in autoimmune disease therapy.
The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review.
The effects of lipid-lowering agents on acute renal allograft rejection.
The Effects of Statin Therapy on the Human Airway.
The effects of statins on endothelium, inflammation and cardioprotection.
The Impact of Exercise on Statin-Associated Skeletal Muscle Myopathy.
The impact of statins on physical activity and exercise capacity: an overview of the evidence, mechanisms, and recommendations.
The role of HMGCR alternative splicing in statin efficacy.
The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes.
The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy.
The use of fluvastatin in cardiovascular risk management.
Therapeutic value of statins for vascular remodeling.
Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits.
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes.
[18F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats.
[HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials]
[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease]
[Inhibitors of HMG CoA reductase: new modes of action, new indications?]
[New kidney, but a sick heart. Why many patients with renal failure and kidney transplant patients die of cardiovascular disease]
[Regulatory Mechanisms and Practical Management in Vascular Calcification. Can statins slow the process of vascular calcification? Possibilities of lipid-lowering therapy and pleiotropic effect by statin treatment.]
[Statins and asthma].
Carotid Artery Diseases
Modulation of genes involved in zinc homeostasis in old low-grade atherosclerotic patients under effects of HMG-CoA reductase inhibitors.
Prevention and regression of atherosclerosis: effects of HMG-CoA reductase inhibitors.
Results of the primary outcome measure and clinical events from the Asymptomatic Carotid Artery Progression Study.
Carotid Stenosis
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy.
Cataract
Cataracts by lipid lowering drugs? Three different HMG-CoA reductase inhibitors studied in hypercholesterolemic rabbits.
Discordant expression of the sterol pathway in lens underlies simvastatin-induced cataracts in Chbb: Thom rats.
On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors.
The Polymorphism rs2968 of LSS Gene Confers Susceptibility to Age-Related Cataract.
Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens.
Central Nervous System Diseases
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of central nervous system diseases.
Functional Expression of Organic Anion Transporting Polypeptide 1a4 (Oatp1a4) is Regulated by Transforming Growth Factor-/Activin Receptor-like Kinase 1 (TGF-/ALK1) Signaling at the Blood-Brain Barrier.
Central Nervous System Neoplasms
Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.
Cerebellar Ataxia
Statin-associated cerebellar ataxia. A Brazilian case series.
Cerebral Hemorrhage
HMG-CoA reductase inhibitor, atorvastatin, promotes sensorimotor recovery, suppressing acute inflammatory reaction after experimental intracerebral hemorrhage.
Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study.
Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats.
Mechanism Study of the Protective Effects of Sodium Tanshinone IIA Sulfonate Against Atorvastatin-Induced Cerebral Hemorrhage in Zebrafish: Transcriptome Analysis.
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor simvastatin reduces thrombolytic-induced intracerebral hemorrhage in embolized rabbits.
Cerebral Infarction
Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
Neuroprotection mediated by changes in the endothelial actin cytoskeleton.
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase.
[HMG-CoA reductase inhibitor and risk of stroke]
[Statins (HMG-CoA reductase inhibitors), cholesterol and stroke]
Cerebrovascular Disorders
Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans.
Direct free radical scavenging effects of water-soluble HMG-CoA reductase inhibitors.
Epigallocatechin-3-gallate (EGCG) inhibits 3-hydroxy-3-methylglutaryl-CoA reductase in the presence of glycerol.
Regulatory properties of statins and rho gtpases prenylation inhibitiors to stimulate melanoma immunogenicity and promote anti-melanoma immune response.
Simvastatin Enhances Muscle Regeneration Through Autophagic Defect-Mediated Inflammation and mTOR Activation in G93ASOD1 Mice.
Simvastatin inhibits leukocyte-endothelial cell interactions and protects against inflammatory processes in normocholesterolemic rats.
Simvastatin treatment in surgically induced brain injury in rats.
Statins and neuroprotection: a prescription to move the field forward.
Statins therapy: a review on conventional and novel formulation approaches.
The acute (cerebro)vascular effects of statins.
Chemical and Drug Induced Liver Injury
Glycosphingolipids Prevent APAP and HMG-CoA Reductase Inhibitors-mediated Liver Damage: A Novel Method for "Safer Drug" Formulation that Prevents Drug-induced Liver Injury.
Cholangiocarcinoma
Statins induce apoptosis and inhibit proliferation in cholangiocarcinoma cells.
Cholelithiasis
Cholesterol synthesis inhibitors in cholesterol gallstone disease.
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment.
Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids.
Hepatic microsomal activities of cholesterol 7 alpha-hydroxylase and 3-hydroxy-3-methylglutaryl-CoA reductase in the prairie dog. An animal model for cholesterol gallstone disease.
Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.
Successful dissolution of cholesterol gallstone during treatment with pravastatin.
Ursodeoxycholic acid treatment in cholesterol gallstone disease: effects on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity, biliary lipid composition, and plasma lipid levels.
Cholestasis
Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy.
Synergistic role of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7alpha-hydroxylase in the pathogenesis of manganese-bilirubin-induced cholestasis in rats.
Cholesterol Ester Storage Disease
Long-term administration of the HMG-CoA reductase inhibitor lovastatin in two patients with cholesteryl ester storage disease.
Restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.
Role of lysosomal acid lipase in the metabolism of plasma low density lipoprotein. Observations in cultured fibroblasts from a patient with cholesteryl ester storage disease.
Choriocarcinoma
Regulation by plasma lipoproteins of progesterone biosynthesis and 3-hydroxy-3-methyl glutaryl coenzyme a reductase activity in cultured human choriocarcinoma cells.
Choroidal Neovascularization
Inhibition of laser-induced choroidal neovascularization by atorvastatin by downregulation of monocyte chemotactic protein-1 synthesis in mice.
Choroideremia
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Colitis
Geranylgeranyl pyrophosphate amplifies Treg differentiation via increased IL-2 expression to ameliorate DSS-induced colitis.
Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice.
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis.
Colitis, Ulcerative
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Colonic Neoplasms
Cholesterol metabolism and colon cancer.
Early induction of LDL receptor gene expression by genistein in DLD-1 colon cancer cell line.
Effect of genistein on cholesterol metabolism-related genes in a colon cancer cell line.
Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells.
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.
HMG-CoA reductase regulates CCL17-induced colon cancer cell migration via geranylgeranylation and RhoA activation.
Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth.
Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor.
Statins in the chemoprevention of colorectal cancer in established animal models of sporadic and colitis-associated cancer.
Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer.
Colorectal Neoplasms
Cardiovascular medication use and risk for colorectal cancer.
Current data with HMG-CoA reductase inhibitors (statins) for colorectal cancer prevention.
Dual Targeting of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase and Histone Deacetylase as a Therapy for Colorectal Cancer.
Enhanced 3-hydroxy-3-methyl-glutaryl coenzyme A reductase activity in human colorectal cancer not expressing low density lipoprotein receptor.
Estrogenic regulation of cholesterol biosynthesis and cell growth in DLD-1 human colon cancer cells.
Expression of miR-18a-5p, miR-144-3p, and miR-663b in colorectal cancer and their association with cholesterol homeostasis.
Expression of the low-density lipoprotein receptor, HMG-CoA reductase, and multidrug resistance (Mdr1) genes in colorectal carcinomas.
Gamma-tocopherol enhances apoptotic effects of lovastatin in human colorectal carcinoma cell line (HT29).
Genetic variation in 3-hydroxy-3-methylglutaryl CoA reductase modifies the chemopreventive activity of statins for colorectal cancer.
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2.
Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice.
Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis.
Statin use and risk of colorectal cancer in a cohort of middle-aged men in the US: a prospective cohort study.
Statin use and the risk of colorectal cancer in a population-based electronic health records study.
Statins and the colorectum: hope for chemoprevention?
Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90? in human colorectal cancer.
Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
Targeting triglyceride metabolism for colorectal cancer prevention and therapy.
The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.
Communicable Diseases
Hydroxymethylglutaryl-coenzyme A reductase inhibition stimulates caspase-1 activity and Th1-cytokine release in peripheral blood mononuclear cells.
Confusion
Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction.
Connective Tissue Diseases
Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy.
Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective.
[Necrotizing myopathies: From genetic to acquired forms.]
Corneal Dystrophies, Hereditary
Schnyder Corneal Dystrophy-Associated UBIAD1 is Defective in MK-4 Synthesis and Resists Autophagy-Mediated Degradation.
Coronary Artery Disease
"The lower the better" in hypercholesterolemia therapy: a reliable clinical guideline?.
(TTA)n polymorphism in 3-hydroxy-3-methylglutaryl-coenzyme A and response to atorvastatin in coronary artery disease patients.
Addressing the spectrum of hypercholesterolemia.
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
Atorvastatin affects leukocyte gene expression in dyslipidemia patients: in vivo regulation of hemostasis, inflammation and apoptosis.
Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease.
Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.
Coding-sequence variants are associated with blood lipid levels in 14,473 Chinese.
Cost Effectiveness of HMG-CoA Reductase Inhibitors in the Management of Coronary Artery Disease : The Problem of Under-Treatment.
Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).
Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada.
Do statins prevent heart failure in patients after myocardial infarction?
Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms.
Early introduction of HMG-CoA reductase inhibitors could prevent the incidence of transplant coronary artery disease.
Effect of Atorvastatin on Haemostasis, Fibrinolysis and Inflammation in Normocholesterolaemic Patients with Coronary Artery Disease: A Post Hoc Analysis of Data from a Prospective, Randomized, Double-Blind Study.
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial.
Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography.
Effect of pravastatin on plasma sterols and oxysterols in men.
Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
Effect of statins on atherogenic serum amyloid A and ?1-antitrypsin low-density lipoprotein complexes.
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS).
Effects of lovastatin and pravastatin on cognitive function in military aircrew.
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Effects of short-term atorvastatin treatment on global fibrinolytic capacity, and sL-selectin and sFas levels in hyperlipidemic patients with coronary artery disease.
Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial.
Efficacy of cholesterol-lowering treatment in Japanese elderly patients with coronary artery disease and normal cholesterol level using 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Endothelial progenitor cell mobilization and increased intravascular nitric oxide in patients undergoing cardiac rehabilitation.
Evaluation of the promoter polymorphism -911C>A in the 3-hydroxy-3-methylglutaryl-Coenzyme A reductase gene with coronary artery disease risk and cholesterol levels in a population from Western India.
Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy.
Ezetimibe and Vascular Inflammation.
HMG CoA reductase inhibitors are related to improved systemic endothelial function in coronary artery disease.
HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.
HMG-CoA reductase inhibitors are associated with decreased serum neopterin levels in stable coronary artery disease.
HMG-CoA Reductase Inhibitors in Chronic Heart Failure : Potential Mechanisms of Benefit and Risk.
HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
HMG-CoA reductase inhibitors reduce transplant coronary artery disease and mortality: evidence for antigen-independent mechanisms?
HMG-CoA reductase inhibitors: a look back and a look ahead.
Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease.
IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy.
Increased expression of interleukin-1 in coronary artery disease with downregulatory effects of HMG-CoA reductase inhibitors.
Induction of NAD(P)H oxidase by oxidized low-density lipoprotein in human endothelial cells: antioxidative potential of hydroxymethylglutaryl coenzyme A reductase inhibitor therapy.
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.
Likely gains in life expectancy of patients with coronary artery disease treated with HMG-CoA reductase inhibitors, as predicted by a decision analysis model.
Lipid-lowering treatment in coronary artery disease: a survey in an ambulatory outpatient clinic.
Low-density lipoprotein apheresis therapy during pregnancy.
Medical management of coronary artery disease revisited: the endothelial factor.
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin.
Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease.
Noncholesterol-lowering effects of statins.
Pathophysiology and treatment of lipid perturbation after cardiac transplantation.
Pharmacogenetics of the CD14 endotoxin receptor polymorphism and progression of coronary atherosclerosis.
Pharmacogenetics of Warfarin in a Diverse Patient Population.
Pleiotropic effects of statins on acute kidney injury: involvement of Krüppel-like factor 4.
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. Cholesterol and Recurrent Events CARE Investigators.
Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits.
Proposed synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis.
Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Provider adherence to clinical guidelines related to lipid-lowering medications.
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.
Recent Advances in the Prevention of Coronary Artery Diseases: Focus on Primary Prevention.
Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
Retardation of coronary atherosclerosis: the Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT) and other angiographic trials.
Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors.
Role of circulating lipid abnormalities in chronic renal allograft rejection.
Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients.
Statins enhance clonal growth of late outgrowth endothelial progenitors and increase myocardial capillary density in the chronically ischemic heart.
Statins in stroke: prevention, protection and recovery.
Statins, cardiovascular disease, and drug safety.
The effect of rapid lipid lowering with atorvastatin on autonomic parameters in patients with coronary artery disease.
The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS).
The effect of statin therapy on allergic patients with asthma.
The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells.
The Monitored Atherosclerosis Regression Study (MARS). Design, methods and baseline results.
The potential use of angiotensin-converting enzyme inhibitors in patients with hyperlipidemia.
The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease.
The role of statins in heart failure.
Therapeutic change of HMG-CoA reductase inhibitors in patients with coronary artery disease.
Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study.
Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy.
[Cardiologists and limitations of statins reimbursement]
[Preventive effect of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis in cholesterol-fed rabbits]
[The impact HMG-CoA reductase inhibitors in the modification of the natural history of coronary artery disease]
[The impact HMG-CoA reductase inhibitors on the modification of the natural history of coronary artery disease]
Coronary Disease
8302A/C and (TTA)n polymorphisms in the HMG-CoA reductase gene may be associated with some plasma lipid metabolic phenotypes in patients with coronary heart disease.
A preliminary study of the relationship between promoter methylation of the ABCG1, GALNT2 and HMGCR genes and coronary heart disease.
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).
Aggressive statin therapy for acute coronary syndromes.
Antioxidative effects of statins.
Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels.
Atorvastatin impairs the myocardial angiogenic response to chronic ischemia in normocholesterolemic swine.
Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal.
Beyond lipid-lowering: effects of statins on endothelial nitric oxide.
CHD: a major burden in type 2 diabetes.
Clinical pharmacokinetics of fluvastatin.
Combined QSAR model and chemical similarity search for novel HMG-CoA reductase inhibitors for coronary heart disease.
Coronary event secondary prevention with statins irrespective of LDL-cholesterol.
Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
Cost-effectiveness of primary and secondary prevention in cardiovascular diseases.
Cost-effectiveness of statins.
Debate: at what level of coronary heart disease risk should a statin be prescribed?
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials.
Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study.
Effective use of statins to prevent coronary heart disease.
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model.
Evaluation and management of lipid disorders.
From lipid locus to drug target through human genomics.
Genetic variation at the LDL receptor and HMG-CoA reductase gene loci, lipid levels, statin response, and cardiovascular disease incidence in PROSPER.
Hepatocellular Carcinoma and Statins.
HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice.
HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
HMG-CoA reductase inhibitors: issues in assessing their benefits in coronary heart disease.
Improved fibrinolysis after 1-year treatment with HMG CoA reductase inhibitors in patients with coronary heart disease.
Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease.
Intensive statin therapy in acute coronary syndromes.
Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.
Lipid and non-lipid effects of statins.
Lipid-lowering for prevention of coronary heart disease: what policy now?
Niacin or ezetimibe for patients with, or at risk of coronary heart disease.
Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors.
Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Optimal medical management of peripheral arterial disease.
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.
Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Preventive strategies for reducing coronary heart disease-related morbidity and mortality in patients with multiple risk factors.
Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin.
Proprotein convertase subtilisin/kexin type 9: an update on the cardiovascular outcome studies.
Rac1-Mediated Effects of HMG-CoA Reductase Inhibitors (Statins) in Cardiovascular Disease.
Randomized placebo-controlled study of the effects of simvastatin on haemostatic variables, lipoproteins and free fatty acids. The Oxford Cholesterol Study Group.
Reduction of serum LDL-C levels: a relationship to clinical benefits.
Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
Results of recent large cholesterol-lowering trials and implications for clinical management.
Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor Pravastatin: results of a 2-year investigation.
Statin therapy in the elderly: does it make good clinical and economic sense?
Statin treatment and progression of atherosclerotic plaque burden.
Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
Statins for cardiovascular prevention according to different strategies: a cost analysis.
Statins for primary prevention: at what coronary risk is safety assured?
Structure-based rational quest for potential novel inhibitors of human HMG-CoA reductase by combining CoMFA 3D QSAR modeling and virtual screening.
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
The effects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease.
The Lescol(R) Intervention Prevention Study (LIPS): a double-blind, placebo-controlled, randomized trial of the long-term effects of fluvastatin after successful transcatheter therapy in patients with coronary heart disease.
The management of cholesterol in coronary heart disease risk reduction.
What do the statins tell us?
Withdrawal of statins increases event rates in patients with acute coronary syndromes.
[Combined therapy with cholestyramine and HMG-CoA reductase inhibitors in secondary prevention of coronary disease]
[Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin]
[HMG-CoA reductase inhibitors for prevention and treatment of coronary heart disease. Effective reduction of cardiac events and mortality]
[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease]
[Pharmacoeconomic analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy for the secondary prevention of coronary heart disease]
[The role of cholesterol-lowering drugs in prevention of coronary heart disease]
Coronary Restenosis
Inhibition of human vascular smooth muscle cell proliferation by lovastatin: the role of isoprenoid intermediates of cholesterol synthesis.
Coronary Stenosis
Positron emission tomography and the changing paradigm in coronary artery disease.
Cough
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
COVID-19
Scientific Rationale for a Bottom-Up Approach to Target the Host Response in Order to Try and Reduce the Numbers Presenting With Adult Respiratory Distress Syndrome Associated With COVID-19. Is There a Role for Statins and COX-2 Inhibitors in the Prevention and Early Treatment of the Disease?
The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents.
Cystic Fibrosis
Mechanistic similarities between cultured cell models of cystic fibrosis and niemann-pick type C.
Death, Sudden, Cardiac
Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect?
Deglutition Disorders
[A 81-year old man of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy associated with lung adenocarcinoma cancer].
Dehydration
Effect of prolonged water stress on essential oil content, compositions and gene expression patterns of mono- and sesquiterpene synthesis in two oregano (Origanum vulgare L.) subspecies.
Role of phytosterols in drought stress tolerance in rice.
Delirium
Statins and delirium: is there a role?
Dementia
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Conversion of mild cognitive impairment to dementia among subjects with diabetes: a population-based study of incidence and risk factors with five years of follow-up.
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Non-atheroprotective effects of statins: a systematic review.
Risk factors for dementia in patients over 65 with diabetes.
Risk factors for dementia with type 2 diabetes mellitus among elderly people in China.
The Effect of HMG: CoA Reductase Inhibitors on Cognition in Patients With Alzheimer's Dementia: A Prospective Withdrawal and Rechallenge Pilot Study.
The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia.
Dementia, Vascular
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Demyelinating Diseases
Tellurium causes dose-dependent coordinate down-regulation of myelin gene expression.
Dengue
The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity.
Dermatitis, Phototoxic
Pitavastatin, a new HMG-CoA reductase inhibitor, induces phototoxicity in human keratinocytes NCTC-2544 through the formation of benzophenanthridine-like photoproducts.
The phototoxicity of fluvastatin, an HMG-CoA reductase inhibitor, is mediated by the formation of a benzocarbazole-like photoproduct.
Dermatomyositis
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.
[Pravastatin-induced dermatomyositis]
Diabetes Mellitus
Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus.
Association of plasma sphingomyelin levels and incident coronary heart disease events in an adult population: Multi-Ethnic Study of Atherosclerosis.
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Cost Effectiveness of HMG-CoA Reductase Inhibitors in the Management of Coronary Artery Disease : The Problem of Under-Treatment.
Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.
Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes.
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
Efficacy and safety of statins in the treatment of diabetic dyslipidemia.
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Ezetimibe attenuates experimental diabetes and renal pathologies via targeting the advanced glycation, oxidative stress and AGE-RAGE signalling in rats.
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.
Hydroxy-methylglutaryl-coenzyme A reductase inhibition improves endothelial dysfunction in type-1 diabetes.
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Lipids and stroke: the opportunity of lipid-lowering treatment.
Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus.
Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.
Recrudescence of Old Stroke Deficits Among Transient Neurological Attacks.
Reduced incidence of new-onset diabetes mellitus after renal transplantation with 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors (statins).
REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia.
Risk Factor for Diabetes Mellitus and High Blood Glucose With HMG-CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in Japan.
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Serum soluble CD36, assessed by a novel monoclonal antibody-based sandwich ELISA, predicts cardiovascular mortality in dialysis patients.
Simvastatin treatment of hypercholesterolemia in patients with insulin dependent diabetes mellitus.
The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients.
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
[HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ]
Diabetes Mellitus, Experimental
Influence of streptozotocin diabetes on intestinal 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in the rat.
Diabetes Mellitus, Type 1
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
High-dose atorvastatin is associated with lower IGF-1 levels in patients with type 1 diabetes.
The protective effect of simvastatin against low dose streptozotocin induced type 1 diabetes in mice is independent of inhibition of HMG-CoA reductase.
Diabetes Mellitus, Type 2
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes.
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.
An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.
Association of Genetically Enhanced Lipoprotein Lipase-Mediated Lipolysis and Low-Density Lipoprotein Cholesterol-Lowering Alleles With Risk of Coronary Disease and Type 2 Diabetes.
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
Dose-dependent effect of hydroxymethylglutaryl-coenzyme A reductase inhibitor on serum cholesterol with limited dietary restrictions: a case study.
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus.
Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM.
Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes.
Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia.
Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients.
HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus.
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.
Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
Lipids and stroke: the opportunity of lipid-lowering treatment.
Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus.
Management of dyslipidemia in NIDDM.
Oxidized-LDL levels are changed during short-term serum glucose variations and lowered with statin treatment in early Type 2 diabetes: a study of endothelial function and microalbuminuria.
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.
Pharmaco-economic impact of HMG-CoA reductase inhibitors in type 2 diabetes.
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention.
Randomized trial of atorvastatin in improving endothelial function in diabetics without prior coronary disease and having average cholesterol level.
Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS).
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Should the insulin resistance syndrome be treated in the elderly?
Systemic administration of HMG-CoA reductase inhibitor protects the blood-retinal barrier and ameliorates retinal inflammation in type 2 diabetes.
The antiviral effect of metformin on zika and dengue virus infection.
The Association of 3-Hydroxy-3-Methylglutaryl-CoA Reductase, Apolipoprotein E, and Solute Carrier Organic Anion Genetic Variants with Atorvastatin Response among Jordanian Patients with Type 2 Diabetes.
The effects of pemafibrate in Japanese patients with type 2 diabetes receiving HMG-CoA reductase inhibitors.
The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins.
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Treatment of dyslipidemia in non-insulin-dependent diabetes mellitus with lovastatin.
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Diabetic Angiopathies
Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
Diabetic Foot
Dendrimers, Carotenoids, and Monoclonal Antibodies.
Diabetic Nephropathies
3-Hydroxy-3-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway: Implications for diabetic nephropathy.
Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus.
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Diabetic nephropathy. Its relationship to hypertension and means of pharmacological intervention.
Effect of atorvastatin on aldosterone production induced by glucose, LDL or angiotensin II in human renal mesangial cells.
HMG-CoA reductase inhibitor ameliorates diabetic nephropathy by its pleiotropic effects in rats.
Income-related differences in the use of evidence-based therapies in older persons with diabetes mellitus in for-profit managed care.
Mechanism of preventive effect of HMG-CoA reductase inhibitor on diabetic nephropathy.
Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies.
Renoprotective effects of combining ACE inhibitors and statins in experimental diabetic rats.
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Diabetic Neuropathies
Neuronal nitric oxide synthase mediates statin-induced restoration of vasa nervorum and reversal of diabetic neuropathy.
Diabetic Retinopathy
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Choroideremia: molecular mechanisms and development of AAV gene therapy.
High vitreous concentration of vascular endothelial growth factor in diabetic patients with proliferative retinopathy using statins.
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy.
Drug Eruptions
Lichenoid drug eruption with HMG-CoA reductase inhibitors (fluvastatin and lovastatin).
Pravastatin-induced lichenoid drug eruption.
Drug-Related Side Effects and Adverse Reactions
Detection and incidence of muscular adverse drug reactions: a prospective analysis from laboratory signals.
Genetic Assessment of Potential Long-Term On-Target Side Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors.
HMG-CoA reductase inhibitors and myotoxicity.
HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles.
Judicious evaluation of adverse drug reactions: inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury.
Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity.
Simvastatin-induced lactic acidosis: a rare adverse reaction?
Dwarfism
Altering potato isoprenoid metabolism increases biomass and induces early flowering.
Dyskinesias
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.
Dyslipidemias
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin.
A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.
A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin.
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence.
Acrolein-induced dyslipidemia and acute-phase response are independent of HMG-CoA reductase.
Ameliorative role of Atorvastatin and Pitavastatin in L-Methionine induced vascular dementia in rats.
Are all statins the same?: focus on the efficacy and tolerability of pitavastatin.
ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Case Report: Various Abnormalities in Lipid and Glucose Metabolism Induced by Capecitabine.
Chlorogenic acid-enriched extract from Eucommia ulmoides leaves inhibits hepatic lipid accumulation through regulation of cholesterol metabolism in HepG2 cells.
Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
Comparison of the efficacy and safety of pravastatin and simvastatin in heart transplantation.
Cost-effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD.
Cross-talk between dyslipidemia and renin-angiotensin system and the role of LOX-1 and MAPK in atherogenesis studies with the combined use of rosuvastatin and candesartan.
Degradation versus Inhibition: Development of Proteolysis-Targeting Chimeras for Overcoming Statin-Induced Compensatory Upregulation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase.
Diabetes and metabolic syndrome (MS).
Dyslipidemia and coronary artery disease.
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Dyslipidemia Part 2: Review of Dyslipidemia Treatment in Patients With Noncoronary Vascular Disease.
Dyslipidemias and HMG-CoA reductase inhibitor prescription in heart transplant recipients.
Dyslipidemias in diabetic patients. Is standard cholesterol treatment appropriate?
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
Effect of fluvastatin on lipoprotein profiles in treating renal transplant recipients with dyslipoproteinemia.
Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.
Effects of prickly pear dried leaves, artichoke leaves, turmeric and garlic extracts, and their combinations on preventing dyslipidemia in rats.
Effects of Talinum triangulare leaf flavonoid extract on streptozotocin-induced hyperglycemia and associated complications in rats.
Evidence of combined therapy of dyslipoproteinemia by HMG-CoA reductase inhibitors and "essential" phospholipids.
Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
Genetic Contribution of Variants near SORT1 and APOE on LDL Cholesterol Independent of Obesity in Children.
Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.
Hepatocellular Carcinoma and Statins.
High Maternal Serum Estradiol Levels Induce Dyslipidemia in Human Newborns via a Hepatic HMGCR Estrogen Response Element.
High-Efficacy ?,?-Dehydromonacolin S Improves Hepatic Steatosis and Suppresses Gluconeogenesis Pathway in High-Fat Diet-Induced Obese Rats.
Human proximal tubular epithelium actively secretes but does not retain rosuvastatin.
Implications of recent statin trials for primary care practice.
Influence of simvastatin on the thromboxane and prostacyclin pathways, in vitro and in vivo.
Inhibitory effects of IFN-gamma on HIV-1 replication in latently infected cells.
Interactions between grapefruit juice and cardiovascular drugs.
Investigations of statins in heart failure: inflammatory biomarkers and hormones.
Lipid-lowering medications for children and adolescents.
Low-density lipoprotein apheresis as a treatment option for hyperlipidemia.
Management of diabetic dyslipidemia: need for reappraisal of the goals.
Management of dyslipidemia in adults.
Managing dyslipidemia in chronic kidney disease.
Medicinal plants and bioactive natural compounds as inhibitors of HMG-CoA reductase: A literature review.
Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.
Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.
Myopathy associated with atorvastatin-ezetimibe combination therapy.
Novel Phenoxazinones as potent agonist of PPAR-?: design, synthesis, molecular docking and in vivo studies.
Optimizing cardiovascular outcomes in diabetes mellitus.
Pathogenesis and management of diabetic dyslipidemia.
Periodontal infection and dyslipidemia in type 2 diabetics: association with increased HMG-CoA reductase expression.
Pharmacokinetic and pharmacodynamic interaction of Rosuvastatin calcium with guggulipid extract in rats.
Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers.
Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10-mg tablets: A single-dose, randomized-sequence, open-label, two-period crossover study in healthy fasted Chinese adult males.
Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Pitavastatin: a new HMG-CoA reductase inhibitor.
Potential Correlation between Statins and Pulp Chamber Calcification.
Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
Prevention of atherosclerosis in diabetes: emphasis on treatment for the abnormal lipoprotein metabolism of diabetes.
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Retrospective, Observation Study: Quantitative and Qualitative Effect of Ezetimibe and HMG-CoA Reductase Inhibitors on LDL-Cholesterol: Are There Disappearance Thresholds for Small, Dense LDL and IDL?
Rosuvastatin for the treatment of hypercholesterolemia.
Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
Rosuvastatin: a review of its effect on atherosclerosis.
Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway.
Severe Rhabdomyolysis Associated With Concurrent Use of Simvastatin and Sirolimus After Cisplatin-Based Chemotherapy in a Kidney Transplant Recipient.
Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin.
Simvastatin evokes an unpredicted inhibition of ?-adrenoceptor-mediated vasodilatation in porcine coronary artery.
Statin use and cognitive changes in elderly patients with dementia.
Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong.
Statins in oncological research: from experimental studies to clinical practice.
The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
The effect of rosuvastatin treatment on the mean platelet volume in patients with uncontrolled primary dyslipidemia with hypolipidemic diet treatment.
The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.
The interaction of fluvastatin and cyclosporin A in renal transplant patients.
The Pleiotropic Effects of Statins in Endocrine Disorders.
The potential behavioral and economic impacts of widespread HMG-CoA reductase inhibitor (statin) use.
The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
The Risk of Rosacea According to Chronic Diseases and Medications: A 5-Year Retrospective, Multi-Institutional Case-Control Study.
Therapeutic value of statins for vascular remodeling.
Treatment of Alport syndrome: beyond animal models.
Treatment of diabetic dyslipidemia.
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in various forms of dyslipidemia.
Vascular disease and lipids in diabetes.
[A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism].
[Diabetes and multimetabolic syndrome]
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]
[Effect of the brand and generic medicine of pravastatin on dyslipidemia in rabbits fed a high cholesterol diet]
[Fixed combination atorvastatin-perindopril (Lipercosyl®) for substitution treatment of cardiovascular risk management].
[Lipid-lowering therapy in the prevention of coronary heart disease]
[Statin pharmacokinetics]
[Statins in the management of acute coronary syndrome]
[The treatment of refractory hyperlipoproteinemias]
[Treatment of dyslipidemia of the elderly with simvastatin and pravastatin. Effectiveness and tolerance]
[UPDATED ISRAELI GUIDELINES FOR THE TREATMENT OF DYSLIPIDEMIA 2020].
Encephalomyelitis
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.
Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction.
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
Immunomodulatory effect of combination therapy with lovastatin and 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside alleviates neurodegeneration in experimental autoimmune encephalomyelitis.
Inhibition of phosphoinositide 3 kinase-Akt (protein kinase B)-nuclear factor-kappa B pathway by lovastatin limits endothelial-monocyte cell interaction.
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Therapeutic Impact of Sphingosine 1-phosphate Receptor Signaling in Multiple Sclerosis.
Endometrial Neoplasms
Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer.
Endometriosis
Resveratrol potentiates effect of simvastatin on inhibition of mevalonate pathway in human endometrial stromal cells.
Eosinophilia
Adverse effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors associated with elevated serum IgE and eosinophilia.
Ependymoma
Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.
Epilepsy
Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders.
The association between antiepileptic drug and HMG-CoA reductase inhibitor co-medication and cholesterol management in patients with epilepsy.
The Effect of Statins in Epilepsy: A Systematic Review.
Use of antiepileptic drugs and lipid-lowering agents in the United States.
Erectile Dysfunction
Comment: HMG-CoA reductase inhibitor-induced impotence.
HMG CoA Reductase Inhibitors and Impotence: Two Case Series from the Spanish and French Drug Monitoring Systems.
HMG-CoA reductase inhibitor-induced impotence.
Esophageal Squamous Cell Carcinoma
HMGCR is necessary for the tumorigenecity of esophageal squamous cell carcinoma and is regulated by Myc.
SREBP2 is upregulated in esophageal squamous cell carcinoma and co?operates with c?Myc to regulate HMGCR expression.
Essential Hypertension
Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation.
Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
Effects of combined statin and ACE inhibitor therapy on endothelial function and blood pressure in essential hypertension - a randomised double-blind, placebo controlled crossover study.
Effects of pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on glucose tolerance in patients with essential hypertension.
Functional promoter polymorphisms govern differential expression of HMG-CoA reductase gene in mouse models of essential hypertension.
Exanthema
Generalized eczematous skin rash possibly due to HMG-CoA reductase inhibitors.
Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors.
[Dermatomyositis-like syndrome revealing statin-induced necrotizing autoimmune myopathy with anti-HMGCR antibodies].
Eye Diseases
Therapeutic potential of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors for the treatment of retinal and eye diseases.
Fatigue Syndrome, Chronic
Hypothalamic digoxin, cerebral chemical dominance and myalgic encephalomyelitis.
Fatty Liver
Ameliorative potential of omega 3 fatty acids and HMG-CoA reductase inhibitors on experimentally-induced non-alcoholic steatohepatitis.
Attenuation of fatty liver and prevention of hypercholesterolemia by extract of Curcuma longa through regulating the expression of CYP7A1, LDL-receptor, HO-1, and HMG-CoA reductase.
Feeding induces cholesterol biosynthesis via the mTORC1-USP20-HMGCR axis.
Inhibition of Adenosine Monophosphate-Activated Protein Kinase-3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Signaling Leads to Hypercholesterolemia and Promotes Hepatic Steatosis and Insulin Resistance.
Liver biochemistry abnormalities in a quaternary care lipid clinic database.
miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
Oxysterols and alcoholic liver disease.
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia.
Pyrazinamide alleviates rifampin-induced steatohepatitis in mice by regulating the activities of cholesterol-activated 7?-hydroxylase and lipoprotein lipase.
Rhesus monkey model of liver disease reflecting clinical disease progression and hepatic gene expression analysis.
Rice bran enzymatic extract reduces atherosclerotic plaque development and steatosis in high-fat fed ApoE-/- mice.
Sulfated polysaccharides from Enteromorpha prolifera suppress SREBP-2 and HMG-CoA reductase expression and attenuate non-alcoholic fatty liver disease induced by a high-fat diet.
Suppression of hepatic HMG-CoA reductase activity by beta-muricholic acid in mice fed a diet containing cholesterol and cholic acid.
[Study on lipid-lowering mechanism of active peptide DP17 from Eupolyphaga steleophaga in hyperlipidemia rats].
Fatty Liver, Alcoholic
Protective effect of Codonopsis lanceolata root extract against alcoholic fatty liver in the rat.
Fibrosarcoma
Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells.
Tissue selective drug delivery utilizing carrier-mediated transport systems.
Fragile X Syndrome
The genetics of mental retardation.
Gallstones
3-hydroxy-3-methylglutaryl coenzyme A reductase in human liver microsomes: active and inactive forms and cross-reactivity with antibody against rat liver enzyme.
Aging per se is an independent risk factor for cholesterol gallstone formation in gallstone susceptible mice.
Antilithiasic effect of beta-cyclodextrin in LPN hamster: comparison with cholestyramine.
Biliary lipid synthesis and secretion in gallstone patients before and during treatment with chenodeoxycholic acid.
Cholesterol metabolism in human gallbladder mucosa: relationship to cholesterol gallstone disease and effects of chenodeoxycholic acid and ursodeoxycholic acid treatment.
Cholesterol synthesis inhibition distal to squalene upregulates biliary phospholipid secretion and counteracts cholelithiasis in the genetically prone C57L/J mouse.
Cholesterol synthesis inhibitors in cholesterol gallstone disease.
Circulating markers for biosynthesis of cholesterol and bile acids are not depressed in asymptomatic gallstone subjects.
Deoxycholic acid treatment in patients with cholesterol gallstones: failure to detect a suppression of cholesterol 7alpha-hydroxylase activity.
Dietary cholesterol affects chenodeoxycholic acid action on biliary lipids.
Dissolution of cholesterol gallstones by bile acids in hamsters.
Dissolution of gallstones with simvastatin, an HMG CoA reductase inhibitor.
Effect of chenodeoxycholic acid and phenobarbital on the rate-limiting enzymes of hepatic cholesterol and bile acid synthesis in patients with gallstones.
Effects of bezafibrate on hepatic cholesterol metabolism.
Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.
Effects of short-term treatment with pravastatin on the hepatic synthesis of cholesterol and bile acids in gallstone patients.
Effects of simvastatin and cholestyramine on bile lipid composition and gall bladder motility in patients with hypercholesterolaemia.
Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones.
Hepatic 3-hydroxy-3-methylglutaryl CoA reductase activity in hamsters on a lithogenic diet.
Hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and biliary lipid composition in man: relation to cholesterol gallstone disease and effects of cholic acid and chenodeoxycholic acid treatment.
Hepatic cholesterol and bile acid metabolism in subjects with gallstones: comparative effects of short erm feeding of chenodeoxycholic and ursodeoxycholic acid.
Hepatic cholesterol and bile acid synthesis in Japanese patients with cholesterol gallstones.
Hepatic cholesterol metabolism in obesity: activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Hepatic cholesterol metabolism in patients with cholesterol gallstones: enhanced intracellular transport of cholesterol.
Hepatic cholesterol metabolism in patients with gallstones.
Hepatic expression of cholesterol regulating genes favour increased circulating low-density lipoprotein in HIV infected patients with gallstone disease: a preliminary study.
Hepatic HMGCoA reductase in human cholelithiasis: effects of chenodeoxycholic and ursodeoxycholic acids.
Hepatic microsomal activities of cholesterol 7 alpha-hydroxylase and 3-hydroxy-3-methylglutaryl-CoA reductase in the prairie dog. An animal model for cholesterol gallstone disease.
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Intrahepatic biliary cholesterol and phospholipid transport in humans: effect of obesity and cholesterol cholelithiasis.
Lack of response to chenodeoxycholic acid in obese and non-obese patients. Role of cholesterol synthesis and possible response to ursodeoxycholic acid.
Protective Effects of Yinchenhao Decoction on Cholesterol Gallstone in Mice Fed a Lithogenic Diet by Regulating LXR, CYP7A1, CYP7B1, and HMGCR Pathways.
Regulation of hepatic cholesterol metabolism in humans: stimulatory effects of cholestyramine on HMG-CoA reductase activity and low density lipoprotein receptor expression in gallstone patients.
Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.
Rowachol and ursodeoxycholic acid in hamsters with cholesterol gallstones.
Simvastatin, a competitive inhibitor of HMG-CoA reductase, lowers cholesterol saturation index of gallbladder bile.
Therapeutic Reflections In Cholesterol Homeostasis And Gallstone Disease. A Review.
Treatment with the natural FXR agonist chenodeoxycholic acid reduces clearance of plasma LDL whilst decreasing circulating PCSK9, lipoprotein(a) and apolipoprotein C-III.
[Experimental study on hepatic HMG-CoA reductase activity in relation to the formation and dissolution of cholesterol gallstones (author's transl)]
Gastroesophageal Reflux
Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori?
Glaucoma
The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
Glaucoma, Open-Angle
The Relationship Between Statin Use and Open-Angle Glaucoma.
Glioblastoma
Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
HMG-CoA reductase inhibition causes increased necrosis and apoptosis in an in vivo mouse glioblastoma multiforme model.
HMGCR positively regulated the growth and migration of glioblastoma cells.
Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells.
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Glioma
Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action?
Artesunate inhibits the mevalonate pathway and promotes glioma cell senescence.
HMG CoA reductase inhibitors, NSAIDs and risk of glioma.
In vitro and in vivo antiproliferative effects of simvastatin, an HMG-CoA reductase inhibitor, on human glioma cells.
Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse?
Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells.
Regulation of sterol synthesis and of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lipoproteins in glial cells in primary culture.
Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells.
Glomerulonephritis
Effect of simvastatin on proliferative nephritis and cell-cycle protein expression.
Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group.
Statins and progressive renal disease.
Glomerulonephritis, IGA
Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria.
Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy.
Statins and progressive renal disease.
Glomerulonephritis, Membranous
Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
Glucose Intolerance
Effects of pravastatin on progression of glucose intolerance and cardiovascular remodeling in a type II diabetes model.
HMG-CoA reductase inhibitors do not improve glucose intolerance in spontaneously diabetic Goto-Kakizaki rats.
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes.
glucose-6-phosphate dehydrogenase (nadp+) deficiency
Gene-nutrient interactions in G6PD-deficient subjects--implications for cardiovascular disease susceptibility.
Glucosephosphate Dehydrogenase Deficiency
Gene-nutrient interactions in G6PD-deficient subjects--implications for cardiovascular disease susceptibility.
Goiter
HMG-CoA reductase inhibitors inhibit rat propylthiouracil-induced goiter by modulating the ras-MAPK pathway.
Graft vs Host Disease
Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by Th-2 polarization while sparing graft-versus-leukemia activity.
The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation.
Treatment of Dyslipidemia in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Gynecomastia
Golf-inhibiting gynecomastia associated with atorvastatin therapy.
Statin medications and the risk of gynecomastia.
Statin-associated gynecomastia: evidence coming from the Italian spontaneous ADR reporting database and literature.
Hearing Loss
Fluvastatin protects cochleae from damage by high-level noise.
Irreversible atorvastatin-associated hearing loss.
Hearing Loss, Sensorineural
Possible role of HMG-CoA reductase inhibitors for the treatment of sudden sensorineural hearing loss (SSHL).
Heart Diseases
Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment.
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
Development of thyroid follicular adenoma on simvastatin therapy.
HMG-CoA reductase inhibitors in the prevention of stroke.
Impact of statins on novel risk markers.
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
The promoter of the rat 3-hydroxy-3-methylglutaryl coenzyme A reductase gene contains a tissue-specific estrogen-responsive region.
[Early statin treatment in acute coronary syndrome. Is this evidence-based?]
Heart Failure
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the development of cardiac hypertrophy and heart failure in rats.
Beneficial effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardiac function in ischemic and nonischemic heart failure.
Case Report: Immune Mediated Necrotizing Myopathy With IgG Antibodies to 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase (HMGCR) May Present With Acute Systolic Heart Failure.
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Do statins have a role in the management of diastolic dysfunction?
Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms.
HMG-CoA Reductase Inhibitors in Chronic Heart Failure : Potential Mechanisms of Benefit and Risk.
Impact of Statin Therapy on Clinical Outcomes in Chronic Heart Failure Patients According to Beta-Blocker Use: Results of CIBIS II.
Inflammation in chronic heart failure.
Lipid-lowering drugs and heart failure: where do we go after the statin trials?
Mitochondrial protection by simvastatin against angiotensin II-mediated heart failure.
Neutral effect on markers of heart failure, inflammation, endothelial activation and function, and vagal tone after high-dose HMG-CoA reductase inhibition in non-diabetic patients with non-ischemic cardiomyopathy and average low-density lipoprotein level.
Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
Potential autonomic nervous system effects of statins in heart failure.
Potential role of statins in the treatment of heart failure.
Provider adherence to clinical guidelines related to lipid-lowering medications.
Short-term effects of atorvastatin in normal dogs and dogs with congestive heart failure due to myxomatous mitral valve disease.
Simvastatin normalizes autonomic neural control in experimental heart failure.
Statin therapy for cardiac hypertrophy and heart failure.
Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients.
Statins and left ventricular function.
Statins and the myocardium.
Synergistic effect of combined HMG-CoA reductase inhibitor and angiotensin-II receptor blocker therapy in patients with chronic heart failure: the HF-COSTAR trial.
Synergistic effects of HMG-CoA reductase inhibitor and angiotensin II receptor blocker on load-induced heart failure.
The nutritional and metabolic support of heart failure in the intensive care unit.
The role of statin therapy in the management of cardiomyopathies.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Variation in Generic Drug Manufacturers' Product Characteristics.
Heart Failure, Systolic
Case Report: Immune Mediated Necrotizing Myopathy With IgG Antibodies to 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase (HMGCR) May Present With Acute Systolic Heart Failure.
Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure.
Hemangioma, Cavernous, Central Nervous System
The 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) pathway regulates developmental cerebral-vascular stability via prenylation-dependent signalling pathway.
Hematologic Neoplasms
HMG-CoA reductase inhibitors as adjuvant treatment for hematologic malignancies: what is the current evidence?
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Hemorrhagic Stroke
Prevention of stroke and dementia with statins: Effects beyond lipid lowering.
Hepatitis
Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin.
Cholesterol-induced stimulation of postinflammatory liver fibrosis.
Simvastatin-induced lactic acidosis: a rare adverse reaction?
Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature.
[A one-year prospective and intensive pharmacovigilance of antilipemic drugs in an hospital consultation for prevention of risk factors]
[Acute cholestatic hepatitis after atorvastatin reintroduction.]
Hepatitis C
Anti-ulcer agent teprenone inhibits hepatitis C virus replication: potential treatment for hepatitis C.
Dihydroquercetin: More than just an impurity?
Do statins reduce hepatitis C RNA titers during routine clinical use?
Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: Results from ERCHIVES.
Pharmacokinetic Evaluation of the Interaction Between the HCV Protease Inhibitor Boceprevir and the HMG-CoA Reductase Inhibitors Atorvastatin and Pravastatin.
Hepatitis C, Chronic
Do statins reduce hepatitis C RNA titers during routine clinical use?
Hepatitis, Autoimmune
HMG CoA reductase inhibitor associated myositis and autoimmune hepatitis.
Hepatoblastoma
Growth requirements and expression of LDL receptor and HMG-CoA reductase in Hep G2 hepatoblastoma cells cultured in a chemically defined medium.
Mevalonic acid is limiting for N-linked glycosylation and translocation of the insulin-like growth factor-1 receptor to the cell surface. Evidence for a new link between 3-hydroxy-3-methylglutaryl-coenzyme a reductase and cell growth.
The effect of HMG-CoA reductase inhibitor (CS-514) on the synthesis and secretion of apolipoproteins B and A-1 in the human hepatoblastoma Hep G2.
The molecular mechanism of the induction of the low density lipoprotein receptor by chenodeoxycholic acid in cultured human cells.
Herpes Zoster
Differential ACTH response of immunodetectable HMG CoA reductase and cytochromes P450(17 alpha) and P450(21) in guinea pig adrenal outer zone cell types, zona glomerulosa and zona fasciculata.
Histiocytoma, Malignant Fibrous
Malignant fibrous histiocytoma of visceral organs: clinicopathologic features and diagnostic value of ezrin and HMG-CoA reductase.
HIV Infections
Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.
Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection.
Homozygous Familial Hypercholesterolemia
Biologically active low density lipoprotein in human peripheral lymph.
Early-onset plasmapheresis and LDL-apheresis provide better disease control for pediatric homozygous familial hypercholesterolemia than HMG-CoA reductase inhibitors and ameliorate atherosclerosis.
In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Decreased enzyme catalytic efficiency in familial hypercholesterolemia.
Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia.
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and the esterification of cholesterol in human long term lymphoid cell lines.
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.
Huntington Disease
Cholesterol synthesis in cultured skin fibroblasts from patients with Huntington's disease.
Hyperalgesia
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
RhoA/Rho kinase pathway contributes to the pathogenesis of thermal hyperalgesia in diabetic mice.
Hypercholesterolemia
'Muscle-sparing' statins: preclinical profiles and future clinical use.
3-Hydroxy-3-methylglutaryl coenzyme A reductase deregulation and age-related hypercholesterolemia: a new role for ROS.
3-Hydroxy-3-methylglutaryl coenzyme A reductase regulation by antioxidant compounds: new therapeutic tools for hypercholesterolemia?
3-Hydroxyl-3-methylglutaryl-coenzyme A reductase is up regulated in hepatocellular carcinoma associated with paraneoplastic hypercholesterolemia.
A case of ezetimibe-effective hypercholesterolemia with a novel heterozygous variant in ABCG5.
A comparison of continuous combined hormone replacement therapy, HMG-CoA reductase inhibitor and combined treatment for the management of hypercholesterolemia in postmenopausal women.
A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: the pravastatin anti-atherosclerosis trial in the elderly (PATE).
A controlled trial of pravastatin vs probucol in the treatment of primary hypercholesterolemia.
A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia.
A novel role for thyroid-stimulating hormone: up-regulation of hepatic 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase expression through the cyclic adenosine monophosphate/protein kinase A/cyclic adenosine monophosphate-responsive element binding protein pathway.
A pharmacokinetic drug-drug interaction model of simvastatin and verapamil in humans.
A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
A randomized placebo controlled trial on the effects of simvastatin, a HMG-CoA reductase inhibitor, on blood lipids and fibrinolytic parameters.
A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.
A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism.
A review of current clinical findings with fluvastatin.
A Review on the use of Statins and Tocotrienols, Individually or in Combination for the Treatment of Osteoporosis.
Acute P-407 administration to mice causes hypercholesterolemia by inducing cholesterolgenesis and down-regulating low-density lipoprotein receptor expression.
Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
Adverse effects of long-term exposure to bisphenol A during adulthood leading to hyperglycaemia and hypercholesterolemia in mice.
Age-Related Hypercholesterolemia and HMG-CoA Reductase Dysregulation: Sex Does Matter (A Gender Perspective).
An In Vitro and Molecular Informatics Study to Evaluate the Antioxidative and ?-hydroxy-?-methylglutaryl-CoA Reductase Inhibitory Property of Ficus virens Ait.
Angiotensin II-induced oxidative burst is fluvastatin sensitive in neutrophils of patients with hypercholesterolemia.
Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
Antihypercholesterolemic and antiatherosclerotic potencies of Pandanus tectorius fruits via increasing scavenger receptor-B1 genes expression and inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity.
Astragalus polysaccharides lowers plasma cholesterol through mechanisms distinct from statins.
Atorvastatin affects TLR4 clustering via lipid raft modulation.
Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia.
Atorvastatin attenuates neuropathic pain in rat neuropathy model by down-regulating oxidative damage at peripheral, spinal and supraspinal levels.
Atorvastatin attenuation of ABCB1 expression is mediated by microRNA miR-491-3p in Caco-2 cells.
Atorvastatin induced hepatic oxidative stress and apoptotic damage via MAPKs, mitochondria, calpain and caspase12 dependent pathways.
Atorvastatin induces mitochondrial dysfunction and cell apoptosis in HepG2 cells via inhibition of the Nrf2 pathway.
Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients With Hypercholesterolemia.
Attenuation of fatty liver and prevention of hypercholesterolemia by extract of Curcuma longa through regulating the expression of CYP7A1, LDL-receptor, HO-1, and HMG-CoA reductase.
Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
Biphasic influence of pravastatin on human cardiac microvascular endothelial cell functions under pathological and physiological conditions.
Blocking 3-hydroxy-3-methylglutaryl coenzyme A reductase with ML-236B enhances the plasma cortisol response to adrenocorticotropin in patients with hypercholesterolemia.
Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Caloric restrictions affect some factors involved in age-related hypercholesterolemia.
Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia.
Cerivastatin in primary hyperlipidemia--a multicenter analysis of efficacy and safety.
Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
Cerivastatin, a New Potent Synthetic HMG Co-A Reductase Inhibitor: Effect of 0.2 mg Daily in Subjects With Primary Hypercholesterolemia.
Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis.
Cholesterol and bile acid synthesis during total parenteral nutrition with and without lipid emulsion in the rat.
Cholesterol synthesis inhibitors do not reduce Lp(a) levels in normocholesterolemic patients.
Cholesterol-lowering effect of mevinolin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme a reductase, in healthy volunteers.
Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.
Chronokinetics of Pravastatin Administered in the PM Compared with AM Dosing.
Clinical effects of rosuvastatin, a new HMG-CoA reductase inhibitor, in Japanese patients with primary hypercholesterolemia: an early phase II study.
Colesevelam hydrochloride.
Collision-induced dissociation of the negative ions of simvastatin hydroxy acid and related species.
Combination drug therapy with HMG CoA reductase inhibitors and bile acid sequestrants for hypercholesterolemia.
Combination therapy in cholesterol reduction: focus on ezetimibe and statins.
Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial.
Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.
Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia.
Comparison of Transcriptomic Profiles of MiaPaCa-2 Pancreatic Cancer Cells Treated with Different Statins.
Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects.
Concomitant administration of simvastatin and danazol associated with fatal rhabdomyolysis.
Contribution of increased HMG-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure.
Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Cost-effectiveness of initial therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to treat hypercholesterolemia in a primary care setting of a managed-care organization.
Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans.
Design and recruitment in the United States of a multicenter quantitative angiographic trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I).
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Diabetes and metabolic syndrome (MS).
Diabetogenic effect of pravastatin is associated with insulin resistance and myotoxicity in hypercholesterolemic mice.
Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis.
Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin.
Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.
Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: A bench-to-bedside case study on tissue selective drug distribution.
Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
Disulfiram-associated hypercholesterolemia.
Diverse effects of statins on angiogenesis: new therapeutic avenues.
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease.
Dysfunction of vascular smooth muscle and vascular remodeling by simvastatin.
Early response of hyperlipidemic subjects to simvastatin.
Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
Effect of HMG-CoA reductase inhibitor on plasma cholesteryl ester transfer protein activity in primary hypercholesterolemia: comparison among CETP/TaqIB genotype subgroups.
Effect of low-dose simvastatin on cholesterol levels, oxidative susceptibility, and antioxidant levels of low-density lipoproteins in patients with hypercholesterolemia: a pilot study.
Effect of pravastatin on plasma ketone bodies in diabetics with hypercholesterolemia.
Effect of ScrF I polymorphism in the 2nd intron of the HMGCR gene on lipid-lowering response to simvastatin in Chinese diabetic patients.
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia.
Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects.
Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients.
Effects of fluvastatin, an HMG-CoA reductase inhibitor, on serum levels of interleukin-18 and matrix metalloproteinase-9 in patients with hypercholesterolemia.
Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
Effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits and cholesterol-fed rabbits.
Effects of low-dose simvastatin therapy on serum lipid levels in patients with moderate hypercholesterolemia: a 12-month study. The Simvastatin Study Group.
Effects of simvastatin and cholestyramine in familial and nonfamilial hypercholesterolemia. Multicenter Group I.
Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients.
Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
Effects of treatment with lovastatin and pravastatin on daytime cognitive performance.
Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
Effects of vitamin E and HMG-CoA reductase inhibition on cholesteryl ester transfer protein and lecithin-cholesterol acyltransferase in hypercholesterolemia.
Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia.
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study.
Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. II. Once-daily versus twice-daily dosing.
Efficacy and short-term effects of pravastatin, a potent inhibitor of HMG-Co A reductase, on hypercholesterolemia in climacteric women.
Efficacy of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in the treatment of patients with hypercholesterolemia: a meta-analysis of clinical trials.
Efficacy of simvastatin for lowering cholesterol in non-insulin dependent diabetic patients with hypercholesterolemia.
Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors.
Endothelium modulates contractile response to simvastatin in rat aorta.
Enhanced hypercholesterolemia therapy: the ezetimibe/simvastatin tablet.
Enhancement of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor efficacy through administration of a controlled-porosity osmotic pump dosage form.
Epigallocatechin-3-gallate (EGCG) inhibits 3-hydroxy-3-methylglutaryl-CoA reductase in the presence of glycerol.
Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage).
Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humans.
Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia.
Ezetimibe + simvastatin (Merck/Schering-Plough).
Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin.
Fluvastatin alters platelet aggregability in patients with hypercholesterolemia: possible improvement of intraplatelet redox imbalance via HMG-CoA reductase.
Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide.
Fluvastatin: effects beyond cholesterol lowering.
Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure.
Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
Growth inhibition of Candida species and Aspergillus fumigatus by statins.
Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase inhibitor pravastatin.
Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome.
Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis.
HMG CoA reductase inhibitors: new horizons in the management of hypercholesteremia. XIth Congress of the European Society of Cardiology. Nice, France, September 10-14, 1989.
HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit.
HMG-CoA reductase inhibitor pharmacogenomics: overview and implications for practice.
HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein.
HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis.
HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia.
HMG-CoA reductase inhibitors for hypercholesterolemia.
HMG-CoA reductase inhibitors for treatment of hypercholesterolemia.
HMG-CoA reductase inhibitors. A new approach to the management of hypercholesterolemia.
HMG-CoA reductase inhibitors: a look back and a look ahead.
HMG-CoA reductase inhibitory activity and phytocomponent investigation of Basella alba leaf extract as a treatment for hypercholesterolemia.
HMG-CoA reductase, cholesterol 7alpha-hydroxylase, LCAT, ACAT, LDL receptor, and SRB-1 in hereditary analbuminemia.
HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation.
Hypercholesterolemia and 3-hydroxy-3-methylglutaryl coenzyme A reductase regulation in aged female rats.
Hypercholesterolemia of copper deficiency is linked to glutathione metabolism and regulation of hepatic HMG-CoA reductase.
Hypercholesterolemia, HMG-CoA reductase inhibitors, and risk of intracerebral hemorrhage: a case-control study.
Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors.
Hypolipidemic effects of HMG-CoA reductase inhibitors in patients with hypercholesterolemia.
In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Decreased enzyme catalytic efficiency in familial hypercholesterolemia.
Increased rate of cholesterologenesis--a possible cause of hypercholesterolemia in experimental chronic renal failure in rats.
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.
Increased superoxide anion production by platelets in hypercholesterolemic patients.
Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Influence of cholesterol supply on cell growth and differentiation in cultured enterocytes (CaCo-2).
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
Inhibition of prenyltransferase activity by statins in both liver and muscle cell lines is not causative of cytotoxicity.
Inhibition of Rab1 GTPase and endoplasmic reticulum-to-Golgi trafficking underlies statin's toxicity in rat skeletal myofibers.
Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia.
Interaction of cytosine arabinoside and lovastatin in human leukemia cells.
Interactions of platelets, macrophages, and lipoproteins in hypercholesterolemia: antiatherogenic effects of HMG-CoA reductase inhibitor therapy.
Involvement of interleukin-1 in lead nitrate-induced hypercholesterolemia in mice.
Involvement of multiple transporters in the efflux of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors across the blood-brain barrier.
Is there a role for the adrenals in the development of hypercholesterolemia in Zucker fatty rats?
Isorhamnetin derivatives and piscidic acid for hypercholesterolemia: cholesterol permeability, HMG-CoA reductase inhibition, and docking studies.
Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.
LDL-cholesterol lowering effect of a generic product of simvastatin compared to simvastatin (Zocor) in Thai hypercholesterolemic subjects -- a randomized crossover study, the first report from Thailand.
Lead nitrate-induced development of hypercholesterolemia in rats: sterol-independent gene regulation of hepatic enzymes responsible for cholesterol homeostasis.
Lipid-lowering medications.
Lipid-lowering response of the HMG-CoA reductase inhibitor fluvastatin is influenced by polymorphisms in the low-density lipoprotein receptor gene in Brazilian patients with primary hypercholesterolemia.
Local Application of Pyrophosphorylated Simvastatin Prevents Experimental Periodontitis.
Long-term effects of pravastatin on serum lipid levels in elderly patients with hypercholesterolemia.
Long-term safety and efficacy profile of simvastatin.
Long-term treatment (2 years) with the HMG CoA reductase inhibitors lovastatin or pravastatin in combination with cholestyramine in patients with severe primary hypercholesterolemia.
Lovastatin induced Kruppel like factor 2 (
Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.
Lovastatin production: From molecular basis to industrial process optimization.
Lovastatin-induced apoptosis in macrophages through the Rac1/Cdc42/JNK pathway.
Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro.
Low-density lipoprotein apheresis therapy during pregnancy.
Low-dose effect of simvastatin (MK-733) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia.
Management of hyperlipidemia: goals for the prevention of atherosclerosis.
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.
Mevalonate cascade and its regulation in cholesterol metabolism in different tissue in health and disease.
Mikania micrantha Extract Inhibits HMG-CoA Reductase and ACAT2 and Ameliorates Hypercholesterolemia and Lipid Peroxidation in High Cholesterol-Fed Rats.
Modified HMG-CoA reductase and LDLr regulation is deeply involved in age-related hypercholesterolemia.
Modulation of 3-hydroxy-3-methylglutaryl-CoA reductase gene expression by CuZn superoxide dismutase in human fibroblasts and HepG2 cells.
Modulation of hypercholesterolemia-induced alterations in apolipoprotein B and HMG-CoA reductase expression by selenium supplementation.
National Drug Formulary review of statin therapeutic group using the multiattribute scoring tool.
New concepts of mechanisms of intestinal cholesterol absorption.
New drugs for treating hypercholesterolemia and other hyperlipidaemias--the HMG CoA reductase inhibitors.
New insights into the genetic regulation of intestinal cholesterol absorption.
Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review.
Nutrition classics. Proceedings of the National Academy of Sciences of the United States of America, Volume 71, 1974: Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. By Michael S. Brown and Joseph L. Goldstein.
Omega-3 as well as caloric restriction prevent the age-related modifications of cholesterol metabolism.
Operational aspects of terminating the doxazosin arm of The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Opposing effects of dietary sugar and saturated fat on cardiovascular risk factors and glucose metabolism in mitochondrially impaired mice.
Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice.
Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers.
Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.
Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin.
Pharmacotherapy of dyslipidemia.
Photostability of pitavastatin-A novel HMG-CoA reductase inhibitor.
Phytoconstituents of an ethanolic pod extract of Prosopis cineraria triggers the inhibition of HMG-CoA reductase and the regression of atherosclerotic plaque in hypercholesterolemic rabbits.
Pitavastatin Exerts Potent Anti-Inflammatory and Immunomodulatory Effects via the Suppression of AP-1 Signal Transduction in Human T Cells.
Pitavastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Plasma and thrombocyte levels of coenzyme Q10 in children with Smith-Lemli-Opitz syndrome (SLOS) and the influence of HMG-CoA reductase inhibitors.
Plasma lipoproteins and cholesterol metabolism in Yoshida rats: an animal model of spontaneous hyperlipemia.
Pleiotropic effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: candidate mechanisms for anti-lipid deposition in blood vessels.
Pleiotropic effects of statins on the treatment of chronic periodontitis - a systematic review.
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Polymorphisms in the mitochondrial ribosome recycling factor EF-G2mt/MEF2 compromise cell respiratory function and increase atorvastatin toxicity.
Potential role of nonstatin cholesterol lowering agents.
Potential roles for statins in critically ill patients.
Potential use of HMG-CoA reductase inhibitors (statins) as radioprotective agents.
Preventive effect of MK-733 (simvastatin), an inhibitor of HMG-CoA reductase, on hypercholesterolemia and atherosclerosis induced by cholesterol feeding in rabbits.
Primary prevention: Do the very elderly require a different approach?
Proprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseases.
Protective effect of arjunolic acid against atorvastatin induced hepatic and renal pathophysiology via MAPK, mitochondria and ER dependent pathways.
Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects).
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor.
Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis.
Regulation and degradation of HMGCo-A reductase.
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.
Regulation of hepatic cholesterol biosynthesis by berberine during hyperhomocysteinemia.
Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Role of lipoprotein-X in the pathogenesis of cholestatic hypercholesterolemia. Uptake of lipoprotein-X and its effect on 3-hydroxy-3-methylglutaryl coenzyme A reductase and chylomicron remnant removal in human fibroblasts, lymphocytes, and in the rat.
Role of statins in the treatment of multiple sclerosis.
Rosuvastatin for the treatment of hypercholesterolemia.
Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia.
Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes.
Selenoproteins, cholesterol-lowering drugs, and the consequences: revisiting of the mevalonate pathway.
Short-term effects of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor on cholesterol and bile acid synthesis in humans.
Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment.
Simvastatin and lovastatin inhibit breast cell invasion induced by H-Ras.
Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia.
Simvastatin increases excitability in the hippocampus via a PI3 kinase-dependent mechanism.
Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3? phosphorylation.
Simvastatin inhibits glucose metabolism and legumain activity in human myotubes.
Simvastatin inhibits growth via apoptosis and the induction of cell cycle arrest in human melanoma cells.
Simvastatin retards progression of retinopathy in diabetic patients with hypercholesterolemia.
Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.
Simvastatin-mediated enhancement of long-term potentiation is driven by farnesyl-pyrophosphate depletion and inhibition of farnesylation.
Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.
Statin mediated protection of the ischemic myocardium.
Statin therapy reduces the mycobacterium tuberculosis burden in human macrophages and in mice by enhancing autophagy and phagosome maturation.
Statin Use in Prostate Cancer: An Update.
Statin-associated myopathy and its exacerbation with exercise.
Statin-dependent modulation of mitochondrial metabolism in cancer cells is independent of cholesterol content.
Statin-mediated cholesterol depletion exerts coordinated effects on the alterations in rat vascular smooth muscle cell biomechanics and migration.
Statins and renal diseases: from primary prevention to renal replacement therapy.
Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.
Statins may ameliorate pulmonary hypertension via RhoA/Rho-kinase signaling pathway.
Stimulation of rat liver 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity by o,p'-DDD.
Structural mechanism for statin inhibition of HMG-CoA reductase.
Structure-Based Design and Screen of Novel Inhibitors for Class II 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase from Streptococcus Pneumoniae.
Substituted pyrazoles as hepatoselective HMG-CoA reductase inhibitors: discovery of (3R,5R)-7-[2-(4-fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2H-pyrazol-3-yl]-3,5-dihydroxyheptanoic acid (PF-3052334) as a candidate for the treatment of hypercholesterolemia.
Successful dissolution of cholesterol gallstone during treatment with pravastatin.
Suppression of mevalonate pathway activities by dietary isoprenoids: protective roles in cancer and cardiovascular disease.
Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer.
Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
The antioxidant effect of lovastatin on phagocyte-induced DNA damage: implications for cancer prevention.
The beneficial effects of statins in autoimmune disease therapy.
The cost effectiveness of statin therapies in Spain in 2010, after the introduction of generics and reference prices.
The effect of fluvastatin on fibrinolytic factors in patients with hypercholesterolemia.
The effects of age and gender on the relationship between HMGCR promoter-911 SNP (rs33761740) and serum lipids in patients with coronary heart disease.
The Effects of HMG-CoA Reductase Inhibitors on Endothelial Function.
The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity.
The relationship between HMGCR genetic variation, alternative splicing, and statin efficacy.
The role of colesevelam hydrochloride in hypercholesterolemia and type 2 diabetes mellitus.
The role of low density lipoprotein apheresis in the treatment of familial hypercholesterolemia.
The use of colesevelam hydrochloride in the treatment of dyslipidemia: a review.
The use of simvastatin, an HMG CoA reductase inhibitor, in older patients with hypercholesterolemia and atherosclerosis.
Therapeutic effects of ML-236B in primary hypercholesterolemia.
Therapeutic response to lovastatin (mevinolin) in nonfamilial hypercholesterolemia. A multicenter study. The Lovastatin Study Group II.
Therapeutic targets of hypercholesterolemia: HMGCR and LDLR.
Therapy of severe familial heterozygous hypercholesterolemia by low-density lipoprotein apheresis with immunoadsorption: effects of the addition of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors to therapy.
Thyroid-Stimulating Hormone Decreases HMG-CoA Reductase Phosphorylation via AMP-Activated Protein Kinase in the liver.
Torcetrapib + atorvastatin (Pfizer).
Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
Treatment of hypercholesterolemia with the HMG CoA reductase inhibitor, simvastatin.
Treatment of hyperlipidemia in human renal disease.
Update on Statins: Hope for Osteoporotic Fracture Healing Treatment.
Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients.
Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
Volumetric assessment of plaque progression with 3-dimensional ultrasonography under statin therapy.
[A comparative long-term trial of sodium cerivastatin, a new HMG-CoA reductase inhibitor, in patients presenting with primary hypercholesterolemia]
[Characteristics of a statine of the most recent generation]
[Cholesterol absorption as a target for the treatment of hypercholesterolemia]
[Combined therapy with cholestyramine and HMG-CoA reductase inhibitors in secondary prevention of coronary disease]
[Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia]
[Diabetes and multimetabolic syndrome]
[Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988]
[Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients]
[HMG-CoA reductase inhibitors: anti-atherosclerotic effects other than lipid-lowering]
[Hypolipidemic drugs--ileal Na+/bile acid cotransporter inhibitors (S-8921 etc)]
[Lipid status and basal steroid hormone level following 16 weeks of lovastatin therapy in primary hypercholesterolemia]
[New kidney, but a sick heart. Why many patients with renal failure and kidney transplant patients die of cardiovascular disease]
[New perspectives in the control of hypercholesterolemia with the use of HMG CoA reductase inhibitors]
[New strategies in treatment of severe hypercholesterolemia in coronary patients: HMG-CoA reductase inhibitors and H.E.L.P.-LDL apheresis]
[Personal experience with lovastatin, a HMG-CoA reductase inhibitor (Mevacor, MSD) in the treatment of hypercholesterolemia]
[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors]
[Simvastatin (MK-733), a new HMG-CoA reductase inhibitor, in the treatment of hypercholesterolemia in elderly patients with atherosclerosis]
[Statins: possibly more than just lowering of the lipid level]
[Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia]
[The effects of plasma cholesterol reduction on vasoconstriction due to sympathetic activation in patients with moderate primary hypercholesterolemia]
[The long-term effect of HMG-CoA reductase inhibitor to the hypercholesterolemia in the climacterium and its endocrinological change]
[Therapy of hypercholesterolemia after heart transplantation with the HMG-CoA reductase inhibitor simvastatin in long-term follow-up]
Hyperglycemia
?-Cell-Specific Deletion of HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) Reductase Causes Overt Diabetes due to Reduction of ?-Cell Mass and Impaired Insulin Secretion.
Effects of Talinum triangulare leaf flavonoid extract on streptozotocin-induced hyperglycemia and associated complications in rats.
Glycation and HMG-CoA Reductase Inhibitors: Implication in Diabetes and Associated Complications.
Lipid partitioning after uninephrectomy.
Optimizing cardiovascular outcomes in diabetes mellitus.
Pre-germinated brown rice extract ameliorates high-fat diet-induced metabolic syndrome.
Risk Factor for Diabetes Mellitus and High Blood Glucose With HMG-CoA Reductase Inhibitors Using a Postmarketing Surveillance Database in Japan.
The Effect of Statins on the No-Reflow Phenomenon: An Observational Study in Patients with Hyperglycemia before Primary Angioplasty.
Hyperhomocysteinemia
Fluvastatin ameliorates the hyperhomocysteinemia-induced endothelial dysfunction: the antioxidative properties of fluvastatin.
The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet.
Hyperinsulinism
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Hexosamine Biosynthesis Impairs Insulin Action via a Cholesterolgenic Response.
Opposing effects of dietary sugar and saturated fat on cardiovascular risk factors and glucose metabolism in mitochondrially impaired mice.
The effects of insulin on plasma mevalonate concentrations in man.
Hyperkalemia
Hyperkalemia during treatment with HMG-CoA reductase inhibitor.
Hyperlipidemia, Familial Combined
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.
Hyperlipidemias
A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
A Multicenter Prospective Hospital-based Cohort Study on the Efficacy and Safety of Pitavastatin.
A new TCM formula FTZ lowers serum cholesterol by regulating HMG-CoA reductase and CYP7A1 in hyperlipidemic rats.
A perinatal strategy to prevent coronary heart disease.
A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin.
An update on LDL apheresis for nephrotic syndrome.
Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
Antihyperlipidemic and Hepatoprotective Properties of Vitamin B6 Supplementation in Rats with High-Fat Diet-Induced Hyperlipidemia.
Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient.
Are all statins the same?: focus on the efficacy and tolerability of pitavastatin.
Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice.
Attenuation of plasma low density lipoprotein cholesterol by select 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in mice devoid of low density lipoprotein receptors.
Beneficial Effects of SREBP Decoy Oligodeoxynucleotide in an Animal Model of Hyperlipidemia.
Cassia auriculata flower extract attenuates hyperlipidemia in male Wistar rats by regulating the hepatic cholesterol metabolism.
CE: Triglycerides: Do They Matter?
Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia.
Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison.
Combined treatment with low-dose pravastatin and fish oil in post-renal transplantation dislipidemia.
Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins.
Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor therapy in the managed care era.
Discovery of an orally active VHL-recruiting PROTAC that achieves robust HMGCR degradation and potent hypolipidemic activity in vivo.
Do statins have a role in the management of diastolic dysfunction?
Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease.
Drug treatment of combined hyperlipidemia.
Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression.
Effect of a HMG-CoA reductase inhibitor combined with hormone replacement therapy on lipid metabolism in Japanese women with hypoestrogenic lipidemia: a multicenter double-blind controlled prospective study.
Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia.
Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors.
Effect of geraniol, a plant derived monoterpene on lipids and lipid metabolizing enzymes in experimental hyperlipidemic hamsters.
Effect of HMG-CoA (3-hydroxy-3-methylglutaryl-CoA) reductase inhibitors on the concentration of insulin-like growth factor-1 (IGF-1) in hypercholesterolemic patients.
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Effect of in utero exposure of Toddy (coconut palm wine) on liver function and lipid metabolism in rat fetuses.
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.
Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia.
Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Effect of the polyphenol-rich extract from Allium cepa on hyperlipidemic sprague-dawley rats.
Effects of an HMG-CoA reductase inhibitor, pravastatin, and bile sequestering resin, cholestyramine, on plasma plant sterol levels in hypercholesterolemic subjects.
Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes.
Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
Effects of Honey on Postprandial Hyperlipidemia and Oxidative Stress in Wistar Rats: Role of HMG-CoA Reductase Inhibition and Antioxidant Effect.
Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats.
Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography. The Canadian Coronary Atherosclerosis Intervention Trial.
Effects of oral selenium and magnesium co-supplementation on lipid metabolism, antioxidative status, histopathological lesions, and related gene expression in rats fed a high-fat diet.
Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome.
Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia.
Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia.
Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Energy replacement using glucose does not increase postprandial lipemia after moderate intensity exercise.
Evaluation of DNA damage in Wistar rat tissues with hyperlipidemia induced by tyloxapol.
Extracellular and Intracellular Polysaccharide Extracts of Trametes versicolor Improve Lipid Profiles Via Serum Regulation of Lipid-Regulating Enzymes in Hyperlipidemic Mice.
Extract of Wax Gourd Peel Prevents High-Fat Diet-Induced Hyperlipidemia in C57BL/6 Mice via the Inhibition of the PPAR? Pathway.
Ezetimibe in Renal Transplant Patients with Hyperlipidemia Resistant to HMG-CoA Reductase Inhibitors.
Fabrication and Appraisal of Simvastatin via Tailored Niosomal Nanovesicles for Transdermal Delivery Enhancement: In Vitro and In Vivo Assessment.
Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats.
Genetic variants influencing lipid levels and risk of dyslipidemia in Chinese population.
HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells.
HMG CoA reductase inhibitors (statins) for dialysis patients.
HMG CoA reductase inhibitors and the skeleton: a comprehensive review.
HMG CoA reductase inhibitors for treatment of hyperlipidemia.
HMG-CoA reductase inhibitor cerivastatin prolonged rat cardiac allograft survival by blocking intercellular signals.
HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia.
Hyperlipidemia: effective disease management with a focus on PCSK9 inhibitors.
Hypolipidemic mechanisms of Ananas comosus L. leaves in mice: different from fibrates but similar to statins.
Impact of prescription size on statin adherence and cholesterol levels.
Improvement of hyperlipidemia by aerobic exercise in mice through a regulatory effect of miR-21a-5p on its target genes.
Influence of large molecular polymeric pigments isolated from fermented Zijuan tea on the activity of key enzymes involved in lipid metabolism in rat.
Interactive and Multifactorial Mechanisms of Calcific Vascular and Valvular Disease.
Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.
Kakkalide and irisolidone: HMG-CoA reductase inhibitors isolated from the flower of Pueraria thunbergiana.
Liver biochemistry abnormalities in a quaternary care lipid clinic database.
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
Managed care trends in statin usage.
Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Managing hyperlipidemia: current and future roles of HMG-CoA reductase inhibitors.
Metabolomics study of the therapeutic mechanism of Schisandra Chinensis lignans in diet-induced hyperlipidemia mice.
Methanolic Extract of Piper sarmentosum Attenuates Obesity and Hyperlipidemia in Fructose-Induced Metabolic Syndrome Rats.
Novel anti-obesity effect of scutellarein and potential underlying mechanism of actions.
Pharmacoeconomic analysis of hypertriglyceridemia treatment at medical institutions.
Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers.
Pharmacological cholesterol depletion disturbs ciliogenesis and ciliary function in developing zebrafish.
Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Pitavastatin calcium: clinical review of a new antihyperlipidemic medication.
Pitavastatin Nissan/Kowa Yakuhin/Novartis/Sankyo.
Pitavastatin: a new 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia.
Pitavastatin: a new HMG-CoA reductase inhibitor.
Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review.
Pleiotropic effects of the HMG-CoA reductase inhibitors.
Postprandial dyslipidemia: an atherogenic disorder common in patients with diabetes mellitus.
Potential roles for statins in critically ill patients.
Prenatal exposure of an alcoholic beverage (Arrack) on fetal lipid metabolism in rats.
Protection against osteoporosis by statins is linked to a reduction of oxidative stress and restoration of nitric oxide formation in aged and ovariectomized rats.
Protective role of puerarin on lead-induced alterations of the hepatic glutathione antioxidant system and hyperlipidemia in rats.
Randomized comparative study of the effects of treatment with once-daily, niacin extended-release/lovastatin and with simvastatin on lipid profile and fibrinolytic parameters in taiwan.
Recrudescence of Old Stroke Deficits Among Transient Neurological Attacks.
Regulation of osteoclast differentiation by statins.
Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy.
Rice bran enzymatic extract reduces atherosclerotic plaque development and steatosis in high-fat fed ApoE-/- mice.
Role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors ("statins") in familial combined hyperlipidemia.
Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection.
Selected statins produce rapid spinal motor neuron loss in vitro.
Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery.
Simvastatin (MK 733): an effective treatment for hypercholesterolemia.
Simvastatin protects osteoblast against H2O2-induced oxidative damage via inhibiting the upregulation of Nox4.
Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient.
Spiny keratoderma: a common under-reported dermatosis.
Statin therapy: not just used to lower cholesterol?
Statin use and uterine fibroid risk in hyperlipidemia patients: a nested case-control study.
Statins and liver toxicity: a meta-analysis.
Strategies for minimizing hyperlipidemia after cardiac transplantation.
The effects of berberine on hyperhomocysteinemia and hyperlipidemia in rats fed with a long-term high-fat diet.
The effects of pravastatin on hyperlipidemia in renal transplant recipients.
The HMG-CoA Reductase Pathway, Statins and Angioprevention.
The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke.
The Relationship Between Statin Use and Open-Angle Glaucoma.
The spectrum of statin hepatotoxicity: Experience of the drug induced liver injury network.
Topical application of statin affects bone healing around implants.
Treatment of severe nephrotic syndrome.
Treatment with cerivastatin in primary mixed hyperlipidemia induces changes in platelet aggregation and coagulation system components.
Use of antiepileptic drugs and lipid-lowering agents in the United States.
Use of atorvastatin in hyperlipidemic hypertensive renal transplant recipients.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
Usefulness of HMG-CoA reductase inhibitor in Japanese hyperlipidemic women within seven years of menopause.
Validated LC-MS/MS method for simultaneous determination of SIM and its acid form in human plasma and cell lysate: Pharmacokinetic application.
Vertical bone augmentation with fluvastatin in an injectable delivery system: a rat study.
[A case of drug-induced pneumonia possibly associated with simvastatin]
[Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias]
[Correction of atherogenic exogenously-induced postprandial hyperlipidemia with pravastatin]
[Effect of leech on lipid metabolism and liver in hyperlipidemia rats].
[Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)]
[Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome]
[Etiology of Secondary Hyperlipidemia and Abnormalities of Lipid Laboratory Tests -Chairmen's Introductory Remarks -].
[HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ]
[Mechanisms of statin nephroprotective actions]
[Pravastatin vs. probucol in the treatment of hypercholesterolemia. A double-blind study]
[Study on anti-hyperlipidemia mechanism of high frequency herb pairs by molecular docking method].
[Study on lipid-lowering traditional Chinese medicines based on pharmacophore technology and patent retrieval].
[Treatment of hyperlipidemia with HMG-CoA reductase inhibitors]
Hyperlipoproteinemia Type II
Abnormal induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase in leukocytes from subjects with heterozygous familial hypercholesterolemia.
Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia.
Cholesterol homeostasis in mononuclear leukocytes from patients with familial hypercholesterolemia treated with lovastatin.
Contribution of the WHHL rabbit, an animal model of familial hypercholesterolemia, to elucidation of the anti-atherosclerotic effects of statins.
Effect of HMG-CoA reductase inhibitors on red blood cell membrane lipids and haemorheological parameters, in patients affected by familial hypercholesterolemia.
Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. 1981.
Effects of atorvastatin on electrophoretic characteristics of LDL particles among subjects with heterozygous familial hypercholesterolemia.
Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.
Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.
Effects of pravastatin on lipid transfer protein and lecithin cholesterol acyltransferase in heterozygous familial hypercholesterolemia.
Familial defective apolipoprotein B-100 is clinically indistinguishable from familial hypercholesterolemia.
Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity.
Familial hypercholesterolemia: identification of a defect in the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity associated with overproduction of cholesterol.
Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients.
Genetic determinants of responsiveness to the HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia.
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Hypocholesterolemic effects of mevinolin in patients with heterozygous familial hypercholesterolemia.
In vivo regulation of human mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase. Decreased enzyme catalytic efficiency in familial hypercholesterolemia.
Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on corticosteroid metabolism in patients with heterozygous familial hypercholesterolemia.
Influence of mevinolin on metabolism of low density lipoproteins in primary moderate hypercholesterolemia.
Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase by mevinolin in familial hypercholesterolemia heterozygotes: effects on cholesterol balance.
Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia.
LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.
Metabolism of low-density lipoproteins by cultured hepatocytes from normal and homozygous familial hypercholesterolemic subjects.
Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia.
Nutrition classics. Proceedings of the National Academy of Sciences of the United States of America, Volume 71, 1974: Familial hypercholesterolemia: defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. By Michael S. Brown and Joseph L. Goldstein.
Reappraisal of partial ileal bypass for the treatment of familial hypercholesterolemia.
Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia. Additive effects of compactin and cholestyramine.
Regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured human fibroblasts. Comparison of cells from a normal subject and from a patient with homozygous familial hypercholesterolemia.
Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion ("French Canadian mutation") of the LDL receptor gene.
Restoration of a regulatory response to low density lipoprotein in acid lipase-deficient human fibroblasts.
Role of rs3846662 and HMGCR alternative splicing in statin efficacy and baseline lipid levels in familial hypercholesterolemia.
Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations.
Simvastatin (MK 733) in heterozygous familial hypercholesterolemia: a two-year trial.
Targeted prevention of coronary artery disease: pharmacological considerations in multimodality treatment.
The effect of mevinolin on steroidogenesis in patients with defects in the low density lipoprotein receptor pathway.
The influence of mevinolin on the adrenal cortical response to corticotropin in heterozygous familial hypercholesterolemia.
The influence of simvastatin on adrenal corticosteroid production and urinary mevalonate during adrenocorticotropin stimulation in patients with heterozygous familial hypercholesterolemia.
The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia.
Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system.
Use of mutant fibroblasts in the analysis of the regulation of cholesterol metabolism in human cells.
[Effect of atorvastatin on endothelial function in patients with familial hypercholesterolemia]
[Effects of simvastatin on plasma lipids, lipoproteins and apoproteins (A1 and B). 24 cases of major primary hypercholesterolemia]
[Familial hypercholesterolemia--intensive diet therapy combined with drug therapy]
[HMG-CoA reductase inhibitors in familial hypercholesterolemia. Therapy with simvastatin alone and in combination with cholestyramine in low dosage; a report of 2 years experiences]
[Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia]
Hyperlipoproteinemia Type III
Effect of simvastatin treatment on the dyslipoproteinemia in CAPD patients.
Hyperlipoproteinemias
3-Hydroxy-3-methylglutaryl coenzyme A reductase activity in the human gastrointestinal tract.
Chronic treatment with fluvastatin improves smooth muscle dilatory function in genetically determined hyperlipoproteinemia.
Comparison of different HMG-CoA reductase inhibitors.
Drug therapy of severe hypercholesterolemia in patients with coronary artery disease.
Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia.
Fenofibrate treatment inhibits HMG-CoA reductase activity in mononuclear cells from hyperlipoproteinemic patients.
HMG-CoA reductase inhibitors: an exciting development in the treatment of hyperlipoproteinemia.
Inhibition of HMG-CoA reductase in mononuclear cells during gemfibrozil treatment.
Inhibition of HMG-CoA reductase with cerivastatin lowers dense low density lipoproteins in patients with elevated fasting glucose, impaired glucose tolerance and type 2 diabetes mellitus.
[HMG-CoA reductase inhibitor for therapy of patients with hyperlipoproteinemia ]
Hyperpigmentation
Artemisinic acid inhibits melanogenesis through downregulation of C/EBP ?-dependent expression of HMG-CoA reductase gene.
Hypersensitivity
Drug Allergies Documented in Electronic Health Records of a Large Healthcare System.
Pleiotropic phenotypes caused by an opal nonsense mutation in an essential gene encoding HMG-CoA reductase in fission yeast.
[Polymyositis induced or associated with lipid-lowering drugs: five cases]
Hypertension
A pharmacokinetic and pharmacodynamic drug interaction between rosuvastatin and valsartan in healthy subjects.
A rationale for combined therapy with a calcium channel blocker and a statin: evaluation of basic and clinical evidence.
An evolutionarily-conserved promoter allele governs HMG-CoA reductase expression in spontaneously hypertensive rat.
Anomalous AMPK-regulated angiotensin AT1R expression and SIRT1-mediated mitochondrial biogenesis at RVLM in hypertension programming of offspring to maternal high fructose exposure.
Anti-lipid deposition effect of HMG-CoA reductase inhibitor, pitavastatin, in a rat model of hypertension and hypercholesterolemia.
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Contribution of vascular NAD(P)H oxidase to endothelial dysfunction in heart failure and the therapeutic effects of HMG-CoA reductase inhibitor.
Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.
Effect of atorvastatin on endothelial function and inflammation in long-duration type 1 diabetic patients without coronary heart disease and arterial hypertension.
Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension.
Effects of atorvastatin, amlodipine, and their combination on vascular dysfunction in insulin-resistant rats.
Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.
HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species.
HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension.
Interactions between the single nucleotide polymorphisms in the homocysteine pathway (MTHFR 677C>T, MTHFR 1298 A>C, and CBSins) and the efficacy of HMG-CoA reductase inhibitors in preventing cardiovascular disease in high-risk patients of hypertension: the GenHAT study.
Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27Kip1-independent pathway.
Model of genetic and environmental factors associated with type 2 diabetes mellitus in a Chinese Han population.
Neuroprotective and anti-inflammatory activities of atorvastatin in a rat chronic constriction injury model.
Niacin improves renal lipid metabolism and slows progression in chronic kidney disease.
Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers.
Post-transplant diabetes mellitus: risk reduction strategies in the elderly.
Racial differences in compliance with NCEP-II recommendations for secondary prevention at a Veterans Affairs medical center.
Recent clinical trial highlights in hypertension.
Recrudescence of Old Stroke Deficits Among Transient Neurological Attacks.
Scientific Rationale for a Bottom-Up Approach to Target the Host Response in Order to Try and Reduce the Numbers Presenting With Adult Respiratory Distress Syndrome Associated With COVID-19. Is There a Role for Statins and COX-2 Inhibitors in the Prevention and Early Treatment of the Disease?
Scientific rationale for combination of a calcium channel antagonist and an HMG-CoA reductase inhibitor: a new approach to risk factor management.
Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress.
Simvastatin reverses target organ damage and oxidative stress in Angiotensin II hypertension: comparison with apocynin, tempol, and hydralazine.
Spiny keratoderma: a common under-reported dermatosis.
Sympathoinhibition by Atorvastatin in Hypertensive Patients.
The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia.
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
[Prevention of the manifestation of diabetes in the elderly in the presymptomatic stage]
[Simvastatin attenuates cardiovascular effects and oxidative stress induced by angiotensin II]
Hypertension, Pulmonary
3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension.
Celecoxib but not the combination of celecoxib+atorvastatin prevents the development of monocrotaline-induced pulmonary hypertension in the rat.
Emerging therapies for the treatment of pulmonary hypertension.
HMG-COA reductase inhibitors: An opportunity for the improvement of imatinib safety. An experimental study in rat pulmonary hypertension.
Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase.
Statins inhibit pulmonary artery smooth muscle cell proliferation by upregulation of HO-1 and p21(WAF1).
The HMG-CoA reductase inhibitor, pravastatin, prevents the development of monocrotaline-induced pulmonary hypertension in the rat through reduction of endothelial cell apoptosis and overexpression of eNOS.
The protective effect of HMG-CoA reductase inhibitors against monocrotaline-induced pulmonary hypertension in the rat might not be a class effect: comparison of pravastatin and atorvastatin.
Hypertriglyceridemia
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
Atorvastatin induced hepatic oxidative stress and apoptotic damage via MAPKs, mitochondria, calpain and caspase12 dependent pathways.
Attenuated T-lymphocyte response to HIV therapy in individuals receiving HMG-CoA reductase inhibitors.
Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors.
Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia.
Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.
Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome.
HMG-CoA reductase activity in the liver of rats with hereditary hypertriglyceridemia: effect of dietary fish oil.
Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype.
Hyperlipoproteinemia affects cytokine production in whole blood samples ex vivo. The influence of lipid-lowering therapy.
Hypertriglyceridemia.
Insulin deficiency alters cellular cholesterol metabolism in murine macrophages.
Management of dyslipidemia in NIDDM.
Protective effect of arjunolic acid against atorvastatin induced hepatic and renal pathophysiology via MAPK, mitochondria and ER dependent pathways.
Receptor-mediated uptake of hypertriglyceridemic very low density lipoproteins by normal human fibroblasts.
The effect of simvastatin on dyslipemia in continuous ambulatory peritoneal dialysis patients.
Treatment of hyperlipidemia in human renal disease.
[Goals and practical implementation of lipid therapy in coronary heart disease]
[Treatment for dyslipidemia--a strategy for the prevention of atherosclerosis].
Hypoalbuminemia
Acrolein-induced dyslipidemia and acute-phase response are independent of HMG-CoA reductase.
Hypoglycemia
Development of a model to predict 5-year risk of severe hypoglycemia in patients with type 2 diabetes.
Hypotension
Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.
Hypothyroidism
A Renewed Focus on the Association Between Thyroid Hormones and Lipid Metabolism.
HMG-CoA reductase inhibitors (statins) might cause high elevations of creatine phosphokinase (CK) in patients with unnoticed hypothyroidism.
The effect of hypothyroidism and thyroxine replacement on hepatic and intestinal HMG-CoA reductase and ACAT activities and biliary lipids in the rat.
Hypoxia, Brain
Targeted drug delivery to treat pain and cerebral hypoxia.
Idiopathic Pulmonary Fibrosis
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Infarction, Middle Cerebral Artery
HMG-CoA Reductase Inhibition Promotes Neurological Recovery, Peri-Lesional Tissue Remodeling, and Contralesional Pyramidal Tract Plasticity after Focal Cerebral Ischemia.
Post-ischemic delivery of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor rosuvastatin protects against focal cerebral ischemia in mice via inhibition of extracellular-regulated kinase-1/-2.
Postischemic administration of HMG CoA reductase inhibitor inhibits infarct expansion after transient middle cerebral artery occlusion.
Infections
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus.
Both ganglioside GM2 and cholesterol in the cell membrane are essential for Bombyx mori cypovirus cell entry.
Chemical and genetic validation of the statin drug target to treat the helminth disease, schistosomiasis.
Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.
DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target.
Differential induction and suppression of potato 3-hydroxy-3-methylglutaryl coenzyme A reductase genes in response to Phytophthora infestans and to its elicitor arachidonic acid.
Dihydroquercetin: More than just an impurity?
Down-regulation of single-stranded DNA-binding protein 1 expression induced by HCMV infection promotes lipid accumulation in cells.
Effect of atovastatin treatment on porcine circovirus 2 infection in BALB/c mice.
Endotoxin, tumor necrosis factor, and interleukin-1 decrease hepatic squalene synthase activity, protein, and mRNA levels in Syrian hamsters.
Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study.
HMG CoA reductase is negatively associated with PCV2 infection and PCV2-induced apoptotic cell death.
HMGCR inhibits the early stage of PCV2 infection, while PKC enhances the infection at the late stage.
HmgR, a key enzyme in the mevalonate pathway for isoprenoid biosynthesis, is essential for growth of Listeria monocytogenes EGDe.
Human parainfluenza virus type 1 regulates cholesterol biosynthesis and establishes quiescent infection in human airway cells.
Induced expression of lectin-like oxidized ldl receptor-1 in vascular smooth muscle cells following Chlamydia pneumoniae infection and its down-regulation by fluvastatin.
Intestinal Epithelial Cells and the Microbiome Undergo Swift Reprogramming at the Inception of Colonic Citrobacter rodentium Infection.
Lipid Metabolism in Vascular Smooth Muscle Cells Infuenced by HCMV Infection.
Lipid-derived signals that discriminate wound- and pathogen-responsive isoprenoid pathways in plants: methyl jasmonate and the fungal elicitor arachidonic acid induce different 3-hydroxy-3-methylglutaryl-coenzyme A reductase genes and antimicrobial isoprenoids in Solanum tuberosum L.
Molecular Characterization of Trypanosoma evansi Mevalonate Kinase (TeMVK).
Periodontal infection and dyslipidemia in type 2 diabetics: association with increased HMG-CoA reductase expression.
Porcine HMGCR Inhibits Porcine Circovirus Type 2 Infection by Directly Interacting with the Viral Proteins.
Regulation of HMG-CoA reductase activity in plants.
RhoA is activated during respiratory syncytial virus infection.
Risk factors for osteoporosis in Japan: is it associated with Helicobacter pylori?
Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection.
Serine protease inhibitor AEBSF reduces dengue virus infection via decreased cholesterol synthesis.
The effect of prior statin use on 30-day mortality for patients hospitalized with community-acquired pneumonia.
The effect of rosuvastatin in a murine model of influenza A infection.
The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity.
Infertility, Male
Loss of function of 3-hydroxy-3-methylglutaryl coenzyme A reductase 1 (HMG1) in Arabidopsis leads to dwarfing, early senescence and male sterility, and reduced sterol levels.
Inflammatory Bowel Diseases
Hypothalamic digoxin, hemispheric chemical dominance, and inflammatory bowel disease.
Influenza, Human
Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus.
The effect of rosuvastatin in a murine model of influenza A infection.
Insulin Resistance
A comparison of lovastatin, an HMG-CoA reductase inhibitor, with gemfibrozil, a fibrinic acid derivative, in the treatment of patients with diabetic dyslipidemia.
A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes.
Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia.
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Effect of rosuvastatin on hepatic production of apolipoprotein B-containing lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia.
Effects of atorvastatin on glucose metabolism and insulin resistance in KK/Ay mice.
Effects of diet and simvastatin on serum lipids, insulin, and antioxidants in hypercholesterolemic men: a randomized controlled trial.
High-Efficacy ?,?-Dehydromonacolin S Improves Hepatic Steatosis and Suppresses Gluconeogenesis Pathway in High-Fat Diet-Induced Obese Rats.
Lipid partitioning after uninephrectomy.
Modified HMG-CoA reductase and LDLr regulation is deeply involved in age-related hypercholesterolemia.
Myeloid HMG-CoA Reductase Determines Adipose Tissue Inflammation, Insulin Resistance, and Hepatic Steatosis in Diet-Induced Obese Mice.
New onset diabetes mellitus induced by statins: current evidence.
Optimizing cardiovascular outcomes in diabetes mellitus.
Rauwolfia serpentina improves altered glucose and lipid homeostasis in fructose-induced type 2 diabetic mice.
Should the insulin resistance syndrome be treated in the elderly?
Statins and diabetes risk: how real is it and what are the mechanisms?
The Effect of HMG-CoA Reductase Inhibitor on Insulin Resistance in Patients Undergoing Peritoneal Dialysis.
The influence of the brain-derived neurotropic factor Val66Met genotype and HMG-CoA reductase inhibitors on insulin resistance in the schizophrenia and bipolar populations.
The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.
Intellectual Disability
The genetics of mental retardation.
Intermittent Claudication
Drug treatment of peripheral arterial disease in the elderly.
Peripheral arterial disease: a review of disease awareness and management.
Intracranial Hemorrhages
Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact.
Iron Overload
Iron overload potentiates diet-induced hypercholesterolemia and reduces liver PPAR-? expression in hamsters.
Irritable Bowel Syndrome
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Ischemic Attack, Transient
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Reduction of cerebral infarct size by the AT1-receptor blocker candesartan, the HMG-CoA reductase inhibitor rosuvastatin and their combination. An experimental study in rats.
Ischemic Stroke
Cholesterol and the risk of ischemic stroke.
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke.
HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke.
HMG-CoA reductase inhibitors improve acute ischemic stroke outcome.
Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality.
Pravastatin treatment causes a shift in the balance of hippocampal neurotransmitter binding densities towards inhibition.
Prevention of stroke and dementia with statins: Effects beyond lipid lowering.
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
Simvastatin-induced prevention of the increase in TNF-alpha level in the acute phase of ischemic stroke.
Statins in stroke: prevention, protection and recovery.
The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients.
Vascular protection in brain ischemia.
[Hyperlipidemia in the elderly]
Kidney Diseases
Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats.
Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease.
Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats.
Statins and progressive renal disease.
Kidney Failure, Chronic
Contribution of increased HMG-CoA reductase gene expression to hypercholesterolemia in experimental chronic renal failure.
Dyslipidemia and progression of kidney disease: role of lipid-lowering drugs.
Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease.
Effects of lipid-lowering therapy on reduction of cardiovascular events in patients with end-stage renal disease requiring hemodialysis.
Gene expression of LDL receptor, HMG-CoA reductase, and cholesterol-7 alpha-hydroxylase in chronic renal failure.
HMG-CoA reductase inhibition reverses LCAT and LDL receptor deficiencies and improves HDL in rats with chronic renal failure.
HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients.
Lovastatin has direct renal hemodynamic effects in a rodent model.
Kidney Neoplasms
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
Fluvastatin potentiates anticancer activity of vorinostat in renal cancer cells.
Leber Congenital Amaurosis
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Leiomyoma
The role of atorvastatin in suppressing tumor growth of uterine fibroids.
Leishmaniasis
Residue-Specific Message Encoding in CD40-Ligand.
Leprosy
Indirect assay of beta hydroxy beta methyl glutaryl CoA reductase in the sera of leprosy patients--a further probe into cholesterol metabolism.
Leukemia
Calcium ionophore treatment impairs the sterol-mediated suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, 3-hydroxy-3-methylglutaryl-coenzyme A synthase, and farnesyl diphosphate synthetase.
Coamplification of 3-hydroxy-3-methylglutaryl coenzyme A reductase genes in methotrexate-resistant human leukemia cell lines.
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Increased 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol biosynthesis in freshly isolated hairy cell leukemia cells.
Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo.
P-glycoprotein is downregulated in KG1a-primitive leukemia cells by LDL cholesterol deprivation and by HMG-CoA reductase inhibitors.
Statins enhance efficacy of venetoclax in blood cancers.
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.
The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation.
[Effects of simvastatin on PI3K/AKT signaling pathway in human acute monocytic leukemia cell line SHI-1].
Leukemia, Erythroblastic, Acute
Effects of lovastatin on Rho isoform expression, activity, and association with guanine nucleotide dissociation inhibitors.
Leukemia, Hairy Cell
Increased 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and cholesterol biosynthesis in freshly isolated hairy cell leukemia cells.
Leukemia, Monocytic, Acute
[Effects of simvastatin on PI3K/AKT signaling pathway in human acute monocytic leukemia cell line SHI-1].
Leukemia, Myeloid, Acute
Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression.
Statins induce lethal effects in acute myeloblastic lymphoma cells within 72 hours.
Leukostasis
CD11b+ bone marrow-derived monocytes are the major leukocyte subset responsible for retinal capillary leukostasis in experimental diabetes in mouse and express high levels of CCR5 in the circulation.
Lichen Planus
[Simvastatin-induced lichen planus pemphigoides]
Lipidoses
Effect of pravastatin, a HMG CoA reductase inhibitor, on blood lipids and aortic lipidosis in cholesterol-fed White Carneau pigeons.
Insig proteins mediate feedback inhibition of cholesterol synthesis in the intestine.
Lipodystrophy
Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men-a randomized, placebo-controlled study.
Lipomatosis
Molecular biology of metabolic disease: defects in the regulation of enzymic activity.
Liver Cirrhosis
Cholesterol-induced stimulation of postinflammatory liver fibrosis.
Liver Diseases
Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin.
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Effects of sepsis on the metabolism of sphingomyelin and cholesterol in mice with liver dysfunction.
Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial.
Hepatic Effects of Lovastatin Exposure in Patients with Liver Disease : A Retrospective Cohort Study.
Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
Liver biochemistry abnormalities in a quaternary care lipid clinic database.
miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia.
Sulfated polysaccharides from Enteromorpha prolifera suppress SREBP-2 and HMG-CoA reductase expression and attenuate non-alcoholic fatty liver disease induced by a high-fat diet.
[Etiology of Secondary Hyperlipidemia and Abnormalities of Lipid Laboratory Tests -Chairmen's Introductory Remarks -].
Liver Neoplasms
Rhesus monkey model of liver disease reflecting clinical disease progression and hepatic gene expression analysis.
Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy.
Liver Neoplasms, Experimental
Effect of assay temperature on the kinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in rat liver and Morris hepatoma 5123C.
Inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in Morris hepatoma 7800 after intravenous injection of mevalonic acid.
Lung Diseases
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Innovations in asthma therapy: is there a role for inhaled statins?
Pleiotropic effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in pulmonary diseases: a comprehensive review.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Lung Diseases, Interstitial
Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease.
Statins and Pulmonary Fibrosis: The Potential Role of NLRP3 Inflammasome Activation.
Lung Injury
[A case of drug-induced pneumonia possibly associated with simvastatin]
Lung Neoplasms
In vitro mechanisms of lovastatin on lung cancer cell lines as a potential chemopreventive agent.
Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo.
[A 81-year old man of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy associated with lung adenocarcinoma cancer].
Lupus Erythematosus, Systemic
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin.
Lymphatic Metastasis
Clinical relevance of cholesterol homeostasis genes in colorectal cancer.
Lymphoma
Anti-HMGCR Antibody-Positive Myopathy Shows Bcl-2-Positive Inflammation and Lymphocytic Accumulations.
Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice.
Autophagy contributes to apoptosis in A20 and EL4 lymphoma cells treated with fluvastatin.
HMG CoA reductase inhibitors (statins) to treat Epstein-Barr virus-driven lymphoma.
HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway.
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice.
Statins enhance efficacy of venetoclax in blood cancers.
Lymphoma, B-Cell
Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease.
Lymphoma, Non-Hodgkin
HMG-CoA reductase inhibitors (statins) use and risk of non-Hodgkin lymphoma in HIV-positive persons.
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Macular Degeneration
3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors and the presence of age-related macular degeneration in the Cardiovascular Health Study.
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Marek Disease
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Medulloblastoma
Cell-cycle gene expression in lovastatin-induced medulloblastoma apoptosis.
Mevalonate prevents lovastatin-induced apoptosis in medulloblastoma cell lines.
Melanoma
Autocrine amplification loop in statin-induced apoptosis of human melanoma cells.
Biphenylalkylacetylhydroquinone ethers suppress the proliferation of murine B16 melanoma cells.
Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma.
Decrease of cholesterol in mouse melanoma causes secretion of lysosomal enzymes.
Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression.
Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.
Lipid-Producing Ciliochoroidal Melanoma with Expression of HMG-CoA Reductase.
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells.
Melanoma, Experimental
d-?-Tocotrienol-mediated cell cycle arrest and apoptosis in human melanoma cells.
Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
Memory Disorders
Short-term memory loss associated with rosuvastatin.
Meningioma
Lovastatin is a potent inhibitor of meningioma cell proliferation: evidence for inhibition of a mitogen associated protein kinase.
Metabolic Diseases
Feeding induces cholesterol biosynthesis via the mTORC1-USP20-HMGCR axis.
High Maternal Serum Estradiol Levels Induce Dyslipidemia in Human Newborns via a Hepatic HMGCR Estrogen Response Element.
Metabolic Syndrome
A Mediterranean-style, low-glycemic-load diet reduces the expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in mononuclear cells and plasma insulin in women with metabolic syndrome.
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Correction to: HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.
Corrigendum to: HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.
Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome.
Fluvastatin lowers atherogenic dense low-density lipoproteins in postmenopausal women with the atherogenic lipoprotein phenotype.
HMGCoA reductase inhibition reverses myocardial fibrosis and diastolic dysfunction through AMP-activated protein kinase activation in a mouse model of metabolic syndrome.
Intestinal Population in Host with Metabolic Syndrome during Administration of Chitosan and Its Derivatives.
Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
Prevention of cardiovascular complications of the metabolic syndrome: focus on pharmacotherapy.
The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes.
Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes.
Mevalonate Kinase Deficiency
3-Hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured fibroblasts from patients with mevalonate kinase deficiency: differential response to lipid supplied by fetal bovine serum in tissue culture medium.
Clinical and biochemical phenotype in 11 patients with mevalonic aciduria.
Microvascular Angina
Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity.
Mitochondrial Myopathies
Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors--simvastatin and pravastatin.
Mucocutaneous Lymph Node Syndrome
Effects of HMG-CoA reductase inhibitors on continuous post-inflammatory vascular remodeling late after Kawasaki disease.
Multiple Myeloma
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.
Statins Are Associated With Reduced Mortality in Multiple Myeloma.
The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase.
[In vitro effects of mevastatin on the proliferation and apoptosis in human multiple myeloma cell line U266]
Multiple Sclerosis
Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis.
Atorvastatin induces T cell anergy via phosphorylation of ERK1.
Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.
HMG-CoA reductase inhibitor augments survival and differentiation of oligodendrocyte progenitors in animal model of multiple sclerosis.
Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders.
Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy.
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
The Combination of Interferon-Beta and HMG-CoA Reductase Inhibition in Multiple Sclerosis: Enthusiasm Lost too Soon?
[Direct neuronal effects of statins]
Multiple Sclerosis, Chronic Progressive
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Multiple Sclerosis, Relapsing-Remitting
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Muscle Weakness
Anti-HMG-CoA reductase myopathy, an undesirable evolution of statin induced myopathy: a case report.
Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level.
[Autoimmune myopathy associated with statin use].
Muscular Atrophy
Coenzyme Q10 protects against statin-induced myotoxicity in zebrafish larvae (Danio rerio).
Muscular Diseases
A Case of Statin-Associated Autoimmune Myopathy.
A RARE CASE OF STATIN-INDUCED NECROTIZING AUTOIMMUNE MYOPATHY.
Adaptive immune response to therapy in hmgcr autoantibody myopathy.
Advances in serological diagnostics of inflammatory myopathies.
Anti-HMG-CoA reductase myopathy, an undesirable evolution of statin induced myopathy: a case report.
Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study.
Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Atorvastatin Metabolite Measurements as a Diagnostic Tool for Statin-Induced Myopathy.
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy.
Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy.
Autoimmune necrotising myopathy and HMGCR antibodies.
Benefits and risks of simvastatin in patients with familial hypercholesterolaemia.
Case Report: Immune Mediated Necrotizing Myopathy With IgG Antibodies to 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase (HMGCR) May Present With Acute Systolic Heart Failure.
Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Challenges in Treating Statin-Associated Necrotizing Myopathy.
Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy.
Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy.
Clinical pharmacokinetics and practical applications of simvastatin.
Clinical pharmacokinetics of pravastatin.
Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Dermatomyositis and drugs.
Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats.
Drug interaction potential of 2-((3,4-dichlorophenethyl)(propyl)amino)-1-(pyridin-3-yl)ethanol (LK-935), the novel nonstatin-type cholesterol-lowering agent.
Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese Rats.
Effect of simvastatin on passive strain-induced skeletal muscle injury in rats.
Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells.
Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits.
Efficacy and Safety of High-Dose Immunoglobulin-Based Regimen in Statin-Associated Autoimmune Myopathy: A Multi-Center and Multi-Disciplinary Retrospective Study.
Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method.
Ezetimibe-associated myopathy in monotherapy and in combination with a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors.
High-dose statin use does not impair aerobic capacity or skeletal muscle function in older adults.
High-dose statins and skeletal muscle metabolism in humans: a randomized, controlled trial.
HMG-CoA Reductase Inhibitor Myopathy: Clinical, Electrophysiological, and Pathologic Data in Five Patients.
HMG-CoA reductase inhibitor-induced myopathy in the rat: cyclosporine A interaction and mechanism studies.
HMG-CoA reductase inhibitors, gemfibrozil, and myopathy.
HMGCR antibody-associated myopathy as a paraneoplastic manifestation of esophageal carcinoma.
Identifying statin-associated autoimmune necrotizing myopathy.
Immune-mediated necrotizing myopathy associated with statins: history and recent developments.
Inhibition of cholesterol biosynthesis by squalene epoxidase inhibitor avoids apoptotic cell death in L6 myoblasts.
Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Involvement of tyrosine phosphorylation in HMG-CoA reductase inhibitor-induced cell death in L6 myoblasts.
Itraconazole-induced rhabdomyolysis and acute renal failure in a heart transplant recipient treated with simvastatin and cyclosporine.
Large-scale chemical dissection of mitochondrial function.
Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle.
Mechanism underlying long-term regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase during L6 myoblast differentiation.
Mining directional drug interaction effects on myopathy using the FAERS database.
Myopathy associated with chronic orlistat consumption: a case report.
Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model.
Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature.
Myopathy due to HMGCR antibodies in adult mimicking muscular dystrophy associated with cancer and statin exposure - narrative review of the literature - case report.
Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study.
Myopathy with anti-HMGCR antibodies: Perimysium and myofiber pathology.
Necrotizing Autoimmune Myopathy: A Rare Variant of Idiopathic Inflammatory Myopathies.
Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy.
Pediatric necrotizing myopathy associated with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies.
Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy.
Pharmacokinetics of the combination of fluvastatin and gemfibrozil.
Pitavastatin: a new HMG-CoA reductase inhibitor.
Potential implications of six American Indian patients with myopathy, statin exposure and anti-HMGCR antibodies.
Potential risk of myopathy by HMG-CoA reductase inhibitors: a comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers.
Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.
Preventive effects of bicarbonate on cerivastatin-induced apoptosis.
Rhabdomyolysis after midazolam administration in a cirrhotic patient treated with atorvastatin.
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Rhabdomyolysis from the combination of a statin and gemfibrozil: an uncommon but serious adverse reaction.
Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
Rituximab in the treatment of immune-mediated necrotizing myopathy: a review of case reports and case series.
Role of P-glycoprotein in statin drug interactions.
Rosuvastatin: characterization of induced myopathy in the rat.
Simvastatin-induced lactic acidosis: a rare adverse reaction?
Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure.
Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy.
Spontaneous symptomatic improvement in a pediatric patient with anti-3-hydroxy-3-methylglutraryl-coenzyme A reductase myopathy.
Statin Coadministration Increases the Risk of Daptomycin-Associated Myopathy.
Statin myopathy: the fly in the ointment for the prevention of cardiovascular disease in the 21st century?
Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies: A review.
Statin-associated autoimmune myopathy: A distinct new IFL pattern can increase the rate of HMGCR antibody detection by clinical laboratories.
Statin-Associated Autoimmune Myopathy: Current Perspectives.
Statins and myotoxic effects associated with anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibodies: an observational study in Japan.
Statins and myotoxicity: a therapeutic limitation.
Statins as a possible cause of inflammatory and necrotizing myopathies.
The effects of pemafibrate in Japanese patients with type 2 diabetes receiving HMG-CoA reductase inhibitors.
The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.
Toxic myopathies.
Toxicity of a novel HMG-CoA reductase inhibitor in the common marmoset (Callithrix jacchus).
Treatment experience of Taiwanese patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy.
Update on toxic myopathies.
Updated clinical safety experience with fluvastatin.
What is in the Myopathy Literature?
Which nonautoimmune myopathies are most frequently misdiagnosed as myositis?
[A 81-year old man of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy associated with lung adenocarcinoma cancer].
[A one-year prospective and intensive pharmacovigilance of antilipemic drugs in an hospital consultation for prevention of risk factors]
[Autoimmune myopathy associated with statin use].
[Dermatomyositis-like syndrome revealing statin-induced necrotizing autoimmune myopathy with anti-HMGCR antibodies].
[Diagnosis of Idiopathic Inflammatory Myopathy: A Muscle Pathology Perspective].
[Etiology of Secondary Hyperlipidemia and Abnormalities of Lipid Laboratory Tests -Chairmen's Introductory Remarks -].
[Muscle problems due to statins: underestimated.]
[Myopathy caused by inhibitors of hydroxymethylglutaryl-coenzyme A reductase]
[Myopathy secondary to the treatment with inhibitors of HMG-CoA reductase]
Muscular Dystrophies
Myopathy due to HMGCR antibodies in adult mimicking muscular dystrophy associated with cancer and statin exposure - narrative review of the literature - case report.
Muscular Dystrophies, Limb-Girdle
What is in the Myopathy Literature?
Myalgia
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Hepatoselectivity of statins: design and synthesis of 4-sulfamoyl pyrroles as HMG-CoA reductase inhibitors.
Lomitapide.
Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin.
Thermodynamic and structure guided design of statin based inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Toward "pain-free" statin prescribing: clinical algorithm for diagnosis and management of myalgia.
[Fluvastatin-induced dermatomyositis]
Mycoses
Induction mechanism of 3-hydroxy-3-methylglutaryl-CoA reductase in potato tuber and sweet potato root tissues.
Is there a role for statins in fungal infections?
Myocardial Infarction
A coronary primary intervention study of Japanese men: study design, implementation and baseline data. The Kyushu Lipid Intervention Study Group.
A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?
Acute myocardial infarction and proinflammatory gene variants.
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors.
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction.
Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use.
Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification.
Clinical evidence for Japanese population based on prospective studies-Linking clinical trials and clinical practice.
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke.
Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction.
Compliance and refill pattern behavior with HMG-CoA reductase inhibitors after acute myocardial infarction.
Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.
Effect of long-term cholesterol-lowering treatment with HMG-CoA reductase inhibitor (simvastatin) on myocardial perfusion evaluated by thallium-201 single photon emission computed tomography.
Endothelial dysfunction in heart failure.
Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
HDL-C levels and cardiovascular disease: more is not always better!
HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction.
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size.
How do HMG-CoA reductase inhibitors prevent stroke?
Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction.
Induction of RISK by HMG-CoA reductase inhibition affords cardioprotection after myocardial infarction.
Lipid-lowering for prevention of coronary heart disease: what policy now?
Optimizing cardiovascular outcomes in diabetes mellitus.
Patterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in Canada.
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Prevalent but moderate variation across small geographic regions in patient nonadherence to evidence-based preventive therapies in older adults after acute myocardial infarction.
Preventing cardiovascular outcome in patients with renal impairment: is there a role for lipid-lowering therapy?
Rosuvastatin improves myocardial and neurological outcomes after asphyxial cardiac arrest and cardiopulmonary resuscitation in rats.
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
Secondary prevention of coronary heart disease in elderly patients following myocardial infarction: are all HMG-CoA reductase inhibitors alike?
Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?
Simvastatin reduces infarct size in a model of acute myocardial ischemia and reperfusion in the rat.
Statin therapy in renal disease: harmful or protective?
Statin withdrawal: clinical implications and molecular mechanisms.
Statins and endothelial dysfunction.
Statins: new drugs for treating osteoporosis?
Strategies to increase HMG-CoA reductase inhibitor use after acute myocardial infarction.
Systemic inflammatory markers in acute coronary syndrome: association with cardiovascular risk factors and effect of early lipid lowering.
The role of statins in cancer therapy.
The use of HMG Co-A reductase inhibitors following acute myocardial infarction in hospital practice.
The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men.
Update on acute coronary syndromes and ST-elevation myocardial infarction.
Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI.
[Effect of cholesterol reducing therapy with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor on secondary prevention after myocardial infarction in Japanese patients]
[Regulation of endothelial NO production by Rho GTPase]
Myocardial Ischemia
Advantages of lipid-lowering therapy in cerebral ischemia: role of HMG-CoA reductase inhibitors.
Can simvastatin promote tumor growth by inducing angiogenesis similar to VEGF?
Defining the role of high-dose statins in PCI.
Efficacy of HMG-CoA reductase inhibitors in the prevention of cerebrovascular attack in 1016 patients older than 75 years among 4014 type 2 diabetic individuals.
HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke.
Lovastatin enhances ecto-5'-nucleotidase activity and cell surface expression in endothelial cells: implication of rho-family GTPases.
Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin.
Patients with Alzheimer's disease may be particularly susceptible to adverse effects of statins.
Pre and Post-stroke Use of Statins Improves Stroke Outcome.
Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts.
Statins and endothelial dysfunction.
The expanding role of HMG-CoA reductase inhibitors (statins) in the prevention and treatment of ischemic heart disease.
Myocardial Stunning
Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs.
Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs.
Myocarditis
Effects of HMG-CoA Reductase Inhibitor on Experimental Autoimmune Myocarditis.
HMG-CoA reductase inhibitor attenuates experimental autoimmune myocarditis through inhibition of T cell activation.
Myositis
Analysis of autoantibodies to 3-hydroxy-3-methylglutaryl-coenzyme A reductase using different technologies.
Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies are Associated with DRB1*07:01 and Severe Myositis in Pediatric Myositis Patients.
Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient.
Autoantibodies in polymyositis and dermatomyositis.
Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment.
Clinical implications of the biopharmaceutical properties of fluvastatin.
Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin.
Effect of Coenzyme Q10 Supplementation in Statin-Treated Obese Rats.
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
HMG CoA reductase inhibitor associated myositis and autoimmune hepatitis.
HMGCR-associated myositis: a New Zealand case series and estimate of incidence.
Performance of the 2017 EULAR/ACR classification criteria for inflammatory myopathies in patients with myositis-specific autoantibodies.
Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases.
Simvastatin-induced rhabdomyolysis in a patient with chronic renal failure.
Spectrum of immune-mediated necrotizing myopathies and their treatments.
Spontaneous symptomatic improvement in a pediatric patient with anti-3-hydroxy-3-methylglutraryl-coenzyme A reductase myopathy.
The changing spectrum of drug-induced myopathies.
The effect of HMG-CoA reductase inhibitors on chronic allograft rejection.
Treatment experience of Taiwanese patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy.
Weakness Due to Anemia? Go Fish! Melena as a Red Herring in the Diagnosis of Statin-Induced Myopathy.
[A 81-year old man of anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase antibody-positive myopathy associated with lung adenocarcinoma cancer].
[Diagnosis of Idiopathic Inflammatory Myopathy: A Muscle Pathology Perspective].
Myotonia
Electrical myotonia of rabbit skeletal muscles by HMG-CoA reductase inhibitors.
HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway.
Myotoxicity
(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.
C/EBP homologous protein deficiency inhibits statin-induced myotoxicity.
Coenzyme Q10 in neuromuscular and neurodegenerative disorders.
Considerations for supplementing with coenzyme q10 during statin therapy.
Delineation of myotoxicity induced by 3-hydroxy-3-methylglutaryl CoA reductase inhibitors in human skeletal muscle cells.
Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
Effects of myosin heavy chain (MHC) plasticity induced by HMGCoA-reductase inhibition on skeletal muscle functions.
HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
HMG-CoA reductase inhibitors and coenzyme Q10.
HMG-CoA reductase inhibitors and myotoxicity.
Immune-mediated necrotizing myopathy associated with statins: history and recent developments.
In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes.
Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro.
Myopathy Associated With HMG-CoA Reductase Inhibitors (Statins): A Series of 10 Patients and Review of the Literature.
Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases.
Protective effects of a squalene synthase inhibitor, lapaquistat acetate (TAK-475), on statin-induced myotoxicity in guinea pigs.
Rhabdomyolysis and statin therapy: relevance to the elderly.
Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy.
Statin-associated autoimmune myopathy and anti-HMGCR autoantibodies: A review.
Statins and myotoxicity: a therapeutic limitation.
The effect of HMG-CoA reductase inhibitors on coenzyme Q10: possible biochemical/clinical implications.
Update on toxic myopathies.
[Drug interactions with antilipemics]
[Safety profile of statins]
Neoplasm Metastasis
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis.
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Butyrate inhibits seeding and growth of colorectal metastases to the liver in mice.
Clinical relevance of cholesterol homeostasis genes in colorectal cancer.
Computational Drug Repositioning Identifies Statins as Modifiers of Prognostic Genetic Expression Signatures and Metastatic Behavior in Melanoma.
Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics.
Concomitant attenuation of HMGCR expression and activity enhances the growth inhibitory effect of atorvastatin on TGF-?-treated epithelial cancer cells.
Discussion on 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Genome-Wide Mapping of the Binding Sites and Structural Analysis of Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 2 Reveal that It Is a DNA-Binding Transcription Factor.
HMG-CoA reductase inhibitors (statins) as anticancer drugs (review).
HMGCR positively regulated the growth and migration of glioblastoma cells.
MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1.
Rac1-regulated endothelial radiation response stimulates extravasation and metastasis that can be blocked by HMG-CoA reductase inhibitors.
Simvastatin prevents proliferation and bone metastases of lung adenocarcinoma in vitro and in vivo.
Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer.
Neoplasms
3-hydroxy-3-methylglutaryl coenzyme A reductase in human brain tumors.
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.
3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells.
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest.
3-Hydroxyl-3-methylglutaryl-coenzyme A reductase is up regulated in hepatocellular carcinoma associated with paraneoplastic hypercholesterolemia.
6-Nitrocholesterol inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase and tumor cell growth.
?-ionone induces cell cycle arrest and apoptosis in human prostate tumor cells.
A bovine oviduct epithelial cell suspension culture system suitable for studying embryo-maternal interactions: morphological and functional characterization.
A discoordinate increase in the cellular amount of 3-hydroxy-3-methylglutaryl-CoA reductase results in the loss of rate-limiting control over cholesterogenesis in a tumour cell-free system.
A Retrospective Hospital-Based Study of HMGCR Expression in HER2 IHC 2+ and 3+ Breast Cancer.
A screen for inducers of bHLH activity identifies pitavastatin as a regulator of p21, Rb phosphorylation and E2F target gene expression in pancreatic cancer.
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer.
A single nucleotide polymorphism in the 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene ( HMGCR) influences the serum triacylglycerol relationship with dietary fat and fibre in the European Prospective Investigation into Cancer and Nutrition in Norfolk (EPIC-Norfolk) study.
A Synergistic Anti-Cancer Effect of Troglitazone and Lovastatin in a Human Anaplastic Thyroid Cancer Cell Line and in a Mouse Xenograft Model.
Abnormal cholesterol metabolism in renal clear cell carcinoma.
Additive effects of blood glucose lowering drugs, statins and renin-angiotensin system blockers on all-site cancer risk in patients with type 2 diabetes.
Additive interaction between renin-angiotensin system and lipid metabolism for cancer in type 2 diabetes mellitus.
Adiponectin Attenuates the Inflammation in Atopic Dermatitis-Like Reconstructed Human Epidermis.
Advances in serological diagnostics of inflammatory myopathies.
Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase(®).
Alterations in biosynthesis and homeostasis of cholesterol and in lipoprotein patterns in mice bearing a transplanted lymphoid tumor.
Altered activation state of hydroxymethylglutaryl-coenzyme A reductase in liver tumors.
Anti-proliferative action of endogenous dehydroepiandrosterone metabolites on human cancer cell lines.
Anti-proliferative activity of Origanum vulgare inhibited lipogenesis and induced mitochondrial mediated apoptosis in human stomach cancer cell lines.
Anti-Warburg effect by targeting HRD1-PFKP pathway may inhibit breast cancer progression.
Antihyperlipidemic effect of selected pyrimidine derivatives mediated through multiple pathways.
Antitumor and apoptosis promoting properties of atorvastatin, an inhibitor of HMG-CoA reductase, against Dalton's Lymphoma Ascites tumor in mice.
Antitumor effects of the combination of cholesterol reducing drugs.
Association between serum concentrations of perfluoroalkyl substances (PFAS) and expression of serum microRNAs in a cohort highly exposed to PFAS from drinking water.
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Atorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype.
Atorvastatin-induced senescence of hepatocellular carcinoma is mediated by downregulation of hTERT through the suppression of the IL-6/STAT3 pathway.
Atorvastatin: a potential chemopreventive agent in bladder cancer.
Autoimmune-like drug-induced liver injury: a review and update for the clinician.
Biochemical changes of mevalonate pathway in human colorectal cancer.
Biochemical functions of coenzyme Q10.
Blocking late cholesterol biosynthesis inhibits the growth of transplanted Morris hepatomas (7288CTC) in rats.
Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study.
Cerivastatin prevents tumor necrosis factor-alpha-induced downregulation of endothelial nitric oxide synthase: role of endothelial cytosolic proteins.
Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis.
Cholesterol Biosynthesis and Trafficking in Cortisol-Producing Lesions of the Adrenal Cortex.
Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response.
Cholesterol inhibition, cancer, and chemotherapy.
Cholesterol metabolism in human cancer cells in monolayer culture. V. The effect of progesterone on the regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity by low density lipoprotein.
Clinical Features and Treatment Outcomes of Necrotizing Autoimmune Myopathy.
Clinical relevance of cholesterol homeostasis genes in colorectal cancer.
Comparison of regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in hepatoma cells grown in vivo and in vitro.
Concomitant attenuation of HMG-CoA reductase expression potentiates the cancer cell growth-inhibitory effect of statins and expands their efficacy in tumor cells with epithelial characteristics.
Concomitant attenuation of HMGCR expression and activity enhances the growth inhibitory effect of atorvastatin on TGF-?-treated epithelial cancer cells.
CtBP promotes metastasis of breast cancer through repressing cholesterol and activating TGF-? signaling.
Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells.
d-Dlta-tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells.
Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme A reductase for cancer treatment.
Dietary alpha-tocopherol attenuates the impact of gamma-tocotrienol on hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in chickens.
Differential effects of pravastatin and simvastatin on the growth of tumor cells from different organ sites.
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
Differentiation and apoptosis induction by lovastatin and ?-tocotrienol in HL-60 cells via Ras/ERK/NF-?B and Ras/Akt/NF-?B signaling dependent down-regulation of glyoxalase 1 and HMG-CoA reductase.
Do the cholesterol-lowering properties of statins affect cancer risk?
Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone.
Dysregulation of the mevalonate pathway promotes transformation.
Effect of lovastatin alone and as an adjuvant chemotherapeutic agent on hepatoma tissue culture-4 cell growth.
Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo.
Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell lines.
Efficient Use of Exogenous Isoprenols for Protein Isoprenylation by MDA-MB-231 Cells Is Regulated Independently of the Mevalonate Pathway.
EGFR-targeted immunoliposomes as a selective delivery system of simvastatin, with potential use in treatment of triple-negative breast cancers.
Elevated Levels of StAR-Related Lipid Transfer Protein 3 Alter Cholesterol Balance and Adhesiveness of Breast Cancer Cells: Potential Mechanisms Contributing to Progression of HER2-Positive Breast Cancers.
Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL.
Enhancement of sterol synthesis by the monoterpene perillyl alcohol is unaffected by competitive 3-hydroxy-3-methylglutaryl-CoA reductase inhibition.
Enhancement of the herpes simplex virus thymidine kinase/ganciclovir bystander effect and its antitumor efficacy in vivo by pharmacologic manipulation of gap junctions.
Expression of the low-density lipoprotein receptor, HMG-CoA reductase, and multidrug resistance (Mdr1) genes in colorectal carcinomas.
Farnesyl-O-acetylhydroquinone and geranyl-O-acetylhydroquinone suppress the proliferation of murine B16 melanoma cells, human prostate and colon adenocarcinoma cells, human lung carcinoma cells, and human leukemia cells.
Gamma-tocotrienol reverses multidrug resistance of breast cancer cells with a mechanism distinct from that of atorvastatin.
Genome-Wide Mapping of the Binding Sites and Structural Analysis of Kaposi's Sarcoma-Associated Herpesvirus Viral Interferon Regulatory Factor 2 Reveal that It Is a DNA-Binding Transcription Factor.
Geraniol and beta-ionone inhibit proliferation, cell cycle progression, and cyclin-dependent kinase 2 activity in MCF-7 breast cancer cells independent of effects on HMG-CoA reductase activity.
Geranylgeraniol suppresses the viability of human DU145 prostate carcinoma cells and the level of HMG CoA reductase.
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation.
HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.
HMGCoA reductase inhibition partially mediates tumor necrosis factor alpha-induced apoptosis in human U-937 and HL-60 cells.
HMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma.
HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells.
HMGCR positively regulated the growth and migration of glioblastoma cells.
Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells.
Identification of developmental competence-related genes in mature porcine oocytes.
Impact of statin therapy on survival in epithelial ovarian cancer.
Impaired cholesterol metabolism in the mouse model of cystic fibrosis. A preliminary study.
Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549.
In vitro and in vivo anticancer effects of mevalonate pathway modulation on human cancer cells.
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Increased sensitivity of multidrug-resistant myeloid leukemia cell lines to lovastatin.
Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Inflammation in chronic heart failure.
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis.
Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.
Inhibition of lysophosphatidic acid-induced RhoA activation and tumor cell invasion by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
Inhibition of N-methyl-N-nitrosourea- and 7,12-dimethylbenz[a] anthracene-induced rat mammary tumorigenesis by dietary cholesterol is independent of Ha-Ras mutations.
Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels.
Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma.
Inhibitory effect of simvastatin on the TNF-alpha- and angiotensin II-induced monocyte adhesion to endothelial cells is mediated through the suppression of geranylgeranyl isoprenoid-dependent ROS generation.
Ionone Is More than a Violet's Fragrance: A Review.
Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer.
Kinetics of G1 progression in 3T6 and SV-3T3 cells following treatment by 25-hydroxycholesterol.
Lipid composition and 3-hydroxy-3-methylglutaryl-CoA reductase activity of acinar cell carcinoma of rat pancreas.
Lipid metabolism in cultured cells. XVI. Lipoprotein binding and HMG CoA reductase levels in normal and tumor virus-transformed human fibroblasts.
Lipophilic but not hydrophilic statins selectively induce cell death in gynecological cancers expressing high levels of HMGCoA reductase.
Lipophilic statins limit cancer cell growth and survival, via involvement of Akt signaling.
Liposomal nanocarriers for statins: A pharmacokinetic and pharmacodynamics appraisal.
Lovastatin and perillyl alcohol inhibit glioma cell invasion, migration, and proliferation--impact of Ras-/Rho-prenylation.
Lovastatin induced Kruppel like factor 2 (
Lovastatin induces a pronounced differentiation response in acute myeloid leukemias.
Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance.
Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells.
Lovastatin induces neuronal differentiation and apoptosis of embryonal carcinoma and neuroblastoma cells: enhanced differentiation and apoptosis in combination with dbcAMP.
Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins.
Low density lipoprotein receptor activity in human intracranial tumors and its relation to the cholesterol requirement.
Low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase mRNA levels are coordinately reduced in human renal cell carcinoma.
Lycopene induces cell growth inhibition by altering mevalonate pathway and Ras signaling in cancer cell lines.
Mendelian Randomization Study of ACLY and Cardiovascular Disease.
Metabolome of Mammary Tumors Differs from Normal Mammary Glands But Is Not Altered by Time-restricted Feeding Under Obesogenic Conditions.
Mevastatin can increase toxicity in primary AMLs exposed to standard therapeutic agents, but statin efficacy is not simply associated with ras hotspot mutations or overexpression.
Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.
Modulation of cholesterol metabolism affects tumor growth in hamsters.
Modulation of the mevalonate pathway and cell growth by pravastatin and d-limonene in a human hepatoma cell line (Hep G2).
MYC Phosphorylation, Activation, and Tumorigenic Potential in Hepatocellular Carcinoma Are Regulated by HMG-CoA Reductase.
Myopathy due to HMGCR antibodies in adult mimicking muscular dystrophy associated with cancer and statin exposure - narrative review of the literature - case report.
New molecular targets of breast cancer therapy.
Non-atheroprotective effects of statins: a systematic review.
Novel synthetic inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity that inhibit tumor cell proliferation and are structurally unrelated to existing statins.
Organ- and tissue-specific expression of the low density lipoprotein receptor. Rapid quantitation by competitive reverse transcriptasepolymerase chain reaction.
Perillyl alcohol and genistein differentially regulate PKB/Akt and 4E-BP1 phosphorylation as well as eIF4E/eIF4G interactions in human tumor cells.
Periodontal infection and dyslipidemia in type 2 diabetics: association with increased HMG-CoA reductase expression.
Pleiotropic Effects of a Schweinfurthin on Isoprenoid Homeostasis.
Posttranscriptional regulation of mRNA levels in rat liver associated with deoxycholic acid feeding.
Predicting the effect of statins on cancer risk using genetic variants from a Mendelian randomization study in the UK Biobank.
Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice.
Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
Protective effect of Codonopsis lanceolata root extract against alcoholic fatty liver in the rat.
Proteomics and bioinformatics analysis of lovastatin-induced differentiation in ARO cells.
Proto oncogene/eukaryotic translation initiation factor (eIF) 4E attenuates mevalonate-mediated regulation of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase synthesis.
Rapid quantitation of mRNA species in ethidium bromide-stained gels of competitive RT-PCR products.
Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Reversal of HER2 Negativity: An Unexpected Role for Lovastatin in Triple-Negative Breast Cancer Stem Cells.
Reversion of transformed phenotype of human adenocarcinoma A549 cells by expression of 3-hydroxy-3-methylglutaryl coenzyme A reductase complementary DNA.
Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.
Simvastatin effects on a human lung carcinoma and cholesterol homeostasis of host and non-host mice.
Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study.
Simvastatin induces interleukin-18 production in human peripheral blood mononuclear cells.
Simvastatin Inhibits the Malignant Behaviors of Gastric Cancer Cells by Simultaneously Suppressing YAP and ?-Catenin Signaling.
Simvastatin modulates TNFalpha-induced adhesion molecules expression in human endothelial cells.
Simvastatin suppresses breast cancer cell proliferation induced by senescent cells.
Simvastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N'-bis(2-chloroethyl)-N-nitrosourea and beta-interferon on human glioma cells.
Statin as anti-cancer therapy in autochthonous T-lymphomas expressing stabilized gain-of-function mutant p53 proteins.
Statin use, candidate mevalonate pathway biomarkers, and colon cancer survival in a population-based cohort study.
Statin use, HMGCR expression, and breast cancer survival - The Malmö Diet and Cancer Study.
Statin-mediated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma.
Statins and cancer development.
Statins and prostate cancer risk: a case-control study.
Statins and risk of cancer: a systematic review and metaanalysis.
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women.
Sterol regulatory element-binding protein 1 inhibitors decrease pancreatic cancer cell viability and proliferation.
Sterol synthesis pathway inhibition as a target for cancer treatment.
Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells.
Strategies to enhance epidermal growth factor inhibition: targeting the mevalonate pathway.
Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).
Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention.
Suppression in Mevalonate Synthesis Mediates Antitumor Effects of Combined Statin and gamma-Tocotrienol Treatment.
Suppression of MET Signaling Mediated by Pitavastatin and Capmatinib Inhibits Oral and Esophageal Cancer Cell Growth.
Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer.
Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin.
Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
Targeting Fatty Acid Synthase Modulates Metabolic Pathways and Inhibits Cholangiocarcinoma Cell Progression.
Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Targeting SREBP-2-Regulated Mevalonate Metabolism for Cancer Therapy.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Targeting tumor cell metabolism with statins.
Taxifolin binds with LXR (? & ?) to attenuate DMBA-induced mammary carcinogenesis through mTOR/Maf-1/PTEN pathway.
The effect of factors released from the tumor-transformed cells on DNA synthesis, mitosis, and cellular enlargement in 3T3 fibroblasts.
The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia.
The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.
The importance of LDL and cholesterol metabolism for prostate epithelial cell growth.
The potential hepatoprotective effects of lovastatin combined with oral hypoglycemic agents in streptozotocin-induced diabetes in rats.
The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
The risk of cancer in users of statins.
The role of atorvastatin in suppressing tumor growth of uterine fibroids.
Tissue selective drug delivery utilizing carrier-mediated transport systems.
Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
Treatment and outcomes in necrotising autoimmune myopathy: An Australian perspective.
Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin.
Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen.
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.
Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer.
Warburg's Ghost-Cancer's Self-Sustaining Phenotype: The Aberrant Carbon Flux in Cholesterol-Enriched Tumor Mitochondria via Deregulated Cholesterogenesis.
[Effects of celecoxib combined with fluvastatin on tumor growth and cell apoptosis in a xenograft model of hepatocellar carcinoma].
[Necrotizing myopathies: From genetic to acquired forms.]
[The cytotoxicity of mevalonate, lovastatin and carminomycin with respect to MOLT-4 human malignant T-lymphoblasts in vitro]
Nephritis
HMG-CoA reductase inhibitor suppression of glomerular cell proliferation in rats with anti-Thy-1.1 nephritis.
Nephrosclerosis
A 3-hydroxy-3-methylglutaryl co-enzyme A reductase inhibitor reduces hypertensive nephrosclerosis in stroke-prone spontaneously hypertensive rats.
Nephrosis
Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.
Fluvastatin, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, suppresses very low-density lipoprotein secretion in puromycin aminonucleoside-nephrotic rats.
Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis.
The role of circulating mevalonate in nephrotic hypercholesterolemia in the rat.
Nephrotic Syndrome
Effect of Genistein and L-Carnitine and Their Combination on Gene Expression of Hepatocyte HMG-COA Reductase and LDL Receptor in Experimental Nephrotic Syndrome.
Effect of simvastatin on plasma lipid and lipoprotein concentrations and low-density lipoprotein metabolism in the nephrotic syndrome.
Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome.
Effects of lovastatin on hepatic expression of the low-density lipoprotein receptor in nephrotic rats.
Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group.
Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.
The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.
Treatment of hyperlipidemia in human renal disease.
[Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)]
[Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome]
Nervous System Diseases
Lovastatin attenuates nerve injury in an animal model of Guillain-Barré syndrome.
Role of HMG-CoA Reductase Inhibitors in Neurological Disorders : Progress to Date.
Neural Tube Defects
HMG-CoA reductase mRNA in the post-implantation rat embryo studied by in situ hybridization.
Neuritis
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Neuritis, Autoimmune, Experimental
Small GTPase RAS in multiple sclerosis - exploring the role of RAS GTPase in the etiology of multiple sclerosis.
Neuroblastoma
24S-hydroxycholesterol effects on lipid metabolism genes are modeled in traumatic brain injury.
Characterization of the response of growth and differentiation to lipoproteins and agents affecting cholesterol metabolism in murine neuroblastoma cells.
Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.
HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: lovastatin specifically targets P-glycoprotein-expressing cells.
Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach.
Induction of differentiation in murine neuroblastoma cells by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Lovastatin induces a pronounced differentiation response in acute myeloid leukemias.
RNA-binding protein hnRNPR reduces neuronal cholesterol levels by binding to and suppressing HMGCR.
Suppression of murine neuroblastoma growth in vivo by mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
Synergistic Effect of Statins and Abiraterone Acetate on the Growth Inhibition of Neuroblastoma via Targeting Androgen Receptor.
Neurodegenerative Diseases
Mevastatin promotes neuronal survival against A?-induced neurotoxicity through AMPK activation.
Statins and neuroprotection: a prescription to move the field forward.
Neuroectodermal Tumors, Primitive
Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint.
Neurofibromatoses
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.
Neurofibromatosis 1
The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1.
Neuroinflammatory Diseases
Atorvastatin induces T cell anergy via phosphorylation of ERK1.
Rosuvastatin Attenuates High-Salt and Cholesterol Diet Induced Neuroinflammation and Cognitive Impairment via Preventing Nuclear Factor KappaB Pathway.
Statins and delirium: is there a role?
Neurologic Manifestations
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Neuromuscular Diseases
Association between serum neopterin, obesity and daytime sleepiness in patients with obstructive sleep apnea.
Nevus, Pigmented
Cholesterol was identified as a biomarker in human melanocytic nevi using DESI and DESI/PI mass spectrometry imaging.
Niemann-Pick Diseases
Type C Niemann-Pick disease fibroblasts and their transformed cell lines are hypersensitive to HMG-CoA reductase inhibitors.
Non-alcoholic Fatty Liver Disease
Co-Administration of Cholesterol-Lowering Probiotics and Anthraquinone from Cassia obtusifolia L. Ameliorate Non-Alcoholic Fatty Liver.
Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease.
Integrated analysis of hepatic mRNA and miRNA profiles identified molecular networks and potential biomarkers of NAFLD.
Liver biochemistry abnormalities in a quaternary care lipid clinic database.
Meta-analysis reveals up-regulation of cholesterol processes in non-alcoholic and down-regulation in alcoholic fatty liver disease.
miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR.
Regulation effects of total flavonoids in Morus alba L. on hepatic cholesterol disorders in orotic acid induced NAFLD rats.
Sulfated polysaccharides from Enteromorpha prolifera suppress SREBP-2 and HMG-CoA reductase expression and attenuate non-alcoholic fatty liver disease induced by a high-fat diet.
The Chinese medicine Chai Hu Li Zhong Tang protects against non-alcoholic fatty liver disease by activating AMPK?.
[Effect of leech on lipid metabolism and liver in hyperlipidemia rats].
Non-ST Elevated Myocardial Infarction
Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization.
Obesity
African walnut (Tetracarpidium conophorum) modulates hepatic lipid accumulation in obesity via reciprocal actions on HMG-CoA reductase and paraoxonase.
Chlorogenic acid-enriched extract from Eucommia ulmoides leaves inhibits hepatic lipid accumulation through regulation of cholesterol metabolism in HepG2 cells.
Effects of fibre-enriched diets on tissue lipid profiles of MSG obese rats.
Evaluation of lipid and cholesterol-lowering effect of bioflavonoids from bergamot extract.
Feeding induces cholesterol biosynthesis via the mTORC1-USP20-HMGCR axis.
Genetic Contribution of Variants near SORT1 and APOE on LDL Cholesterol Independent of Obesity in Children.
Hepatic cholesterol metabolism in obesity: activity of microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Hepatic transcriptomic signatures of statin treatment are associated with impaired glucose homeostasis in severely obese patients.
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
Methanolic Extract of Piper sarmentosum Attenuates Obesity and Hyperlipidemia in Fructose-Induced Metabolic Syndrome Rats.
Myeloid HMG-CoA Reductase Determines Adipose Tissue Inflammation, Insulin Resistance, and Hepatic Steatosis in Diet-Induced Obese Mice.
Statin as a Potential Chemotherapeutic Agent: Current Updates as a Monotherapy, Combination Therapy, and Treatment for Anti-Cancer Drug Resistance.
Structural Modification of Natural Product Ganomycin I Leading to Discovery of a ?-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo.
The statin class of HMG-CoA reductase inhibitors demonstrate differential activation of the nuclear receptors PXR, CAR and FXR, as well as their downstream target genes.
What model organisms and interactomics can reveal about the genetics of human obesity.
Obesity, Abdominal
Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
[Dyslipidemia in visceral obesity: pathophysiological mechanisms, clinical implications and therapy]
Optic Nerve Injuries
Sirtuin 1 regulates lipid metabolism associated with optic nerve regeneration.
Osteoarthritis
Atorvastatin inhibited TNF-? induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF-?B signaling.
Effect of atorvastatin, a HMG-CoA reductase inhibitor in monosodium iodoacetate-induced osteoarthritic pain: implication for osteoarthritis therapy.
Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation.
Osteoarthritis, Hip
Association of statin use and development and progression of hip osteoarthritis in elderly women.
Osteolysis
Promotion of bone formation by simvastatin in polyethylene particle-induced osteolysis.
The effect of simvastatin on polyethylene particle-induced osteolysis.
Osteoporosis
?-Tocotrienol protects against ovariectomy-induced bone loss via mevalonate pathway as HMG-CoA reductase inhibitor.
Association of dyslipidemia and effects of statins on nonmacrovascular diseases.
Comparison of the effects of D-003, a mixture of high-molecular-weight aliphatic acids from sugarcane wax, and pravastatin on bones and osteoclast apoptosis of ovariectomized rats.
Complementary therapies for reducing the risk of osteoporosis in patients receiving luteinizing hormone-releasing hormone treatment/orchiectomy for prostate cancer: a review and assessment of the need for more research.
Efficacy of HMG-CoA reductase inhibitors in treating osteoporosis.
HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture?
Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management.
No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria.
Non-atheroprotective effects of statins: a systematic review.
Potential use of HMG-CoA reductase inhibitors for osteoporosis.
Statins and fracture risk. A systematic review.
Statins and osteoporosis: a clinical review.
The effect of atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (HMG-CoA), on the prevention of osteoporosis in ovariectomized rabbits.
The impact of co-payment increases on dispensings of government-subsidised medicines in Australia.
The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia.
[Inhibitors of HMG-CoA reductase in prevention of osteoporosis and bone fractures. Similar mechanism of action of statins and bisphosphonates]
[Statin and BMP]
Osteosarcoma
Blockade of the RhoA-JNK-c-Jun-MMP2 cascade by atorvastatin reduces osteosarcoma cell invasion.
Cyr61 downregulation reduces osteosarcoma cell invasion, migration and metastases.
Genomic analysis of circulating cells: a window into atherosclerosis.
Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth.
Ovarian Neoplasms
Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Distinct cholesterogenic and lipidogenic gene expression patterns in ovarian cancer - a new pool of biomarkers.
HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome.
Preclinical evaluation of statins as a treatment for ovarian cancer.
The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer.
Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.
Pancreatic Neoplasms
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
d-Dlta-tocotrienol-mediated suppression of the proliferation of human PANC-1, MIA PaCa-2, and BxPC-3 pancreatic carcinoma cells.
Discussion on 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
HMG-CoA reductase inhibitors for the treatment of pancreatic cancer.
Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.
Prospective analysis of association between statins and pancreatic cancer risk in the Women's Health Initiative.
Statins are not associated with a reduced risk of pancreatic cancer at the population level, when taken at low doses for managing hypercholesterolemia: evidence from a meta-analysis of 12 studies.
YAP Inhibition by Nuciferine via AMPK-Mediated Downregulation of HMGCR Sensitizes Pancreatic Cancer Cells to Gemcitabine.
[Antiproliferating effect of HMG-CoA reductase inhibitor on human pancreatic cancer cell]
Pancreatitis
Statins and pancreatitis: a systematic review of observational studies and spontaneous case reports.
Paralysis
The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.
Parkinson Disease
A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.
Isoprenoid pathway and free radical generation and damage in neuropsychiatric disorders.
Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.
Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer's disease and Parkinson's disease: Mendelian randomisation study.
Statins and neuroprotection: a prescription to move the field forward.
The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.
Ubiquitin ligase HMG-CoA reductase degradation 1 (HRD1) prevents cell death in a cellular model of Parkinson's disease.
Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.
Zonisamide alleviates cardiac hypertrophy in rats by increasing Hrd1 expression and inhibiting endoplasmic reticulum stress.
Parkinsonian Disorders
A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in LRRK2-G2019S parkinsonism.
Pericarditis
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model.
Peripheral Arterial Disease
The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease.
The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease.
Peripheral Nervous System Diseases
HMG-CoA reductase inhibitor therapy and peripheral neuropathy.
Peripheral neuropathy and lipid-lowering therapy.
Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
Peripheral Vascular Diseases
Peripheral arterial disease: a review of disease awareness and management.
Recrudescence of Old Stroke Deficits Among Transient Neurological Attacks.
Phenylketonurias
Effect of phenylalanine derivatives on the main regulatory enzymes of hepatic cholesterogenesis.
Pinguecula
Hyperexpression of low-density lipoprotein receptors and hydroxy-methylglutaryl-coenzyme A-reductase in human pinguecula and primary pterygium.
Pityriasis Lichenoides
Pityriasis lichenoides chronica associated with use of HMG-CoA reductase inhibitors.
Polycystic Kidney Diseases
Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease.
Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.
Polycystic Kidney, Autosomal Dominant
Effect of simvastatin on renal function in autosomal dominant polycystic kidney disease.
Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.
Polycystic Ovary Syndrome
Review of Mendelian Randomization Studies on Ovarian Cancer.
Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.
Polymyositis
Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review.
Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases.
[Diagnosis of Idiopathic Inflammatory Myopathy: A Muscle Pathology Perspective].
Porphyria Cutanea Tarda
[Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin]
Porphyrias
[Porphyria cutanea tarda induced by HMG CoA reductase inhibitors: simvastatin, pravastatin]
Prediabetic State
The differences in the incidence of diabetes mellitus and prediabetes according to the type of HMG-CoA reductase inhibitors prescribed in Korean patients.
Prehypertension
Dendrimers, Carotenoids, and Monoclonal Antibodies.
Preleukemia
In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma.
Prostatic Neoplasms
?-ionone induces cell cycle arrest and apoptosis in human prostate tumor cells.
Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model.
Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE.
Blood lipid genetic scores, the HMGCR gene and cancer risk: a Mendelian randomization study.
Blood lipids and prostate cancer: a Mendelian randomization analysis.
Citral Induced Apoptosis through Modulation of Key Genes Involved in Fatty Acid Biosynthesis in Human Prostate Cancer Cells: In Silico and In Vitro Study.
Correction to: "Human Chorionic Gonadotropin Modulates Prostate Cancer Cell Survival after Irradiation or HMG CoA Reductase Inhibitor Treatment".
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Geranylgeraniol suppresses the viability of human DU145 prostate carcinoma cells and the level of HMG CoA reductase.
Human chorionic gonadotropin modulates prostate cancer cell survival after irradiation or HMG CoA reductase inhibitor treatment.
Impact of diet on prostate cancer: a review.
Improved Biochemical Outcomes with Statin Use in Patients with High-Risk Localized Prostate Cancer Treated with Radiotherapy.
Inhibiting geranylgeranyl diphosphate synthesis reduces nuclear androgen receptor signaling and neuroendocrine differentiation in prostate cancer cell models.
Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC).
MicroRNA-185 and 342 Inhibit Tumorigenicity and Induce Apoptosis through Blockade of the SREBP Metabolic Pathway in Prostate Cancer Cells.
Rhabdomyolysis in a Prostate Cancer Patient Taking Ketoconazole and Simvastatin: Case Report and Review of the Literature (February).
Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer.
Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Stromal regulation of prostate cancer cell growth by mevalonate pathway enzymes HMGCS1 and HMGCR.
The importance of LDL and cholesterol metabolism for prostate epithelial cell growth.
Use of statins and prostate cancer recurrence among patients treated with radical prostatectomy.
[Statins and probiotics in the prevention of urologic diseases]
Proteinuria
Behçet's disease complicated by IgA nephropathy with nephrotic syndrome.
Effect of fluvastatin and dipyridamole on proteinuria and renal function in childhood IgA nephropathy with mild histological findings and moderate proteinuria.
Hepatic fatty acid and cholesterol metabolism in nephrotic syndrome.
Hepatic HMG-CoA reductase gene expression during the course of puromycin-induced nephrosis.
Niacin improves renal lipid metabolism and slows progression in chronic kidney disease.
Simvastatin in nephrotic syndrome. Simvastatin in Nephrotic Syndrome Study Group.
Simvastatin therapy for hypercholesterolemic patients with nephrotic syndrome or significant proteinuria.
Statins and proteinuria.
Psoriasis
Linking phenotypes and modes of action through high-content screen fingerprints.
Pterygium
Hyperexpression of low-density lipoprotein receptors and hydroxy-methylglutaryl-coenzyme A-reductase in human pinguecula and primary pterygium.
Pulmonary Arterial Hypertension
Mevastatin can cause G1 arrest and induce apoptosis in pulmonary artery smooth muscle cells through a p27Kip1-independent pathway.
Pulmonary Aspergillosis
Triazole-Resistant Aspergillus fumigatus in an Israeli Patient with Chronic Cavitary Pulmonary Aspergillosis Due to a Novel E306K Substitution in Hmg1.
Pulmonary Disease, Chronic Obstructive
Association Between Statin Medications and COPD-Specific Outcomes: A Real-World Observational Study.
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
The stats are in: an update on statin use in COPD.
Purpura, Thrombocytopenic
Thrombocytopenic purpura during therapy with simvastatin.
Rectal Neoplasms
Association of statin use with a pathologic complete response to neoadjuvant chemoradiation for rectal cancer.
Simvastatin enhances radiation sensitivity of colorectal cancer cells.
Renal Insufficiency
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient.
A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.
Atorvastatin Improves Hepatic Lipid Metabolism and Protects Renal Damage in Adenine-Induced Chronic Kidney Disease in Sprague-Dawley Rats.
Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment.
Colchicine-induced acute myopathy in a patient with concomitant use of simvastatin.
Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative : A Critical Review of Potential Benefits and Drawbacks.
Effects of lipids on the pathogenesis of progressive renal failure: role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the prevention of glomerulosclerosis.
HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions.
HMG-CoA reductase inhibitor treatment in renal insufficiency.
Lipids, 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors, and progression of renal failure.
Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency.
Post-transcriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and cholesterol 7 alpha-hydroxylase in rats with subtotal nephrectomy.
Protective Effects of Rosuvastatin in Experimental Renal Failure Rats via Improved Endothelial Function.
Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
Statins and renal diseases: from primary prevention to renal replacement therapy.
The pharmacokinetics of cerivastatin in patients on chronic hemodialysis.
Renal Insufficiency, Chronic
3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor simvastatin ameliorates renal fibrosis through HOXA13-USAG-1 pathway.
Cardiac risk factors and the use of cardioprotective medications in patients with chronic renal insufficiency.
Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.
Fluvastatin for dyslipoproteinemia, with or without concomitant chronic renal insufficiency.
HMG CoA reductase inhibition and endothelial function in children with chronic kidney disease (CKD)--a pilot study.
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
HMG-CoA Reductase Inhibitors in Chronic Kidney Disease.
Klotho and chronic kidney disease.
Low utilization of secondary preventive medications and its potential impact in patients with chronic kidney disease and acute coronary syndromes.
Nephroprotective and clinical potential of statins in dialyzed patients.
Optimal Medical Management in Patients with Renovascular Hypertension.
The Efficacy and Safety of the 3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors in Chronic Kidney Disease, Dialysis, and Transplant Patients.
Therapeutic considerations for the use of statin therapy in chronic renal disease.
Use of medications to reduce cardiovascular risk among individuals with psychotic disorders and Type 2 diabetes.
[Statins in patients with renal failure--the current therapeutic status]
Reperfusion Injury
HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury.
Protective effect of HMG-CoA reductase inhibitor on experimental renal ischemia-reperfusion injury.
Simvastatin-induced myocardial protection against ischemia-reperfusion injury is mediated by activation of ATP-sensitive K+ channels.
The endothelial-protective effects of HMG-CoA reductase inhibition in the setting of ischemia and reperfusion injury.
Retinal Diseases
Choroideremia: molecular mechanisms and development of AAV gene therapy.
Suppression of autoimmune retinal disease by lovastatin does not require Th2 cytokine induction.
Retinal Neovascularization
HMG-CoA reductase inhibitors (statins) prevents retinal neovascularization in a model of oxygen-induced retinopathy.
Retinoblastoma
3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1).
Reye Syndrome
Hypothalamic digoxin, cerebral chemical dominance, and regulation of gastrointestinal/hepatic function.
Rhabdomyolysis
3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and rhabdomyolysis: considerations in the renal failure patient.
Antihyperlipidaemic agents. Drug interactions of clinical significance.
Approaches to the treatment of hyperlipidemia in the solid organ transplant recipient.
Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
Case of the month: February 1999--54 year old man with severe muscle weakness.
Cerivastatin-induced rhabdomyolysis: 11 case reports.
Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Clinical pharmacokinetics and practical applications of simvastatin.
Comparative tolerability of the HMG-CoA reductase inhibitors.
Currently available hypolipidaemic drugs and future therapeutic developments.
Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant?
Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors.
Diclofenac- and Pantoprazole-Induced Rhabdomyolysis: A Potential Drug Interaction.
Differential sensitivity of C2-C12 striated muscle cells to lovastatin and pravastatin.
Drug-induced changes in P450 enzyme expression at the gene expression level: a new dimension to the analysis of drug-drug interactions.
Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells.
Fluvastatin-induced rhabdomyolysis.
Fluvastatin: a review of its pharmacology and use in the management of hypercholesterolaemia.
Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors.
HMG CoA reductase inhibitor-induced myotoxicity: pravastatin and lovastatin inhibit the geranylgeranylation of low-molecular-weight proteins in neonatal rat muscle cell culture.
HMG-CoA reductase inhibitor-induced L6 myoblast cell death: involvement of the phosphatidylinositol 3-kinase pathway.
Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Influence of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors on endothelial nitric oxide synthase and the formation of oxidants in the vasculature.
Influence of regulatory measures on the rate of spontaneous adverse drug reaction reporting in Italy.
Interactions between grapefruit juice and cardiovascular drugs.
Levofloxacin-induced rhabdomyolysis in a patient on concurrent atorvastatin: Case report and literature review.
Low-dose lovastatin safely lowers cholesterol after cardiac transplantation.
Massive postoperative rhabdomyolysis following combined CABG/abdominal aortic replacement: a possible association with HMG-CoA reductase inhibitors.
Overexpression of neural cell adhesion molecule in regenerative muscle fibers in 3-hydroxy-3-methylglutaryl coenzyme: A reductase inhibitor-induced rhabdomyolysis.
Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy.
Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy.
Pharmacokinetic model for the inhibition of simvastatin metabolism by itraconazole.
Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
Pharmacokinetics of pravastatin in heart-transplant patients taking cyclosporin A.
Pharmacokinetics of the combination of fluvastatin and gemfibrozil.
Polymyositis evolving after rhabdomyolysis associated with HMG-CoA reductase inhibitors: a report of two cases.
Proton Pump Inhibitors and Risk of Rhabdomyolysis.
Red mold dioscorea: a potentially safe traditional function food for the treatment of hyperlipidemia.
Rhabdomyolysis after concomitant use of cyclosporine, simvastatin, gemfibrozil, and itraconazole.
Rhabdomyolysis after the administration of itraconazole to an asthmatic patient with bronchopulmonary aspergillosis.
Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor.
Rhabdomyolysis and HMG-CoA reductase inhibitors.
Rhabdomyolysis and statin therapy: relevance to the elderly.
Rhabdomyolysis associated with cerivastatin: six cases within 3 months at one hospital.
Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine.
Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy.
Rhabdomyolysis in heart transplant patients on HMG-CoA reductase inhibitors and cyclosporine.
Rhabdomyolysis with concurrent atorvastatin and diltiazem.
Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?
Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy.
Risk factors for rhabdomyolysis with HMG-CoA reductase inhibitors identified using a postmarketing surveillance database in Japan?.
Risk factors for rhabdomyolysis with simvastatin and atorvastatin.
Severe Rhabdomyolysis Associated With Concurrent Use of Simvastatin and Sirolimus After Cisplatin-Based Chemotherapy in a Kidney Transplant Recipient.
Short- and long-term regulation of 3-hydroxy 3-methylglutaryl coenzyme A reductase by a 4-methylcoumarin.
Simvastatin-fluconazole causing rhabdomyolysis.
Simvastatin-induced lactic acidosis: a rare adverse reaction?
Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient.
Skeletal muscle-specific HMG-CoA reductase knockout mice exhibit rhabdomyolysis: A model for statin-induced myopathy.
Statin-induced apoptosis linked with membrane farnesylated Ras small G protein depletion, rather than geranylated Rho protein.
Statins and myotoxicity: a therapeutic limitation.
Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
Updated clinical safety experience with fluvastatin.
[Fluvastatin-induced dermatomyositis]
[Muscle problems due to statins: underestimated.]
[Neurological complication due to the drug and the maneuver for the treatment and prevention of cerebrovascular diseases: iatrogenic neurology]
[New kidney, but a sick heart. Why many patients with renal failure and kidney transplant patients die of cardiovascular disease]
[Rhabdomyolysis and cholestatic hepatitis under treatment with simvastatin and chlorzoxazone]
[Rhabdomyolysis following cerivastatin monotherapy--implications for therapy with HMG-CoA reductase inhibitors]
Rheumatic Diseases
An integrative biology approach for analysis of drug action in models of human vascular inflammation.
An observational study of musculoskeletal pain among patients receiving bisphosphonate therapy.
Rosacea
The Risk of Rosacea According to Chronic Diseases and Medications: A 5-Year Retrospective, Multi-Institutional Case-Control Study.
Sarcoidosis
Hypothalamic digoxin, cerebral chemical dominance, and pathogenesis of pulmonary diseases.
Sarcoma
Malignant fibrous histiocytoma of visceral organs: clinicopathologic features and diagnostic value of ezrin and HMG-CoA reductase.
Sarcoma, Ewing
Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications.
Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint.
Scarlet Fever
Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women.
Seizures
Evidence for a pharmacokinetic interaction between eslicarbazepine and rosuvastatin: Potential effects on xenobiotic transporters.
Fragile X syndrome therapeutics: translation, meet translational medicine.
Pharmacodynamic potentiation of antiepileptic drugs' effects by some HMG-CoA reductase inhibitors against audiogenic seizures in DBA/2 mice.
Sepsis
Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for Gram-Negative rods.
Effectiveness of statins in reducing the rate of severe sepsis: a retrospective evaluation.
Effects of sepsis on the metabolism of sphingomyelin and cholesterol in mice with liver dysfunction.
Effects of simvastatin in abdominal sepsis in rats.
HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis.
HMG-CoA Reductase Inhibitors for Prevention and Treatment of Severe Sepsis.
Impact of previous statin and angiotensin II receptor blocker use on mortality in patients hospitalized with sepsis.
Incidence of Sepsis and Mortality With Prior Exposure of HMG-COA Reductase Inhibitors in a Surgical Intensive Care Population.
Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis.
Reduction in mortality associated with statin therapy in patients with severe sepsis.
Renal cortical cholesterol accumulation is an integral component of the systemic stress response.
Sepsis outcomes in patients receiving statins prior to hospitalization for sepsis: comparison of in-hospital mortality rates between patients who received atorvastatin and those who received simvastatin.
Sepsis syndrome stimulates proximal tubule cholesterol synthesis and suppresses the SR-B1 cholesterol transporter.
Statins in candidemia: clinical outcomes from a matched cohort study.
The role of statin therapy in sepsis.
Shock, Septic
Low Low-Density Lipoprotein Levels Are Associated With, But Do Not Causally Contribute to, Increased Mortality in Sepsis.
Simvastatin decreases nitric oxide overproduction and reverts the impaired vascular responsiveness induced by endotoxic shock in rats.
The role of statin therapy in sepsis.
Skin Diseases
Spiny keratoderma: a common under-reported dermatosis.
Sleep Initiation and Maintenance Disorders
Comparison of the effects of pravastatin and lovastatin on sleep disturbance in hypercholesterolemic subjects.
Smith-Lemli-Opitz Syndrome
Plasma and thrombocyte levels of coenzyme Q10 in children with Smith-Lemli-Opitz syndrome (SLOS) and the influence of HMG-CoA reductase inhibitors.
Spasm
Effects of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, fluvastatin, on coronary spasm after withdrawal of calcium-channel blockers.
Spinal Stenosis
Severe muscle symptoms with lipid-lowering agents may be confused with neurogenic claudication associated with spinal canal stenosis.
Squamous Cell Carcinoma of Head and Neck
Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas.
Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors.
ST Elevation Myocardial Infarction
Methylated arginines in stable and acute patients with coronary artery disease before and after percutaneous revascularization.
Starvation
Acute effects of starvation and treatment of rats with anti-insulin serum, glucagon and catecholamines on the state of phosphorylation of hepatic 3-hydroxy-3-methylglutaryl-CoA reductase in vivo.
Acute effects of starvation and treatment of rats with anti-insulin serum, glucagon and catecholamines on the state of phosphorylation of hepatic 3-hydroxy-3-methylglutaryl-CoA reductase.
Glucose restriction drives spatial reorganization of mevalonate metabolism.
Kinetics of G1 progression in 3T6 and SV-3T3 cells following treatment by 25-hydroxycholesterol.
Serum cholesterol, lecithin-cholesterol acyltransferase, and hepatic hydroxymethylglutaryl coenzyme A reductase activities of lean and obese Zucker rats.
[Activities of 3-hydroxyl-3-methylglutaryl-CoA reductase and acetyl-CoA carboxylase and the rate of mevalonic acid, squalene, sterol and fatty acid biosynthesis from [1-14C]acetyl-CoA and [2-14C]malonyl-CoA in rat liver: effects of Triton WR 1339, starvation and cholesterol diet]
Stomach Neoplasms
3-Hydroxy-3-methylglutaryl coenzyme A reductase activity and low-density lipoprotein receptor expression in diffuse-type and intestinal-type human gastric cancer.
HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells.
Synergistic Effect of Simvastatin Plus Radiation in Gastric Cancer and Colorectal Cancer: Implications of BIRC5 and Connective Tissue Growth Factor.
Stroke
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy.
Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact.
Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury.
C-reactive protein level and traditional vascular risk factors in the prediction of carotid stenosis.
Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification.
Chemokine, vascular and therapeutic effects of combination Simvastatin and BMSC treatment of stroke.
Clinical implications of pharmacogenetic variation on the effects of statins.
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke.
Does cholesterol lowering prevent stroke?
Drug Insight: statins and stroke.
Drug therapy of neurovascular disease.
Effect of HMGcoA reductase inhibitors on stroke. A meta-analysis of randomized, controlled trials.
Effects of long-term administration of HMG-CoA reductase inhibitor, atorvastatin, on stroke events and local cerebral blood flow in stroke-prone spontaneously hypertensive rats.
Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke.
Endothelial dysfunction and coronary atherosclerosis.
Endothelium-targeted pharmacotherapeutics for the treatment of stroke.
Ezetimibe and Vascular Inflammation.
HMG CoA reductase inhibitors (statins): use in stroke prevention and outcome after stroke.
HMG-CoA Reductase Inhibition Promotes Neurological Recovery, Peri-Lesional Tissue Remodeling, and Contralesional Pyramidal Tract Plasticity after Focal Cerebral Ischemia.
HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats.
HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data.
HMG-CoA reductase inhibitors (statins): a promising approach to stroke prevention.
HMG-CoA reductase inhibitors in the prevention of stroke.
HMG-CoA reductase inhibitors reduce stroke risk, total mortality.
HMGCR gene polymorphism is associated with stroke risk in the EPIC-Norfolk study.
How do HMG-CoA reductase inhibitors prevent stroke?
Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction.
Immunomodulatory and anti-inflammatory activities of statins.
Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Mechanism Study of the Protective Effects of Sodium Tanshinone IIA Sulfonate Against Atorvastatin-Induced Cerebral Hemorrhage in Zebrafish: Transcriptome Analysis.
Mevastatin, an HMG-CoA reductase inhibitor, reduces stroke damage and upregulates endothelial nitric oxide synthase in mice.
Molecular mechanisms underlying the effects of statins in the central nervous system.
Noncholesterol-lowering effects of statins.
Optimizing cardiovascular outcomes in diabetes mellitus.
Patterns of medical therapy in patients with peripheral artery disease in a tertiary care centre in Canada.
Pravastatin therapy and the risk of stroke.
Pre and Post-stroke Use of Statins Improves Stroke Outcome.
Prevention of cardiovascular events in elderly people.
Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.
Rosuvastatin improves myocardial and neurological outcomes after asphyxial cardiac arrest and cardiopulmonary resuscitation in rats.
Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.
Secondary stroke prevention: inside the vessels and beyond.
Statin therapy in renal disease: harmful or protective?
Statin use before and after acute ischemic stroke onset improves neurological outcome.
Statin use is independently associated with smaller infarct volume in nonlacunar MCA territory stroke.
Statins and cerebral hemodynamics.
Statins and endothelial dysfunction.
Statins Promote Long-Term Recovery after Ischemic Stroke by Reconnecting Noradrenergic Neuronal Circuitry.
Statins: multiple mechanisms of action in the ischemic brain.
Stroke, statins, and cholesterol. A meta-analysis of randomized, placebo-controlled, double-blind trials with HMG-CoA reductase inhibitors.
The influence of statin therapy on platelet activity markers in hyperlipidemic patients after ischemic stroke.
The relationship between cholesterol and stroke: implications for antihyperlipidaemic therapy in older patients.
The role of statins in cancer therapy.
[Anti-inflammatory effect of HMG-CoA reductase inhibitors]
[Antilipemics and prevention of cerebrovascular accidents. Meta-analysis]
[Direct neuronal effects of statins]
[HMG-CoA reductase inhibitor and risk of stroke]
[Novel actions of HMG-CoA reductase inhibitors(statins)--vascular and cerebral protection through inhibition of small GTPase Rho]
[Regulation of endothelial NO production by Rho GTPase]
Subacute Sclerosing Panencephalitis
Hypothalamic digoxin-mediated model for subacute sclerosing panencephalitis.
Subarachnoid Hemorrhage
Statin treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage.
Tachycardia
[Thyroid hormones and lipid metabolism]
Tachycardia, Ventricular
Statins and the reduction of sudden cardiac death: antiarrhythmic or anti-ischemic effect?
Tendinopathy
The influence of atorvastatin on tendon healing: an experimental study on rabbits.
Thromboinflammation
The effect of rosuvastatin on thromboinflammation in the setting of acute coronary syndrome.
Thrombosis
Clinical effects of antiplatelet drugs and statins on D-dimer levels.
HMG-CoA reductase inhibitor protects against in vivo arterial thrombosis by augmenting platelet-derived nitric oxide release in rats.
HMG-CoA reductase inhibitors inhibit endothelial exocytosis and decrease myocardial infarct size.
Inhibition of platelet-rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy.
Pharmacogenetics of Warfarin in a Diverse Patient Population.
Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells.
Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
Statins for the prevention of venous thromboembolism? a narrative review.
Thymoma
Fluvastatin is effective against thymic carcinoma.
Thyroid Carcinoma, Anaplastic
Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway.
Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells.
Thyroid Neoplasms
Redifferentiation therapy in advanced thyroid cancer.
Thyroid Nodule
Reduced thyroid volume and nodularity in dyslipidaemic patients on statin treatment.
Thyroiditis
The effect of statin therapy on thyroid autoimmunity in patients with Hashimoto's thyroiditis: A pilot study.
Tinnitus
Irreversible atorvastatin-associated hearing loss.
Simvastatin and Ginkgo biloba in the treatment of subacute tinnitus: a retrospective study of 94 patients.
Tourette Syndrome
Hypothalamic digoxin deficiency in obsessive compulsive disorder and la Tourette's syndrome.
Tuberculosis
Effect of HMG-CoA reductase inhibitors on activation of human gammadeltaT cells induced by Mycobacterium tuberculosis antigens.
Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias.
Tuberous Sclerosis
Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.
Uterine Cervical Neoplasms
Simvastatin enhances chemotherapy in cervical cancer via inhibition of multiple prenylation-dependent GTPases-regulated pathways.
Varicose Veins
HMG-CoA reductase inhibitors reduce matrix metalloproteinase-9 activity in human varicose veins.
Vascular Diseases
Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV.
Detection of familial hypercholesterolemia in patients from a general practice database.
Emerging non-statin LDL-lowering therapies for dyslipidemia and atherosclerosis.
Fluvastatin in combination with rad significantly reduces graft vascular disease in rat cardiac allografts.
HMG-CoA reductase inhibitors: a look back and a look ahead.
How to balance cardiorenometabolic benefits and risks of statins.
Impact of dyslipidaemia in renal transplant recipients.
Lipid-lowering for prevention of coronary heart disease: what policy now?
Lipids and stroke: the opportunity of lipid-lowering treatment.
Optimal medical management of peripheral arterial disease.
Selected statins produce rapid spinal motor neuron loss in vitro.
Statins for primary prevention: at what coronary risk is safety assured?
Statins Promote Long-Term Recovery after Ischemic Stroke by Reconnecting Noradrenergic Neuronal Circuitry.
Vascular oxidative stress: the common link in hypertensive and diabetic vascular disease.
[HMG-CoA reductase inhibitors: a brief review of their pharmacological properties and clinical efficacy in cardiovascular disease]
[Statins: possibly more than just lowering of the lipid level]
Vascular System Injuries
gamma-Tocotrienol ameliorates intestinal radiation injury and reduces vascular oxidative stress after total-body irradiation by an HMG-CoA reductase-dependent mechanism.
How do HMG-CoA reductase inhibitors prevent stroke?
Rosuvastatin reduces neointima formation in a rat model of balloon injury.
Vasospasm, Intracranial
Proposed mechanism of cerebral vasospasm: our hypothesis and current topics.
Venous Thromboembolism
Statin therapy and levels of hemostatic factors in a healthy population: the Multi-Ethnic Study of Atherosclerosis.
Why might statins prevent venous thromboembolism: what needs to be done to know more?
Venous Thrombosis
HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women.
HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis.
Pharmacogenetics of Warfarin in a Diverse Patient Population.
Venous thrombosis associated with HMG-CoA reductase inhibitors.
Ventricular Dysfunction, Left
How do HMG-CoA reductase inhibitors prevent stroke?
Statins ameliorate pulmonary hypertension secondary to left ventricular dysfunction through the Rho-kinase pathway and NADPH oxidase.
Viremia
Impact of HMG-CoA reductase inhibitors on the incidence of polyomavirus-associated nephropathy in renal transplant recipients with human BK polyomavirus viremia.
Virus Diseases
Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy.
Do viruses subvert cholesterol homeostasis to induce host cubic membranes?
Effect of atovastatin treatment on porcine circovirus 2 infection in BALB/c mice.
HMGCR inhibits the early stage of PCV2 infection, while PKC enhances the infection at the late stage.
The increase in cholesterol levels at early stages after dengue virus infection correlates with an augment in LDL particle uptake and HMG-CoA reductase activity.
Vitamin D Deficiency
Increase of circulating cholesterol in vitamin D deficiency is linked to reduced vitamin D receptor activity via the Insig-2/SREBP-2 pathway.
Vitiligo
Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo.
Review of Mendelian Randomization Studies on Ovarian Cancer.
Xanthomatosis
Decreased cholesterol biosynthesis in sitosterolemia with xanthomatosis: diminished mononuclear leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase activity and enzyme protein associated with increased low-density lipoprotein receptor function.
Familial xanthomatous hypercholesterolemia: abnormal exogenous lipid metabolism evidenced by the vitamin A test.
Histologic, hematologic, and biochemical characteristics of apo E-deficient mice: effects of dietary cholesterol and phytosterols.
Pathophysiology of apolipoprotein E deficiency in mice: relevance to apo E-related disorders in humans.
Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits.
Xanthomatosis, Cerebrotendinous
Combined treatment with chenodeoxycholic acid and pravastatin improves plasma cholestanol levels associated with marked regression of tendon xanthomas in cerebrotendinous xanthomatosis.
Combined treatment with LDL-apheresis, chenodeoxycholic acid and HMG-CoA reductase inhibitor for cerebrotendinous xanthomatosis.